MELANOMA A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Melanoma: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84031-8 1. Melanoma-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on melanoma. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON MELANOMA .............................................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Melanoma...................................................................................... 6 E-Journals: PubMed Central ....................................................................................................... 64 The National Library of Medicine: PubMed ................................................................................ 76 CHAPTER 2. NUTRITION AND MELANOMA .................................................................................. 123 Overview.................................................................................................................................... 123 Finding Nutrition Studies on Melanoma .................................................................................. 123 Federal Resources on Nutrition ................................................................................................. 131 Additional Web Resources ......................................................................................................... 132 CHAPTER 3. ALTERNATIVE MEDICINE AND MELANOMA ............................................................ 133 Overview.................................................................................................................................... 133 National Center for Complementary and Alternative Medicine................................................ 133 Additional Web Resources ......................................................................................................... 163 General References ..................................................................................................................... 167 CHAPTER 4. DISSERTATIONS ON MELANOMA .............................................................................. 169 Overview.................................................................................................................................... 169 Dissertations on Melanoma ....................................................................................................... 169 Keeping Current ........................................................................................................................ 171 CHAPTER 5. CLINICAL TRIALS AND MELANOMA ........................................................................ 173 Overview.................................................................................................................................... 173 Recent Trials on Melanoma ....................................................................................................... 173 Keeping Current on Clinical Trials ........................................................................................... 197 CHAPTER 6. PATENTS ON MELANOMA ........................................................................................ 199 Overview.................................................................................................................................... 199 Patents on Melanoma ................................................................................................................ 199 Patent Applications on Melanoma............................................................................................. 228 Keeping Current ........................................................................................................................ 264 CHAPTER 7. BOOKS ON MELANOMA ............................................................................................ 265 Overview.................................................................................................................................... 265 Book Summaries: Federal Agencies............................................................................................ 265 Book Summaries: Online Booksellers......................................................................................... 266 The National Library of Medicine Book Index ........................................................................... 271 Chapters on Melanoma .............................................................................................................. 272 CHAPTER 8. MULTIMEDIA ON MELANOMA ................................................................................. 273 Overview.................................................................................................................................... 273 Video Recordings ....................................................................................................................... 273 Bibliography: Multimedia on Melanoma ................................................................................... 274 CHAPTER 9. PERIODICALS AND NEWS ON MELANOMA .............................................................. 277 Overview.................................................................................................................................... 277 News Services and Press Releases.............................................................................................. 277 Newsletter Articles .................................................................................................................... 282 Academic Periodicals covering Melanoma................................................................................. 282 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 283 Overview.................................................................................................................................... 283 U.S. Pharmacopeia..................................................................................................................... 283 Commercial Databases ............................................................................................................... 284 Researching Orphan Drugs ....................................................................................................... 285 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 291
viii Contents
Overview.................................................................................................................................... 291 NIH Guidelines.......................................................................................................................... 291 NIH Databases........................................................................................................................... 293 Other Commercial Databases..................................................................................................... 295 The Genome Project and Melanoma .......................................................................................... 295 APPENDIX B. PATIENT RESOURCES ............................................................................................... 301 Overview.................................................................................................................................... 301 Patient Guideline Sources.......................................................................................................... 301 Finding Associations.................................................................................................................. 310 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 313 Overview.................................................................................................................................... 313 Preparation................................................................................................................................. 313 Finding a Local Medical Library................................................................................................ 313 Medical Libraries in the U.S. and Canada ................................................................................. 313 ONLINE GLOSSARIES................................................................................................................ 319 Online Dictionary Directories ................................................................................................... 321 MELANOMA DICTIONARY...................................................................................................... 323 INDEX .............................................................................................................................................. 415
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with melanoma is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about melanoma, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to melanoma, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on melanoma. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to melanoma, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on melanoma. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON MELANOMA Overview In this chapter, we will show you how to locate peer-reviewed references and studies on melanoma.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and melanoma, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “melanoma” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Amelanotic Melanoma of the Palate: Report of Case Source: Journal of Oral and Maxillofacial Surgery. 59(5): 580-583. May 2001. Contact: Available from W.B. Saunders Company. Periodicals Department, P.O. Box 629239, Orlando, FL 32862-8239. (800) 654-2452. Website: www.harcourthealth.com. Summary: Malignant melanoma arises primarily in the skin and represents the leading cause of death from cutaneous malignancy in the United States. Fewer than 1 percent of all reported primary melanomas arise in the oral cavity. The cutaneous form of this lesion normally is highly visible, with irregular borders and dark pigmentation. Rarely, melanoma may present without clinically evident pigmentation (coloration). Termed amelanotic melanoma, these lesions tend to have a worse prognosis because of delayed recognition and subsequent treatment. This article reports a case of amelanotic
4
Melanoma
melanoma of the palate. A 68 year old Caucasian female presented with a 2 centimeter nodular lesion on the right soft palate found on routine dental examination. The patient's medical history was significant for a stroke, which resulted in left hemiplegia. She had lost all her teeth from periodontal disease; she had been wearing complete upper and lower dentures for the preceding 15 years. After diagnosis, surgical excision (removal) was performed. The patient did well postoperatively and has undergone successful prosthetic rehabilitation. The surgical margins were clear of disease, and the patient remains disease free at 1 year. The authors note that because oral cavity melanomas are extremely rare, it is difficult to determine the optimum method of staging, prognosis, and treatment. 3 figures. 17 references. •
Spontaneous Regression of Cutaneous Melanoma with Subsequent Metastasis Source: Journal of Oral and Maxillofacial Surgery. 60(5): 588-591. May 2002. Contact: Available from W.B. Saunders Company. Periodicals Department, P.O. Box 629239, Orlando, FL 32862-8239. (800) 654-2452. Website: www.harcourthealth.com. Summary: There has been a four-fold increase in the incidence of cutaneous malignant melanoma during the past 25 years. However, the ratio of expected deaths from melanoma to new melanoma cases has actually decreased steadily during this time period, largely as a result of increased public awareness leading to earlier diagnosis and treatment. The relationship between malignant melanoma and melanocytic nevi (pigmented skin blemishes, present at birth) is well recognized; more than 80 percent of patients with melanoma reported a change in a preexisting nevus as the initial sign of their disease. This article presents the case of a patient with an apparent spontaneous regression of a presumed malignant melanoma that arose from a longstanding cutaneous melanocytic nevus followed by the development of a regional lymph node metastasis (spread of the cancer). The authors describe the patient's multimodal therapy with wide surgical excision of the gross lesion, noting that this offers the most favorable opportunity for locoregional control and, therefore, prolonged disease-free survival. 6 figures. 16 references.
•
Oral Melanoma: Diagnosis and Treatment Source: Seminars in Cutaneous Medicine and Surgery. 16(4): 320-322. December 1997. Summary: This article reviews the diagnosis and treatment of oral melanoma. The author notes that melanoma of the mouth is rare, most commonly occurring on the upper jaw of patients older than 50 years. Because of a frequent delay in diagnosis (the oral cavity is often neglected during the physical examination, and pain is often nonexistent), the tumors are often diagnosed after they are deeper than the average cutaneous melanoma. Hence, the prognosis tends to be poor. The 5-year survival rate is 15 to 38 percent. Surgery is the mainstay of treatment, but often it is difficult because of anatomic restraints. Although melanoma is classically not radiosensitive, occasional patients have had a good response to radiation therapy, sometimes with temporary palliation. Other treatment modalities are similar to those used for cutaneous melanoma. Immunotherapy, including interferon, has been used. Chemotherapy has a low response rate. The author reiterates that, as with the skin, early diagnosis of oral melanoma is important. 4 figures. 13 references. (AA-M).
•
Melanoma: A Strategy For Detection And Treatment Source: Patient Care. 30(11):126-28, 30, 34-36, 41-42, 45, 48, 53; June 1995.
Studies
5
Summary: This journal article examines the diagnosis and treatment options of skin cancer, including the types of drugs available, identification tips, and patient counseling. The authors discuss the difficulties in identifying suspicious growths on the skin; when an autopsy is needed; monitoring when a biopsy is inconclusive; prognostic indicators in cases of positive biopsies; the clinical staging examination; and available courses of action such as surgery, adjuvant therapy, palliative therapy, and experimental treatments. Concluding comments address long-term follow-up and patient counseling. 11 references, 2 figures, 3 tables. •
Pigment Clues Guide Melanoma Risk Diagnosis Source: Skin and Allergy News. 28(9):22; September 1997. Summary: This journal article for health professionals reports on the use of epiluminescence microscopy (ELM) for determining whether an equivocal lesion is melanoma. If a lesion seen with ELM has a pigment network with a fishnet or honeycomb pattern it is most likely melanocytic. In addition, other features that suggest a high, medium, or low risk of melanoma are identified.
•
Preventing Mortality in Cutaneous Melanoma Source: Patient Care. 33(9): 34-36,39-40,43-44,46,49,56-58,60. May 15, 1999. Summary: This journal article provides health professionals with information on detecting early cutaneous melanomas. It addresses screening issues, describes the features of suspicious lesions, and presents methods of treating melanoma. The main early detection tools are screening by physicians and skin self-examination by patients. Although many medical organizations do not recommend routine screening for skin cancer, the American Academy of Dermatology, the American Cancer Society, the National Institutes of Health, and the Skin Cancer Foundation do recommend skin examination or annual screening. The risk level of a particular patient is an important factor in the decision to screen for melanoma. The most effective skin examination is comprehensive, and some experts recommend dermatologic photography as a supplement to total skin examination in high-risk patients. Tools that can help diagnose a suspicious lesion include optimal illumination, side-lighting, a hand lens, and a Wood's lamp. The types of melanoma are superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral-lentiginous melanoma. A biopsy is needed for all lesions meeting the ABCD (asymmetry, borders, color, diameter) criteria for melanoma. The histopathology report will indicate whether the lesion is benign or malignant. Treatment consists of surgical excision. Other treatments include chemotherapy for patients who have metastatic disease, liquid nitrogen cryosurgery, radiation therapy, and Mohs' micrographic surgery. Experimental therapies include melanoma vaccines and isolated limb perfusion. Involvement of regional lymph nodes is the most significant prognostic risk factor, followed by primary tumor thickness. The frequency of follow-up and the laboratory studies that should be obtained at each followup visit depend on the stage of disease and the risk of recurrence. Patient education is important in increasing the chances of early detection. 8 figures, 2 tables, and 11 references.
•
How to Diagnose Malignant Melanoma Source: Nurse Practitioner. 27(2): 26-27,31-35. February 2002. Summary: This journal article, a continuing nursing education activity, provides nurse practitioners with information on diagnosing malignant melanoma. The incidence of
6
Melanoma
malignant melanoma has increased dramatically in recent decades. Malignant melanoma can either begin de novo or develop in association with a preexisting nevus. Although curable if caught early, malignant melanoma often presents a diagnostic challenge. Clinicians can use various methods, both old and new, to evaluate melanoma, including the ABCD method, total body photography, skin surface microscopy, and machine vision. The ABCD method involves evaluating a lesion for asymmetry, border, color variegation, and diameter. Benign nevi tend to be round and symmetric; have smooth, regular borders; be homogeneously colored; and be less than 6 millimeters in diameter. However, melanomas are often asymmetric; have irregular, uneven, and ragged edges; have multiple colors and various hues of light and dark brown, black, red, blue, or gray; and be larger than 6 millimeters in diameter. The inaccuracy of the ABCD method has prompted clinicians to use other modalities such as total body photography for high risk patients. Although potentially more accurate than the ABCD method, total body photography is still based on clinical visual inspection. In contrast, skin surface microscopy, also known as dermoscopy or epiluminescence microscopy, uses a handheld instrument to provide a 10 times illuminated view of the skin surface. This technique bridges clinical experience with histopathology. Learning dermoscopy requires understanding color, structures, and borders. Although skin surface microscopy improves diagnostic accuracy, it is labor intensive with a fairly high learning curve. Machine vision is a promising diagnostic tool that is being studied in various countries. This technique uses an electronic digital dermatoscopic camera to acquire and process images. A computer then segments the image, separating the boundaries of the pigmented lesion from the surrounding skin. The article discusses practice implications. 16 figures and 27 references. (AA-M).
Federally Funded Research on Melanoma The U.S. Government supports a variety of research studies relating to melanoma. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to melanoma. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore melanoma. The following is typical of the type of information found when searching the CRISP database for melanoma: •
Project Title: A MOUSE MODEL FOR UV-INDUCED JUNCTIONAL MELANOMA Principal Investigator & Institution: Noonan, Frances P.; Professor; Immunology; George Washington University 2121 I St Nw Washington, Dc 20052
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
7
Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: Cutaneous malignant melanoma (CMM), already notorious for its highly aggressive behavior and its recalcitrance to currently available therapeutics is one of the the fastest increasing cancers in the USA. Recent studies have provided compelling evidence for a significant underlying genetic basis for CMM, as well as an initiating role for sunlight exposure in its etiology. The functional relationship, however, between genes and environment in the pathogenesis of melanoma is virtually unknown. Until now, research on this deadly disease has been badly hampered by the lack of an animal model which adequately recapitulates human disease. We have developed a new transgenic mouse model for UV-induced melanoma which, for the first time, shows an etiology, histopathology and molecular pathogenesis remarkably similar to human CMM. In this proposal, we seek to characterize and further validate this model which shows great promise for melanoma investigations. Preliminary data to date have demonstrated that a single neonatal burning dose of UV exposure is necessary and sufficient to induce highly penetrant cutaneous melanoma, arising in apposition to epidermal elements with a junctional morphology and a molecular pathogenetic profile remarkably reminiscent of human melanoma. Specifically, the UV responsiveness and waveband dependence of this model will be established, the role of critical genetic alterations in the tumor suppressor loci Ink4a and p53 occurring in early lesions and in malignant tumors will be investigated using an in vivo genetic approach, and we propose to establish if UV-induced immune alterations play a fundamental role in the early pathogenesis of disease in this model. We anticipate that these studies will provide the major basis for development of this system for application in the design of preventive strategies and therapeutic interventions and for further investigations of the fundamental biology of cutaneous malignant melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AN INTELLIGENT MELANOMA DIAGNOSTIC TRAINING SYSTEM Principal Investigator & Institution: Crowley, Rebecca S.; Pathology; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2003; Project Start 21-AUG-2003; Project End 31-JUL-2006 Summary: (provided by applicant): This project will determine whether the welldescribed paradigm of the model-tracing Intelligent Tutoring System can be adapted to create a multimedia, knowledge-based, medical training system. We propose to develop the Melanoma Diagnostic Training System, a virtual-slide based tutor for pathology residents. The system is designed to provide instruction in detection, classification, and reporting of Malignant Melanoma and other melanocytic skin lesions. Melanocytic lesions are a difficult area of histologic cancer diagnosis. False negative and false positive diagnoses of Melanoma can result in significant morbidity and mortality, and are among the most commonly litigated pathology case types. New advances in treatment of Melanoma have placed an increasing responsibility on the pathologist to identify and report on a range of histologic prognostic indicators. We propose to develop a diagnostic training system in this domain using the paradigm of the Intelligent Tutoring Systems (ITS). ITS are computer-based systems that provide individualized instruction by incorporating models of expert performance and dynamically building a unique student model for each user. ITS can be highly effective in systems that simulate real-world tasks, enabling students to work through case-based scenarios as the ITS offers guidance, points out errors and organizes the curriculum to address the needs of that individual learner. As part of the project, we will develop a library of whole-slide digital images of melanocytic lesions and melanoma, each with a
8
Melanoma
gold-standard diagnosis. System development will be accompanied by a controlled, randomized laboratory evaluation in which we will examine the effect of the system on accuracy of detection, classification, and reporting using pre-test and post-test methods. In the final year of the project, we will deploy the system across multiple sites in the Pennsylvania Cancer Alliance Bioinformaties Consortium, and evaluate acceptance and use of the system using surveys, interviews, and log-file analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANALYSIS OF BREAST/MELANOMA MULTIPLE PRIMARY CANCERS Principal Investigator & Institution: Gerrero, Michelle Renee.; Pediatrics; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2003; Project Start 12-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): The proposed project is centered on cancer susceptibility gene discovery. This project is based on the hypothesis that a subset of individuals with multiple primary cancers has an underlying susceptibility gene mutation that is common to all tumors in that individual. Earlier studies using population-based tumor registries have demonstrated an increased risk of melanoma as a second malignancy in women diagnosed with breast cancer. Conversely, an increased risk of breast cancer has been demonstrated in women who have been previously diagnosed with melanoma. This bi-directional increased risk of a second malignancy deserves further attention and is suggestive of a common mechanism as the etiology of these two tumors. To this end, we intend to define and characterize a population of women who have been diagnosed with both breast cancer and melanoma. Outside of defined syndromes, little had been documented regarding multiple primary cancers. What data exist strongly support the hypothesis that women with multiple primary cancers are more likely to harbor germline susceptibility alleles than those with a single malignancy. We hypothesize that women with the multiple primary cancers, breast and melanoma, represent a clinically significant variation in disease phenotype for one of the known candidate genes. We will screen this population for germline and somatic mutations in genes known to be involved in cancer predisposition or progression. In addition, we will use array-based comparative genomic hybridization (aCGH) to identify the critical genetic changes that are necessary to transform normal melanocytes or breast epithelium into cells with malignant potential. A DNA-based microarray platform using bacterial artificial chromosomes (BACs) containing human genomic DNA representative of the entire genome at 1-2 Mb intervals, will be utilized to define regions of chromosomal gain and loss using DNA from breast and melanoma tumors both from a single individual as well as versus matched sporadic tumors. The overall objective of this proposal is the identification of additional cancer susceptibility genes, which will enable the study of the genes themselves and advance our understanding of the etiology of breast cancer and malignant melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANCHOR MODIFIED PEPTIDES FOR IMMUNIZATION IN MELANOMA Principal Investigator & Institution: Linette, Gerald P.; Internal Medicine; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2002; Project Start 29-SEP-1999; Project End 31-JAN-2003
Studies
9
Summary: Recent experimental evidence suggests that therapeutic immunization for certain malignancies is a realistic approach. Pre-clinical models based upon immunization of tumor-bearing hosts with antigen-pulsed dendritic cells (DC) demonstrate that regression of established tumors can be induced. Tumor regression is dependent upon an intact immune system and is mediated by antigen specific CD8+ T lymphocytes. This proposal is built upon the premise that delivery of an immunogenic peptide vaccine with subsequent intensive immunologic monitoring is required to optimally elicit an effective T cell response capable of eradicating residual tumor. Compelling evidence suggests that immunogenicity correlates with peptide binding affinity for molecules encoded by the major histocompatibility complex. The principal goal of this study is to create better, more immunogenic vaccines for melanoma by designing peptide antigens modified in crucial (anchor) residues that affect binding affinity for HLA class I molecules. Melanoma antigen gp100 and Mart-1 anchor modified peptides will be used with DC in clinical immunization trials designed to optimize the in vivo generation of antigen specific CD8+ cytotoxic T lymphocytes. Immunologic, pathologic, as well as radiologic endpoints will be used to judge the efficacy of each peptide. Newer methodologies such as T cell receptor beta chain repertoire analysis and four color flow cytometry will be incorporated into vaccine trials for melanoma to allow more precise monitoring. Immunogenicity of selected peptides will be validated using HLA transgenic mice. The specific aims of this application are: 1) to create anchor modified peptides of the gp100 melanoma antigen restricted by HLAA2; 2) to identify HLA-B7 restricted epitopes of gp100 and Mart-1; 3) to develop better strategies to characterize human T cell activation and recruitment after DC vaccination. The issues addressed in this application are designed to provide a more detailed understanding of the relationship between cellular immunity, tumor regression, and clinical response. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANGIOGENIC FACTORS ASSOCIATED WITH UVEAL MELANOMA Principal Investigator & Institution: Polans, Arthur S.; Ophthalmology and Visual Sci; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2001; Project Start 01-JUL-2000; Project End 31-MAY-2003 Summary: Uveal melanoma is the most prevalent primary ocular tumor found in adults. The annual incidence of uveal melanoma is equivalent to the number of new cases of retinitis pigmentosa. The genetic alterations underlying the disease are unknown, and there are few prognostic indicators that can be observed clinically, contributing to enucleation as a principal method of treatment. Unfortunately, events leading to systemic metastases may have occured by the time the ocular symptoms are recognized, and death due to hepatic disease and other complications usually ensues. Clearly, improved methods are needed for the early detection and treatment of the disease. The current application focuses on the contributions of angiogenic growth factors and inhibitors to the progression of the disease. We hypothesize that the malignant and metastatic properties of such tumors depend on the simultaneous expression of multiple angiogenic factors, specifically Cyr61, Tissue Factor, and VEGF. Further, the balance between the expression of these growth factors and inhibitors determines the quiescent period prior to detectable metastases. Specific Aims include: 1. Verify the expression of Cyr61, Tissue Factor and VEGF in primary ocular melanoma using both archival specimens and fresh biopsies of tumor tissue. Methods of detection will include immunohistochemistry, Northern blot hybridization, RT-PCR, and in situ hybridization. Expression will be correlated with vascular density. 2. Assess the importance of Cyr61,
10
Melanoma
Tissue Factor and VEGF during growth of the primary tumor and its metastases using an animal model. Transfected cell lines of uveal melanoma with varying levels of expression of these three genes will be transplanted into the anterior chambers of nude mice, and the growth of the primary ocular tumors, the extent of hepatic lesions, and the vascular density at both sites will be measured. 3. Determine the cellular localization of Cyr61, Tissue Factor and VEGF using a combination of immunocytochemical methods and cellular fractionation. 4. Identify additional angiogenic growth factors (angiopoietin-1) and inhibitors (angiostatin and endostatin) associated with uveal melanoma by RT_PCR, immunoblotting and Northern blot hybridization. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MELANOMA
ANTI-GD3
NKT
CELLS
AS
EFFECTOR
CELLS
AGAINST
Principal Investigator & Institution: Chapman, Paul B.; Associate Attending Physician; Sloan-Kettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2007 Summary: (provided by applicant): GD3 ganglioside is expressed on neuroectodermal tissue and on tumors such as melanoma, sarcoma, and small-cell lung cancer. Antibodies against GD3 can shrink melanoma in rodents and patients. In clinical trials designed to immunize patients against GD3 in the adjuvant setting, we saw surprisingly low relapse rates that did not correlate with induction of anti-GD3 antibodies. Since GD3 is not presented by MHC class I or class II, we considered the alternative possibility that immunization might induce a NKT response against GD3. We have induced CD1restricted NKT cells against GD3 in mice and in this project; we propose to characterize further the anti-GD3 murine NKT cell response. Specific Aim 1 - Define the T cell receptor usage, cytokine profile, and specificity of mouse CD1-restricted NKT cells against GD3. Most murine CD1-restricted NKT cells described to date recognize glycolipids derived from bacteria or invertebrates. Much less is known about CD1restricted NKT cells that recognize self-glycolipids expressed on mammalian cells. Specific Aim 2 - Characterize how GD3 is loaded on to mouse CD1. In the human system, some CD1-restricted glycolipid antigens require internalization and loading in acidified late endosomes; other CD1-restricted glycolipids are loaded in post-Golgi vesicles not requiring acidification. Little is known about how self gangliosides are loaded on to CD1 although in the human system there is some evidence that GM1 ganglioside does not even require internalization to be presented. Using the mouse system, we will characterize how GD3 is loaded on to mouse CD1 assessing requirements for internalization, acidification of endosomes and Golgi function. We plan to map the intracellular processing pathway using confocal immunomicroscopy. Specific Aim 3 -Test the hypothesis that mouse NKT cells against GD3 can mediate antitumor effects in an antigen-specific manner. CD1-restricted NKT cells activated by alpha-galactosylceramide (from marine invertebrates) can mediate antitumor effects in a manner that does not appear to be antigen-specific. It is not known if CD1-restricted NKT cells specific for an antigen expressed on tumor cells can have anti-tumor effects. We will test the ability of CD1-restricted NKT cells against GD3 to lyse GD3+ mouse melanoma in vitro and to reject GD3+ mouse tumors in vivo. This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
11
Project Title: ATYPICAL NEVI IN MELANOMA--A CASE-CONTROL STUDY Principal Investigator & Institution: Titus-Ernstoff, Linda T.; Associate Professor; Community and Family Medicine; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, Nh 03755 Timing: Fiscal Year 2001; Project Start 01-APR-1996; Project End 31-JAN-2002 Summary: Despite substantial interest in atypical nevi as melanoma risk factors and precursors, little is known about risk factors for these lesions, or their role in melanoma etiology. Previous case-control studies that have assessed atypical nevi as melanoma risk factors were small and/or clinic based. Similarly, only a few small, clinic-based studies have examined risk factors for atypical nevi. Our primary aims are to 1) conduct a large, population-based, case-control study of nonfamilial melanoma to evaluate atypical nevi, benign nevi, sun sensitivity, and solar exposure as risk factors, and 2) conduct a large, population-based evaluation of risk factors for atypical nevi. In separate analyses, we will explore risk factors associated with melanoma subgroups based on a) presence or absence of atypical nevi, and b) tumor histologic type. As a tertiary aim, we propose a validation substudy that will evaluate whether subjects can accurately selfdiagnose atypical nevi. At least 535 cases of melanoma, ascertained through the NH State Cancer Registry, will be enrolled over a five year study period. We will enroll 800 population controls identified from drivers' license lists (age 65 or less), and medicare beneficiary lists (age greater than 65). Consenting subjects will complete a telephone interview, conduct skin self-examination, and participate in a dermatologist-conducted skin examination. Based on the dermatology examination, all subjects will be classified as "with" or "without" atypical nevi. Our statistical approach will include two primary case-control analyses to evaluate 1) risk factors for melanoma, and 2) risk factors for atypical nevi. In addition, we will conduct separate case-control comparisons to explore risk factors for specific melanoma subsets. Our approach will elucidate the etiology of melanoma, and identify risk factors for atypical nevi. Finally, we will evaluate subjects' ability to self-screen for atypical nevi by comparing the results of self-examination to the results of the dermatologist examination. The ability to self-diagnose atypical nevi has important implications for melanoma prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: AUTOLOGOUS HAPTEN MODIFIED VACCINE FOR HUMAN CANCER Principal Investigator & Institution: Berd, David A.; Professor of Medicine; Medicine; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2001; Project Start 01-MAY-1985; Project End 31-MAR-2003 Summary: We have developed a novel approach to immunotherapy of human cancer: autologous tumor cells modified with the hapten, dinitrophenyl (DNP). Administration of DNP-vaccine to patients with metastatic melanoma induces a unique response - the development of inflammation in metastatic masses. Histologically, this response is characterized by infiltration of activated T cells that are predominantly CD8+. Moreover, molecular analysis of the T cell receptor (TCR) structures within metastases indicates that the T cell infiltration consists, at least in part, of novel T cell clones not found in pre-treatment metastases. Occasionally, administration of DNP-vaccine results in regression of established metastases; small lung metastases are most likely to respond. Moreover, administration of DNP-vaccine to melanoma patients with bulky regional node metastases following lymphadenectomy results in a remarkably high
12
Melanoma
relapse-free (about 45 percent) and overall (about 58 percent) survival at five years. Now we propose to extend the work in the following directions: 1)Determine whether comparable immunological and clinical results can be obtain with a second tumor type adenocarcinoma of the ovary. Preliminary experiments suggest that patients with stage III ovarian cancer develop delayed-type hypersensitivity (DTH) to autologous tumor cells following administration of DNP-vaccine. We will expand these studies to determine whether the positive immunological response is associated with tumor regression and/or prolonged survival. 2)Determine whether modification with a second hapten, sulfanilic acid, further augments the immunogenicity of melanoma cells. The use of a second hapten, one that modifies peptide residues that are different from those modified by DNP, is based on extensive animal data. We will test the immunogenicity of tumor cells modified with sulfanilic acid and with a combination of DNP and sulfanilic acid. 3)Determine whether haptenized cell membranes can substitute for intact melanoma cells as test materials and immunogen. The substitution of haptenized cell membranes for intact cells has theoretical and practical advantages. We will prepare cell membranes from hapten-modified tumor cells and test their ability to elicit DTH and to immunize patients against intact cells. 4)Characterize the T cell repertoire of lymphocytes infiltrating metastases following hapten-modified vaccine. We will build on the data obtained during the last grant period showing that the lymphocytic infiltration induced by the vaccine represents clonal T cell expansion. Using established molecular techniques, we will characterize the TCR structures found in inflamed and/or regressing metastases. This work may lead to the development of reagents useful in identifying the target antigens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BILIVERDIN IN MELANOMA CELL DIFFERENTIATION Principal Investigator & Institution: Falchuk, Kenneth H.; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: We reported that biliverdin is required for formation of eyes, brain, spinal cord and other dorsal organs in amphibia. Beyond that mandatory requirement for embryogenesis, we found that biliverdin is a pleiotropic molecule capable of altering the phenotypes of a number of cancer cells to a more differentiated state. An early and common behavior caused by biliverdin is an arrest of proliferation in six cancer cells (melanoma, colon adenocarcinoma, liposarcoma, thyroid carcinoma, T and B cell lymphomas). In colon adenocarcinoma, the c Myc oncogene disapp9ears within two days of incubating with 5 x 10-7 M biliverdin. Concurrently, biliverdin slows their G1 to S transition. Subsequently, two differentiation markers, CEA and alkaline phosphatase, are up-regulated. These findings suggest that biliverdin reverses the phenotypic consequences of APC and beta catenin mutations characteristic of colon adenocarcinoma. Central to the current proposal are the documented findings that, like in colon adenocarcinoma, melanoma cells characteristically exhibit mutations in the same signaling system including GSK3beta phosphorylation sites of beta catenin and/or abnormally expressing high amounts of beta catenin itself. These mutations and overexpression lead to an increase in stable cytoplasmic beta catenin and enhanced transcription of beta catenin/Tef/Lef oncogenes, such as c Myc. The common alterations in beta catenin signaling found in colon cancer and melanoma cells calls for examination of the possibility that the dermatological malignancy also may be responsive to the effects of biliverdin and be directed along a differentiation pathway. In favor of this premise is a) our finding that biliverdin arrests cell division if SJ NEK 24 melanoma cell
Studies
13
and b) literature reports that 12-o-tetra decanoyl phorbol 13 acetate (TPA), a molecule that up-regulates heme oxygenase 1 (HO 1) in cancer cells and, therefore, must lead to an increase in biliverdin content of these cells, also inhibits proliferation of melanoma cells. Consequently, we propose to examine the effect of biliverdin on SK MEL 24 phenotype focusing on oncogene molecules transcriptionally regulated by the beta catenin signaling system (Aim 1) and on beta catenin itself and GSK3beta, the enzyme responsible for its phosphorylation and degradation (Aim 2). These two aims will be examined by incubating the SK MEL 24 cells with biliverdin. If the results are positive, we will examined these same molecules in SK MEL 24 cells induced to synthesize biliverdin in response to phenylarsine oxide, a known activator of heme oxygenase 1 (Aim 3). Positive results will demonstrate that melanoma cells can be made to undergo differentiation and open the door to possible novel therapeutic interventions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELL LUMPHOCYTES
BASED
TUMOR
VACCINES
TARGETING
CD4+
T
Principal Investigator & Institution: Ostrand-Rosenberg, Suzanne O.; Professor; Biological Sciences; University of Maryland Balt Co Campus Baltimore, Md 21250 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: We are developing vaccine strategies for inducing immunity to ocular melanoma, the most common malignancy of the eye. Although primary tumor can be treated, 50% of patients develop metastatic disease for which there is no successful therapy. We hypothesize that the generation of tumor-specific, long-term immunity may be a useful therapy for established primary and metastatic disease. During the past 8 years we have developed a unique immunization therapy using genetically modified tumor cell-based vaccines for enhancing antigen presentation of tumor antigens. Our strategy focuses on activating tumor-specific CD4+ T helper lymphocytes. CD4+ T cells are particularly important in anti- tumor immunity because they provide the requisite "help" for optimal CD8+ activity, and because they are critical for long-term memory. We have shown in 3 mouse models that tumor cells transfected with syngeneic MHC class II, CD80 and superantigen genes are potent immunotherapeutic agents. Given the promising animal results, we would like to test our approaches in patients. The animal studies used autologous tumor cells for the "base" vaccine. Autologous human tumor material, however, is not always available, and customization for individual patients is neither cost effective nor feasible. As an alternative approach we will use established human ocular melanoma tumor cell lines as the "base" vaccine. We believe that optimal vaccine efficacy can be achieved if we understand the mechanism by which the vaccines stimulate anti- tumor immunity. We will, therefore, not only assess vaccine efficacy, but also test several hypothesis on which the vaccine strategy is based by performing the following Specific Aims: 1) Identify human ocular melanoma cell lines are the "base" lines for the vaccine, and transfect them with CD80, HLA-DR, and superantigen genes. 2) Determine the ability of the transfectants to stimulate tumor-specific HLA-DR restricted CD4+ T cell responses. 3) Determine if the stage or extent of disease affects patients' ability to respond to the vaccine. 4) Determine if individuals with tumor are "tolerant" to their tumor antigens and hence less likely to respond; and 5) Determine if the vaccines function as antigen presenting cells for tumor-encoded endogenously synthesized antigens. Completion of these studies will provide the framework for conducting a clinical trial, and will provide mechanistic information for further improvement of the vaccines. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
14
Melanoma
•
Project Title: CHARACTERIZATION OF TUMOR SPECIFIC T CELLS IN MELANOMA Principal Investigator & Institution: Lee, Peter P.; Assistant Professor of Medicine; Medicine; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (Applicant's Abstract) The goal of this proposal is to study in detail the biological properties of T cells specific for tumor-associated antigens (TAAs) that arise either de novo (Aim 1) or postvaccination (Aim 2) in patients with melanoma. Using powerful and novel tools such as peptide/MHC tetramers and 10-color FACS analysis, we will assess the expression of up to 45 surface and intracellular markers, cytokine expression, and functional status of TAA-specific T cells isolated directly from melanoma patients. We will also determine the gene expression profiles of such cells (Aim 3) to elucidate the molecular differences between functional and dysfunctional TAA-specific T cell populations. By correlating these data with the clinical state of the patient from which each population is isolated and the eventual clinical outcome, we hope to understand why TAA-specific T cells are protective in some patients but not in others. Lastly, we will dissect the factors which mediate T cell dysfunction in cancer by testing various individual and combinations of immunomodulatory agents to induce or reverse T cell dysfunction (Aim 4). Together, these data should lead to a better understanding of the biology of the T cell response to melanoma, and may lead to improvements in current cancer immunotherapy approaches. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHEMO AND CYTOKINE IMMUNOTHERAPY IN HIGH RISK MELANOMA Principal Investigator & Institution: Atkins, Michael; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: Cytokine-based therapy has shown considerable promise in melanoma, producing high-quality responses and freedom from relapse in some patients with Stage IV or high-risk Stage III disease. Interferon alpha, FDA approved in 1996, is able to prevent relapse in up to 1/3 of patients with high-risk melanoma, with high-dose IL-2, FDA approval in 1998, produces durable responses in a 6-10% of patients with distant metastases. Efforts to improve upon these approaches have to date been unsuccessful. Perhaps the most promising approach involves combinations of IL-2 and IFN with chemotherapy, so called biochemotherapy. We developed a concurrent biochemotherapy regimen (cisplatin, vinblastine, DTIC, IL-2 and IFN) that produces tumor responses in about 45-50% of patients with metastatic melanoma and is sufficiently tolerable and practical to allow for testing in a Cooperative Group setting. This regimen in currently being explored in two large phase II Intergroup trials: a) E3695 that compares the concurrent biochemotherapy regimen with CVD chemotherapy in patients with Stage IV disease and b) SOOO8 that compares 3 cycles of biochemotherapy to a year of the standard high dose IFN in patients with stage III disease. In this project, patients treated on these two trials, as well those treated at DF/HCC institutions on similar treatments, will be asked to provide serial samples of blood, tumor and lymph node tissue. This material will be analyzed in a variety of ways to determine the mechanisms of responses and resistance to cytokine-based and cytotoxic therapy. Evidence of generation of specific immunity directed against melanoma antigens will be assessed using tetramer and ELISPOT analyses against
Studies
15
defined melanoma peptide antigens and autologous tumor cells. Results will then by correlated with tumor response, therapy and disease status. The memory and homing properties of tetramer reactive cells will be explored using multi-parameter flow cytometry in order to determine the characteristics of T cells that best correlate with long acting immunity to melanoma antigens. In addition, T cell receptor signaling properties of peripheral blood T cells will be examined for evidence of tumor based immune dysfunction and the results correlated with treatment, disease status, and effects of therapy. Finally, melanoma tissues will be examined for the presence of various recently discovered factors associated with resistance to apoptosis (STAT1 and 2, STAT 3, Flip, Apaf-1 etc) and the findings will be correlated with treatment, treatment results and disease status. Taken together, this ambitious evaluation, should fully define the capabilities and limitations of existing therapies for advanced melanoma and, as such, will pave the way for the application of new treatments, perhaps in combination with the most promising of these standard approaches. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHEMOPREVENTION IN AN INDUCIBLE MOUSE MELANOMA MODEL Principal Investigator & Institution: Spanjaard, Remco A.; Associate Professor; Otolaryn & Head & Neck Surgery; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118 Timing: Fiscal Year 2003; Project Start 25-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): The number of cases of malignant cutaneous melanoma has been rising at an alarming rate over the last decades, at about 4% per year, and it has been estimated that up to 1 in 80 Americans will develop melanoma. Despite years of research, there are no viable treatment modalities for advanced melanoma, and mortality rates remain exceptionally high. This saddening fact emphasizes the urgent need for new effective drugs, not only to treat existing tumors, but also to inhibit occurrence of second primary cancers after convential treatment modalities, or prevent further transformation of premalignant cells in high-risk patients. This application aims to address these issues by assessing the chemopreventive activity of a promising selection of drugs in a novel, inducible murine melanoma model. This uniquely suitable model is the only one to allow synchronization of the onset of development of cutaneous melanoma on a genetic background, which accurately mimics that of human disease. By adding doxycyclin (Dox) to the drinking water, expression of H-RASV12G is induced in melanocytes on a p16INK4A-ARF null background. This cooperativity then results in development of largely non-metastatic, cutaneous melanomas in 25% of mice with an average latency of 60 26 days. The mouse model itself has already been thoroughly analyzed in terms of tumor pathology, which closely resembles that of human disease, and the essential role for H-Ras in maintaining tumor growth. However, these mice have never been used to develop new chemoprevention protocols. We will test the efficacy of the following drugs: suberohydroxamic acid (SHA), celecoxib, retinoic acid (RA) and lovastatin. These drugs were selected because they i) are non-toxic (except for RA, but 13-cisRA provides a less toxic clinical alternative), ii) are widely used already, iii) affect different biochemical pathways, iv) have shown promise as chemopreventive agents in other studies, and v) have shown potential to enhance each other's activity when combined. Our working hypothesis is that these drugs will inhibit tumor growth to some degree, but that the combination of at least some of these drugs will inhibit proliferation of premalignant melanoma cells to a much larger extent than any drug alone can achieve, without
16
Melanoma
significantly increasing toxicity. We propose to induce 4-week old animals drugs, and determine chemopreventive antitumor efficacy by monitoring size, number and location of skin tumors. Specific Aim I proposes to establish an optimal chemoprevention drug protocol to suppress tumor development. Specific Aim II proposes to establish expression of key cell cycle regulatory genes in control, drug-responsive and nonresponsive transgenic tumors to determine whether expression is associated with tumor growth and responsiveness to therapy. The results of these experiments in this inducible melanoma model will allow us to assess whether our protocol should be considered for use in phase I trials in high risk patients, which is the long term goal of this application. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLASSIFICATION OF AMBIGUOUS MELANOCYTIC TUMORS Principal Investigator & Institution: Bastian, Boris C.; Assistant Clinical Professor; Cancer Center; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2002; Project Start 25-SEP-2002; Project End 31-JUL-2006 Summary: (provided by applicant) While current histopathological criteria permit classifying the majority of melanocytic tumors as either benign nevi or melanoma, welldocumented uncertainty exists in a significant number of cases. Misclassification results in inappropriate over- or under-treatment of patients. Our recent work using comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) on primary tumors has shown that the pattern of genomic aberrations differs significantly between clearly identifiable melanoma and benign nevi. The vast majority of primary melanomas have multiple chromosomal aberrations, whereas the vast majority of nevi do not have any. The few benign nevi that do have aberrations typically have a very restricted set, which does not occur in melanoma. This project will determine if a similar genomic analysis would help distinguish between benign and malignant lesions that are ambiguous by current histopathological criteria, and if those morphological criteria can be improved. In this project we will use two separate cohorts of histologically ambiguous melanocytic tumors that have extensive follow-up in order to systematically screen for genomic and histopathological markers that can predict outcome. The first cohort will serve as a training set and the second as a test set for validation. Cases will be contributed by a panel of internationally recognized pathologists with great expertise in melanocytic tumors. The genomic analysis will take advantage of array-based CGH. This technology has recently been developed in our laboratories and provides a resolution of approximately 1 megabase across the human genome. This technique can be performed with small amounts of DNA extracted from routinely fixed archival tissue from primary tumors. First, we will use array CGH on the training set to screen for genomic aberrations that distinguish metastasizing and nonmetastasizing cases and the expert panel will use these same tumors to develop improved morphological classification criteria. The genetic and morphological criteria will be built into classification rules using the training set. The vies that work best on the training set will be validated on the independent set of tumors. Finally, we will implement the genomic rule in form of hybridization probes for a few specific loci and develop a FISH-based test. The long-term goals of this project are to find genetic and morphological criteria that can classify melanocytic tumors that are low ambiguous and to develop a prototype clinical test for this purpose. Such a test would be of significant clinical relevance, as it would help to identify patients who need additional treatment, and prevent others from getting inappropriately aggressive treatment. In addition, this
Studies
17
project will provide a detailed view of the aberrations found in melanocytic tumors, their prevalence and prognostic relevance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL RELEVANCE OF MICROMETASTASES IN MELANOMA Principal Investigator & Institution: Ghossein, Ronald A.; Professor; Sloan-Kettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: The candidate is a diagnostic surgical pathologist whose immediate research goals are the detection and molecular characterization of circulating tumor cells (CTC) and micrometastases in solid tumors, especially in malignant melanoma (MM). His long term goals are the 1) development of these molecular tests into clinically relevant prognostic markers and 2) an in depth analysis of the mechanisms of metastases in solid tumors. Memorial Sloan-Kettering Cancer Center has the clinical and laboratory facilities appropriate for the development of junior faculty members into independent researchers, and for the conduct of this type of research. There is a need for better prognostic markers in advanced MM. The objectives of this proposal are to assess the prognostic significance of CTC and bone marrow (BM) micrometastases in patients with advanced melanoma (i.e patients with melanoma >4mm thickness, with lymph node or distant metastases). Blood and BM from 250 patients with advanced melanoma who were rendered surgically free of disease will be tested for CTC and micrometastases using reverse transcriptase po1yrnerase chain reaction (RT PCR) for the presence of tyrosinase, MART1/Melan-A and GAGE mRNAs. The test data will be correlated with outcome and other clinico-pathologic parameters - The investigators will also study the variation in blood RT PCR results in relation to serial sampling and its prognostic significance. The expression of these markers will be also studied in the primary tumors and metastatic tissue deposits by immunohistochemistry and RT PCR. This latter tissue data will be correlated with the RT PCR tests for CTC and BM micrometastases in order to study how these markers are modified during the metastatic process. This will increase our understanding of the metastatic process in MM, and provide new prognostic markers aimed at better stratifying and therefore more accurately treat MM patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: COARSE MELANIN IN HUMAN MELANOMA Principal Investigator & Institution: Pawelek, John M.; Senior Research Scientist; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: A clinical feature of primary cutaneous melanoma is variegate pigmentation, yet little is known of its cellular basis. Clark (1977) observed melanoma cells with "melanin deposited in a coarsely granular fashion, commonly seen in vertical phase melanomas". The purpose of this study was to investigate these coarse melanin structures and their potential role in melanoma progression. Archival biopsies of primary and metastatic melanomas were surveyed for coarse melanin-containing melanoma cells and characterized through immunohistochemistry. In 14 of 18 cases of primary vertical phase tumors, coarse melanin structures were found in hypermelanotic areas in both melanoma cells and melanophages. The structures had a characteristic glycosylation pattern of beta 1-6 branched N-glycans, detected by staining with the lectin LPHA. They also stained with HMB45 and anti-CD63 (phagolysosomal membrane
18
Melanoma
component. Thus, coarse melanin was associated with phagolysosomal membrane component). Thus, coarse melanin was associated with phagolysosomal vesicles having melanosomal components. Further, similar vesicles were detected in non-melanized melanomas, staining positively for LPHA, HMB45, and CD63, yet lacking melanin. Since betaI-6 branched N-glycans are highly correlated with metastasis, and are indicators of poor prognosis in breast and colon carcinomas, the possibility is raised that these LPHA-staining melanoma cells may be involved in metastatic progression. Consistent with this, an initial survey of archival melanoma metastases revealed an abundance of cells with coarse melanin vesicles. The purpose of this study is to expand our initial observations to a larger cohort of primary and metastatic melanomas, matched from individual patients, to determine the prevalence and distribution of such vesicles in melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTROL OF EYE MELANOMA METASTASIS Principal Investigator & Institution: Grossniklaus, Hans E.; Professor; Ophthalmology; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2001; Project Start 05-MAR-2001; Project End 31-JAN-2004 Summary: (provided by applicant): The long-term goals of this research are to identify compounds that may be used in human trials to prevent and control eye melanoma metastasis. Despite advances in the treatment of primary ocular melanoma, there been no decrease in the mortality rate of this disease. In humans, ocular melanoma often spreads to the liver as micrometastases that have the potential to grow into vascularized metastases and lead to death. There is evidence that downregulation of the natural killer (NK) response is associated with an increase in micrometastases, and upregulation with immunotherapeutic agents such as interferon (IFN) decrease the number of micrometastases. Additionally, there is evidence that primary ocular melanoma produces angiostatin, an anti-angiogenic compound that suppresses growth of micrometastases into vascularized metastases. The objective of this proposal is to test the mechanisms of immunotherapeutic and anti-angiogenic/anti-melanoma invasion agents in a murine model of ocular melanoma that spreads to the liver and causes micrometastases that potentially grow into metastases. Intramuscular (IM) injections of IFN alpha-2b wil1 be given prior to enucleation and subcutaneous (SC) injections of angiostatin will be given just after enucleation of the eyes that contain melanoma. The IFN will eliminate micrometastases by enhancing the host NK response. Both the IFN and angiostatin will prevent the progression of micrometastases into metastases by antiangiogenesis. Angiostatin will prevent metastases by an anti-melanoma invasion effect. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--IMMUNE MONITORING Principal Investigator & Institution: Mier, James W.; Associate Professor of Medicine; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: The Immunologic Monitoring Laboratory (IML) will serve three of the five primary projects and two of the developmental projects of this SPORE application. This laboratory has two primary responsibilities: 1) It will perform the majority of assays proposed to assess the effects of treatment (e.g. with dendritic cell vaccines, biochemotherapy) on the number, phenotype, and function of melanoma antigenspecific T cells isolated from serial blood specimens, lymph nodes, and tumor biopsies.
Studies
19
These assays will consist primarily of peptide- and tumor cell-based ELISPOT analyses, tetramer analyses, as well as assays of cytolytic activity, cytokine induction and proliferation. 2.) The IML will also be responsible for the studies proposed to evaluate the homing characteristics of cutaneous T cell lymphoma (CTCL) cells (Project 3) and those of lymphocytes obtained from the blood, lymph nodes, or tumor tissues of melanoma patients (Projects 4 and 5). These assays consist of extensive multi-parameter flow cytometry studies of adhesion molecule and chemokine receptor expression. The laboratory studies conducted by the IML will determine the extent to which various immune-based therapies immunize patients against melanoma antigens and the extent to which the results of surrogate assays of specific immune responses correlate with treatment outcome and other clinical parameters. They will also provide a great deal of new information about the chemokine receptors and adhesion molecules expressed by CTCL cells and by the PBL and TIL of patients undergoing immunotherapy for melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DENDRITIC CELL-BASED GENETIC IMMUNOTHERAPY FOR MELANOMA Principal Investigator & Institution: Economou, James S.; Surgery; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2003; Project Start 01-JAN-1999; Project End 31-JAN-2007 Summary: (provided by applicant): This is a competitive renewal for ROI CA79976 "Dendritic cell-based genetic immunotherapy for melanoma" in which we request support for years 05-08. Our accomplishments in the previous funding period include: 1. defining the immunological events taking place in a murine melanoma model using dendritic cell (DC) engineered with a defined tumor antigen MART-1, 2. completing a phase l/II clinical trial in melanoma patients receiving MART-1/27-35 peptide pulsed DC and 3. opening a gene therapy trial using adenovirus (AdV) MART-1-transduced DC. Based on this progress, we propose to continue our translational studies of genetic immunotherapy of human melanoma centered around three specific aims. Aim 1: Genetic Immunotherapy in a CDS-Deficient Environment. We have made the remarkable and original observations that CD8 or Class I knock out mice immunized with AdVMART1-transduced DC have superior levels of protection to B16 melanoma than wild type (wt) mice. Since wt mice depleted of CD8 cells are unable to generate protective immunity, CD8 KO mice have developed a compensatory mechanism from generating robust tumor immunity to DC vaccination. We present preliminary evidence that this antitumor immunity is mediated by collaboration between effector cells of the innate (NK-like) and adaptive (CD4) arms of the immune systems. We propose to characterize the underlying mechanism. Aim 2: The Biology of Class I and Class IIRestricted T Cell Responses in AdVMART1/DC Immunized Patients with Melanoma. This clinical trial, in which patients with stage IV MART-1-positive melanoma are immunized with AdVMART1/DC, provides a unique opportunity to define immunological events triggered by genetic immunization to a defined "self" tumor antigen. Only two epitopes have been described for this small protein-HLA-A2.1restricted MART-1/27-35 and HLA-DK4 restricted MART-1/51-73. Using ELISPOT and tetramer assays for this class I and II epitopes, we will quantitate, isolate and study MART-1-reactive CD8 and CD4 T cell in immunized patients. We will also study the role of determinant spreading and cross-presentation in clinical response, the biology of DC used for vaccination and the possible participation of innate (NK) immunity in DCbased immunotherapy. Aim 3: CTLA4 Blockade in Clinical Dendritic Cell-Based
20
Melanoma
Immunotherapy. DC-based immunotherapy generates occasional but dramatic clinical antitumor responses. We have closely studied one subject in whom the administration of MART-1/DC vaccines was followed by a CTLA4 blocking antibody. Immunological analysis suggests that the antitumor immune response initiated by the DC vaccines was maintained by CTLA4 blockade. To test this hypothesis, we have designed a phase II randomized trial with the primary goal of detecting the effect of MART-1/27-35/DC + CTLA4 blockade on the frequency of melanoma antigen-specific activated T cells using ELISPOT assays. This trial will provide insight in the autoregulatory mechanisms that govern the activity of DC-based immunotherapy. In summary, we propose to continue our translational program in genetic immunotherapy with an emphasis on immune mechanism and clinical hypothesis-testing. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DENDRITIC CELL-BASED VACCINES IN STAGE IV MELANOMA PATIENTS Principal Investigator & Institution: Nickoloff, Brian J.; Professor; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2001; Project Start 30-SEP-1992; Project End 31-MAR-2006 Summary: The purpose is to perform carefully controlled vaccine-based trials to determine the optimal therapeutic approach by which tumor reactive T lymphocytes can be safely and efficiently generated for treatment of advanced melanoma patients, coupled with alternative methods of immunological monitoring that move beyond changes in the blood to detailed cellular and molecular tissue-based analyses. Since melanoma will be diagnosed in 43,000 new patients annually, and 7,300 deaths result from melanoma, new treatment approaches are indicated because melanoma generally progresses despite conventional chemotherapy and radiation. A promising approach for melanoma involves immunotherapy in which the patient's immuno system is stimulated to generate effective anti-tumor responses. The primary antigen presenting cell used in these trials are dendritic cells (DCs) pulsed with autologous tumor-cell lysate containing T-cell stimulatory tumor cell-derived antigens. Incentives for this immunotherapy approach include the capacity of appropriately selected DCs to stimulate both CD4+ as well as CD8+ effector T cells. Our therapeutic strategy is designed to by-pass several known methods by which melanoma cells normally thwart the immune system. Thus, we will expand both immature and mature DCs ex-vivo (using CD40L) apart from the systemic immunosuppressive factors produced by melanoma cells, and create lysates from autologous tumor cells. Studies are designed to identify immunological in-vivo activity in blood, and at various tissue sites for mature versus immature DCs, and the preferred method of vaccination, to generate the highest number of cytotoxic T cells and positive clinical responses. Since many Stage IV patients will not respond to treatment with complete remissions, focus will be directed at methods to monitor and explore the mechanistic basis by which tumor cells escape the activated immune response following vaccination. Specific protocols include an initial randomized Phase I study of 24 patients to compare immature DCs versus mature DCs loaded with tumor lysate-containing antigens injected intradermally, followed by a randomized Phase II clinical trial of 40 patients using the best DC (immature vs. mature) and comparing intradermal versus intranodal routes of delivery. Immunological monitoring of patients will include a comparison of traditional blood-derived markers versus assays performed on cells with serial gene profiling of samples derived from sequential fine needle aspirates of metastatic melanoma lesions before and after vaccination, as well as normal lymph nodes and the sentinel node draining from
Studies
21
vaccination sites. The vaccination site itself will also be examined in the phase I trial comparing the local tissue response to mature versus immature DCs. Taken together the guiding tenant of this grant is that we can best mimic the physiological protective immune pathway by carefully isolating specific types of DCs and exposing them ex-vivo to appropriate tumor antigens, followed by re-infusing them in a manner that takes advantage of the immunological potency of DCs, with concommitant avoidance or bypassing local and systemic immunosuppressive or immune-escape mechanisms created by melanoma cells. In this way greater understanding and better treatment protocols and immunological monitoring strategies will be developed for patients undergoing vaccination to eliminate metastatic melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETECTION OF METASTASIS ASSOCIATED ANTIGENS IN MELANOMA Principal Investigator & Institution: Hamby, Carl V.; Microbiology and Immunology; New York Medical College Valhalla, Ny 10595 Timing: Fiscal Year 1999; Project Start 06-APR-1999; Project End 31-MAR-2004 Summary: (adapted from the investigator's abstract) The major cause of mortality in patients with malignant melanoma is metastatic dissemination of primary tumors. Currently, there are no highly specific cellular markers for evaluating the metastatic potential of primary melanoma tumors. The long-term goals of this project are to discover diagnostic markers for the early detection of metastatic disease in patients with melanoma and to evaluate these markers as prognostic indicators for the clinical course of disease. To identify these molecules we proposed to use a phage display library of human single-chain variable fragment (scFv) antibodies. The library contains >108 different scFv antibody specificities, which they expect is sufficiently diverse to contain scFv antibodies recognizing metastasis-associated antigens. They will utilize a panning procedure to select a subset of scFv antibodies that bind to a line of cultured human melanoma tumor cells, which are highly metastatic in nude mice. From this subset they will remove scFv antibodies that can bind to an autologous subline of weakly metastatic human melanoma tumor cells. The scFv that remain will be screened for reactivity against tissue samples of primary tumor and metastatic lesions obtained from melanoma patients. They expect to discover scFv antibodies that specifically recognize metastasis-associated antigens in human melanoma lesions. These scFv antibodies will be used for the development of early diagnostic markers and prognostic indicators of metastatic dissemination of human melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MELANOMA
DIRECT
COMPARISON
DENDRITIC
CELL
VACCINES
IN
Principal Investigator & Institution: Halusa, Frank; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: Melanoma is a lethal malignancy that is poorly responsive to conventional treatments, but it is potentially an immunoresponsive disease. Several approaches to melanoma immunotherapy have demonstrated the feasibility of eliciting RT cell responses to melanoma- associated antigens. In this proposal we focus on the use of dendritic cells (DC) to induce anti-tumor immunity in patients with advanced melanoma. Because of the manner in which they process protein, express co-stimulatory
22
Melanoma
molecules, and elaborate cytokines that support the development of cytolytic T lymphocyte (CTL) responses, DC are uniquely capable of antigen presentation. They appear to be ideal vehicles for delivery of antigen in tumor vaccination strategies. However, the optimum strategy for antigen delivery has not been determined. Our laboratories have in parallel studied two methodologies for antigen delivery: peptide pulsing of DC with melanoma antigen-derived peptide epitopes, and production of cell fusions between DC and tumor cells. We carried out pre-clinical studies on DC production and function. In doing so, we demonstrated our ability to reliably produce DC in high yields by culturing PBMCs obtained via leukapheresis. Phenotypic and functional analyses showed that these cells express a profile of cell-surface markers characteristic of DC. Concurrently we utilized DC to verify that specific substitutions of the gp100 280 epitope result in peptides that bind to HLA-A2 with higher affinity than the native epitope. Based on these studies, w4e are carrying out a phase I, dose escalation trial of peptide- pulsed DC therapy. To date we have shown that this approach is safe. Immunogenicity of vaccination has been documented by the production of CTL specific for the immunizing antigen, and clinical responses have been observed. We also studied the production of DC/tumor fusions. Pre- clinical data demonstrated our ability to generate heterokaryons from DC and breast, ovary, renal cell and melanoma tumors. Such hybridomas express both DC-derived co-stimulatory molecules and tumor-associated antigens and reproducibly stimulate the production of anti-tumor T cell immunity in vitro. We are conducting a phase I trial and preliminary have demonstrated that clinical administration of DC/tumor fusion is safe. DC/fusions also elicit T cell anti-tumor immunity, documented by enhanced interferon secretion in response to stimulation by tumor. Based on these pre-clinical and phase I clinical data, we propose to translate these findings into a phase II, randomized clinical study. Patients will be recruited to both approaches using uniform eligibility criteria at our four institutions. The primary endpoint of the study is the comparison of immunologic data obtained from the approaches. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DORMANCY VERSUS PROGRESSION OF HUMAN PRIMARY MELANOMA Principal Investigator & Institution: Kerbel, Robert S.; Director; Sunnybrook & Women's Coll Hlth Scis Ctr Health Sciences Centre Toronto, Timing: Fiscal Year 2001; Project Start 01-JUN-1992; Project End 31-DEC-2002 Summary: (adapted from the investigator's abstract) The majority of primary cutaneous melanomas go through a prolonged period of dormant growth before acquiring malignant properties. Unlike most other primary tumors, however, this dormancy stage is visible in melanomas, subdermal/orthotopic injection of human melanoma cell lines, obtained from different stages of disease progression, into nude mice. Thus, whereas almost all advanced stage primary or metastatic-derived cell lines give rise to progressively small slow-growing, plaque-like lesions -- similar to radial growth phase (RGP) or thin vertical growth phase (VGP) tumors in humans. Using various methods, e.g. retroviral insertional mutagenesis or gene transfection, this applicant has recently succeeded in isolating tumorigenic variants from a number of such early-stage primary melanomas. These cell lines present an outstanding opportunity to study the basis of pre-malignant melanoma dormancy and the reasons for its termination. First, (based on their recent results), they believe there are three major interconnected factors which govern primary melanoma dormancy. These are: (i) sensitivity to inhibitory controls mediated by several cytokines, including IL-6; (ii) a deficient capacity of melanoma cells
Studies
23
to survive in a multicellular growth context; (iii) a deficient ability to induce angiogenesis; Second, overcoming these 'defects' results in acquisition of overt malignant growth characteristics. Third, genetic alterations thought to be involved in the progression of melanomas, such as loss of p21WAF1 or p16INK4, do so by affecting several, or all three phenotypes simultaneously (i.e., cell proliferation, survival, and angiogenesis). Examination of these hypotheses comprise the three specific aims of the research program. The proposed research will shed new light on what is probably the most crucial stage of melanoma progression, but which, thus far, has received little experimental scrutiny because of the lack of appropriate experimental models. It may also serve as a model for factors influencing premalignant-primary tumor dormancy in other types of cancer where access to early-stage lesional material is severely limited, or non-existent. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ECM MATRIX, PROTEASE AND MELANOMA PROLIFERATION Principal Investigator & Institution: Declerck, Yves A.; Vice President Research, and Director Re; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, Ca 90027 Timing: Fiscal Year 2003; Project Start 10-JAN-2003; Project End 31-DEC-2007 Summary: (provided by applicant): The extracellular matrix (ECM) is a microenvironmental factor that controls cell function. The central theme of this grant proposal is the investigation of the mechanisms by which the ECM controls tumor cell proliferation and how they are affected by proteolytic degradation. We postulate that modification of the ECM by proteases, and in particular matrix metalloproteinases (MMPs), alters the contact between tumor cells and matrix proteins, which subsequently influences the expression of proteins controlling the cell cycle, to favor cell proliferation. In support of this concept we have published observations demonstrating that upon contact with intact fibrillar type I collagen, human M24met melanoma cells are growth arrested at the GI/S interphase and that this arrest involves a specific up-regulation of the cell cyclin dependent kinase inhibitor p27KIP1 (Henriet et al., PNAS, 97:10026-10031, 2000). We have now obtained evidence that up-regulation of p27KIP1 is the consequence of a down-regulation of the S phase kinase associated protein 2 (Skp2) that binds p27KIP1 to ubiquitin conjugase and targets it for degradation by proteasomes. We discovered that down-regulation of Skp2 is dependent on protein kinase Cd (PKCd) activity and have obtained preliminary evidence suggesting that this ECM-dependent regulatory pathway is functional in other melanoma and non-melanoma tumor cell lines. In contrast, in the presence of denatured, non-fibrillar collagen (gelatin), p27KIP1 is down-regulated, cells spread, the focal adhesion kinase protein p125 FAK is phosphorylated, and cells enter into cell cycle. On the basis of these observations, we hypothesize that proteolytic degradation of fibrillar collagen by melanoma cells is necessary to down-regulate p27KIP1, establish functional focal adhesions, and enter the cell cycle, and that preventing collagen deg radation will inhibit cell growth in a p27KIP1/Skp2 dependent manner. Our proposal has 4 specific aims. In the first specific aim we will explore the signaling pathway by which contact with fibrillar collagen activates PKCd and down-regulates Skp2, and obtain proof that p27 and Skp2 are the main regulators downstream of PKCd. In a second specific aim, we will explore the signaling pathway by which contact with denatured and proteolyzed collagen promotes cell proliferation and will determine the role of RhoA, p27KIP1 and Skp2 in this pathway. In the third specific aim, we will examine how proteolytic modification of fibrillar collagen by MMPs changes the environment from growth inhibitory to growth permissive. In a fourth specific aim we will validate our observations in a murine model
24
Melanoma
of melanoma growth and in human melanoma tumor specimens. This information will lead to a better understanding of the role of matrix degrading proteases such as MMPs in cancer, which will be important in the design of better clinical trials involving MMP inhibitors in cancer therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENHANCEMENT OF IMMUNOGENICITY OF HUMAN MELANOMA VACCINE Principal Investigator & Institution: Hsueh, Eddy C.; John Wayne Cancer Institute 2200 Santa Monica Blvd Santa Monica, Ca 90404 Timing: Fiscal Year 2001; Project Start 01-AUG-2000; Project End 31-JUL-2005 Summary: Our group has demonstrated the clinical promise of a whole-cell vaccine composed of irradiated but viable melanoma cells from three human melanoma cell lines (M10, M24, and M101). Because melanoma cells also can express receptors for cytokines currently used in invitro expansion and activation of dendritic cells, we hypothesized that the efficacy of a human whole-cell melanoma vaccine could be significantly increased by using these cytokines to upregulate vaccine expression of costimulatory molecules. This study's objective is to demonstrate the induction of significant immune responses in patients receiving a cytokine- modified M24 whole-cell vaccine for treatment of regional or distant metastatic melanoma. There are three specific aims: 1. To determine whether certain cytokines such as interleukin 4, granuloctye macrophage-colony stimulating factor, and tumor necrosis factor-alpha can upregulate expression of multiple costimulatory molecules (CD54, CD58, CD80, and CD86) on human melanoma cells. 2. To determine how the coexpression of multiple costimulatory molecules and tumor antigens on melanoma cells affects the activation of T cells, the induction of autologous tumor-specific cellular cytotoxicity, and induction of specific cytotoxic T cells against MAGE1, MAGE3, and tyrosinase peptide epitopes. 3. To determine if administration of a cytokine- modified melanoma cell vaccine can induce significant immunological responses, specifically delayed-type hypersensitivity, cellular cytotoxicity, and complement-dependent cytotoxicity, in HLA haplotypematched melanoma patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EVOLUTION OF ANTIMETASTATIC ENZYME Principal Investigator & Institution: Smider, Vaughn V.; Integrigen, Inc. 42 Digital Dr, Ste 6 Novato, Ca 94949 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 31-DEC-2003 Summary: (provided by applicant): Cancer is a devastating disease with few cures. Most treatments rely on damaging cellular DNA or disrupting the cell cycle in tumor cells. Metastatic melanoma is especially devastating, as it is often rapidly fatal due to its relative resistance to conventional chemo and radiation therapy. However, a novel pathway involved in tumorigenesis and metastasis in melanoma and other cancers is activated by the amino acid tyrosine. Remarkably, tumor invasion and metastases are suppressed by depletion of tyrosine in melanoma cell lines, as well as mouse models. Tyrosine depletion can be accomplished by dietary restriction or through catabolism by the enzyme tyrosine phenol-lyase (TPL). The activity of TPL as measured by Km is low, requiring large amounts of the enzyme for further animal investigation or eventual human therapy. "DNA shuffling" is one method capable of evolving enhanced proteins through a DNA homology based process. This method, however, is not applicable to
Studies
25
TPL because its structural homologs are not similar at the DNA level. IntegriGen is developing a method to non-homologously "shuffle" genes. This method will be applied to TPL in order to enhance its function as measured by Km. Thus, this project has two applications: 1) to evolve a novel TPL variant which has enhanced activity, that can subsequently be evaluated as an anti-cancer therapeutic, and 2) to establish a new method to non-homologously "shuffle" genes as a molecular evolution technology applicable in general to protein engineering. PROPOSED COMMERCIAL APPLICATIONS: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GANGLIOSIDE GD2 AS TARGET FOR IMMUNOTHERAPY IN MELANOMA Principal Investigator & Institution: Foon, Kenneth A.; Professor of Medicine; Medicine; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2003; Project Start 01-AUG-1996; Project End 31-AUG-2007 Summary: (Provided by applicant) The objective of this proposal is to apply the antiidiotype (Id) vaccine approach for the therapy of stage III (resected node positive) melanoma patients. Disialoganglioside GD2 is expressed at high density on melanoma cells and will be used as a target for immunotherapy. We have generated a murine monoclonal anti-Id antibody 1A7 (TriGem) which functionally mimics GD2 and acts as a surrogate protein antigen for the ganglioside. In pre-clinical studies, active immunization of mice, rabbits and monkeys with TriGem induced polyclonal IgG antiGD2 responses and TriGemspecific T cell proliferative responses suggesting the generation of CD4+ T cell help. In previous clinical trials, we have demonstrated that patients with advanced metastatic melanoma and patients with high risk melanoma in the postsurgical adjuvant setting generated active immune responses against GD2 following immunization with TriGem. We demonstrated a predominantly IgG polyclonal humoral immune response with specific binding to purified GD2 and GD2 positive cells that mediated antibody-dependent cellular cytotoxicity (ADCC). The vaccinated patients also demonstrated in vitro T cell proliferative responses in the presence of TriGem. Median survival was 16+ months for 47 patients with advanced disease. Eighty-two percent of 69 patients with stage III disease are alive at a median follow up of 2 years. Twenty-five of the 69 patients with stage III disease were treated with high dose interferon Alfa-2b (HDI) plus TriGem. Immune responses were equivalent or superior to TriGem alone and 96 percent are alive and 80 percent are disease free. Toxicity of TriGem was limited to local reactions at the site of injection with occasional mild fevers. In this project, we will conduct a randomized Phase III clinical trial in which 294 patients with node positive local regional melanoma will be stratified by nodal status (IIIA vs IIIB vs IIIC) and then randomized to treatment with either HDI or HDI plus TriGem. The patients will be observed for immune responses and for clinical outcome. We will continue to test the hypothesis that elicitation of a strong immunologic response will eradicate the residual tumor cells, prevent the dissemination of metastatic disease, and prolong survival in high risk patients in the post-surgical adjuvant setting. To achieve this goal, we have proposed four specific aims. The primaryobjective of this clinical study is to compare the effect of HDI versus HDI plus TriGem on relapse free survival. The secondary objective is to compare the effect on overall survival. The third objective is correlation of the quantitative IgG anti-GD2 response with relapse free and overall survival. The fourth is to monitor toxicity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
26
Melanoma
•
Project Title: GENETIC EPIDERMIOLOGY OF MELANOMA Principal Investigator & Institution: Elder, David E.; Professor of Pathology and Laboratory Me; Pathology and Lab Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): The Melanoma Genetics Consortium, comprising groups with diverse expertise from the USA, Europe and Australia, was established in 1997 to facilitate research into: -- the identification and characterisation of melanoma susceptibility genes, and -- the interactions of the effects of these genes with each other, and with relevant environmental exposures -chiefly solar ultraviolet (UV) radiation - in melanoma tumorigenesis. These goals will only be achieved by conducting sufficiently large studies of genetically diverse populations experiencing a range of environmental exposures: objectives beyond the capacity of any single group. The current proposal is specifically motivated by the Consortium's success, over a short period of time, in: -rapidly integrating information from the large number of multiple-case melanoma kindreds ascertained by its individual groups and initiating comparative penetrance and linkage studies, and -- successfully initiating new collaborative projects to map and identify melanoma predisposition genes over the past two years, which have identified significant new candidate loci for melanoma susceptibility genes. The general objectives of this proposal are: -- to maximise the epidemiological and genetic information derived from multiple-case melanoma kindreds ascertained by the Consortium in three continents Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENOME WIDE APPROACH TO MELANOMA CLASSIFICATION Principal Investigator & Institution: Flotte, Thomas; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): The incidence of malignant melanoma is increasing worldwide at rates that have been reported to be between 3 and 7 percent. In the United States, the incidence of melanoma is rising faster than any other malignancy. The overall goal of this project is to evaluate whether gene expression profiling can provide additional diagnostic and prognostic information for patients with malignant melanoma. Despite decades of attempts to identify clinical and histological features that would be useful in predicting which lesions were going to metastasize, only limited success can be claimed. The measured thickness (the Breslow measurement) and the presence or absence of ulceration are the strongest predictors of outcome for localized disease. The identification of patients with a high risk of metastasis is important for the surgical management of the patient as well as to determine which patients should be admitted to clinical trials of adjuvant agents as these become available. A comprehensive knowledge of the genes expressed by melanoma may be helpful in management of these patients. The specific aims are as follows: 1. To use genome-wide gene expression using microarray technology of human metastatic melanoma and congenital nevi in tissue specimens to identify candidates for accurate prognostication of melanoma patients with localized disease (Stages I and II). 2. Develop in situ hybridization assays for the candidate genes identified in Specific Aim 1. The assays will be validated both on from the tissues used in Specific Aim 1 as well as specimens from additional patients. 3. In situ hybridization will be utilized to examine tissue sections of primary melanomas. The pattern of involvement of the primary tumors will be
Studies
27
correlated with clinical outcome. The results will be correlated with known prognostic factors to determine if the information provides additional prognostic information. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIGHLY DIFFERENTIATED TISSUE CULTURE MODELS OF MELANOMA Principal Investigator & Institution: Klausner, Mitchell; Mattek Corporation 200 Homer Ave Ashland, Ma 01721 Timing: Fiscal Year 2002; Project Start 15-AUG-2002; Project End 31-MAR-2003 Summary: (provided by applicant): With the exception of lung cancer in women, the incidence of cutaneous melanoma (CM) is increasing faster than any other cancer. Current estimates are that one of every 75 individuals in the US will contract CM during his or her lifetime. The various stages of melanoma have been well described, however, to devise improved treatments allowing patients to lead longer and more productive lives, a better understanding of progression of CM is needed. The purpose of this proposal is to produce highly differentiated, tissue culture models of the various stages of CM progression. During Phase I, cell lines from the various disease states of CM will be expanded in monolayer culture and characterized. Using a serum free culture system, these cells will be incorporated into an organotypic, full thickness skin model to produce tissue reconstructs which parallel the various stages of CM in vivo. The tissues will be characterized in terms of morphology, tumor progression, and adhesion receptors. Finally, reproducibility of the tissue models will be investigated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IDENTIFICATION OF MELANOMA PREDISPOSITION LOCI Principal Investigator & Institution: Cannon Albright, Lisa A.; Professor; Medical Informatics; University of Utah Salt Lake City, Ut 84102 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2008 Summary: (provided by applicant): Previous investigation of Utah melanoma pedigrees resulted in the identification of the only major melanoma predisposition gene yet identified, cyclin-dependent kinase inhibitor 2A (CDKN2A or p16) (Cannon Albright et al., 1992; Cannon Albright et al., 1994; Kamb et al. 1994). However, only 20-40% of melanoma high-risk pedigrees have a p16 mutation, suggesting that additional melanoma predisposition genes exist. This is also supported by the existence of studied informative melanoma pedigrees that do not have mutations in the coding region of the p16 gene nor demonstrate linkage to the p16 locus on chromosome 9p21. The goal of this project is to identify additional melanoma predisposition genes through the genotypic characterization of Utah high-risk melanoma pedigrees which do not appear to be due to p16, ARF, or CDK4. This investigation will utilize resources that are unique to the University of Utah to identify non-p16 melanoma predisposition genes. These resources include 1) the Utah Population Database (UPDB), which permits identification and recruitment of numerous, extended high-risk melanoma pedigrees and facilitated investigation of the original Utah high-risk pedigree collection used to identify p16 and 2) a highly focused Familial Melanoma Research Clinic (FMRC) that is devoted to the clinical examination and molecular characterization of at-risk relatives in high-risk melanoma pedigrees. We will identify and sample high-risk melanoma pedigrees, perform a genomic search on the pedigrees with no indication of 9p involvement, and fine map any predisposition regions identified. Identification of melanoma predisposition genes will ultimately increase our ability to appropriately screen high-
28
Melanoma
risk patients, and will suggest additional molecular pathways that may serve as targets for the diagnosis and treatment of melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMAGING MALIGNANT MELANOMA WITH RADIOLABELED ALPHA-MSH PEPTIDE ANALOGS Principal Investigator & Institution: Quinn, Thomas P.; Assistant Professor; University of Missouri Columbia 310 Jesse Hall Columbia, Mo 65211 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2008 Summary: (Revised Abstract) (provided by applicant): This application outlines a research effort to develop and evaluate radiolabeled peptides for malignant melanoma imaging. Malignant melanoma is a serious public health problem due to an increase in its incidence and resistance to conventional chemotherapeutics and external beam radiation therapy. Early detection is critical for proper therapeutic management. There is a clear need to develop new and efficacious imaging and therapeutic agents. Our laboratory has developed a new class of metal-cyclized peptide (CCMSH) that target the a-MSH receptor present on melanoma cells. The CCMSH peptides will be radiolabeled with 99mTc, 111In for SPECT and 64Cu for PET imaging of melanoma in murine and human melanoma mouse models. Mice bearing solid tumors and metastatic melanoma in the lungs will be imaged at various times during the course of their disease to determine the detection sensitivity and specificity of the radiolabeled peptides. Micro SPECT and micro PET imaging studies will also be compared to determine the optimal combination of peptide, radionuclide and detection modality for melanoma imaging. The CCMSH imaging agents are envisioned to be part of a matched pair strategy for melanoma imaging and therapy in which the same melanoma targeting vector (CCMSH) can be radiolabeled with radioisotopes that possess imaging or therapeutic properties. We also plan to employ bacteriophage (phage) display technology to discover new melanoma targeting vectors. The random peptide libraries, displaying 5150 peptides per particle, will be selected in human melanoma bearing mice for tumor targeting peptides. In vivo selection strategy should closely simulate the complex targeting environment an imaging agent encounters thus allowing us to select superior melanoma avid phage. We propose to use the tumor avid phage particles themselves as targeting agents in a pretarget approach. The tumor avid phage will be conjugated with <10 copies of Neutravidin per particle. Neutravidin phage will be injected into tumor bearing mice and allowed to localize to the tumor or clear the body over a period of day(s). Indium-111 labeled DTPA-biotin will be injected intravenously and the animals will be imaged over a period of several hours. Pretarget phage imaging will allow us to take advantage of the power of in vivo selection with polyvalent peptide display while not suffering the partitioning consequences of a large radiolabeled molecule. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMMUNITY TO MELANOMA VIA DENDRITIC CELLS Principal Investigator & Institution: Steinman, Ralph M.; Professor & Senior Physician; Lab/Cell Physiol & Immunology; Rockefeller University New York, Ny 100216399 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-JUL-2004 Summary: Human tumor immunology has been advanced by the identification of antigens and the corresponding tumor specific lymphocytes, particularly killer and helper T cells. This program will exploit the dendritic cell [DC] to enhance presentation of melanoma antigens to T cells, primarily in humans but also in mouse models. Our
Studies
29
MHC class I and II products on DCs can be charged with an array of tumor antigens by feeding apoptotic and necrotic cells; 3] antigen-bearing DCs can be charged with an array of tumor antigens by feeding apoptotic and necrotic cells; 3] antigen-bearing DCs can rapidly boost the human immune system in situ. Therefore an integrated program in Dallas and New York can begin to actively immune system in situ. Therefore an integrated program in Dallas and New York can begin to active immunize patients to melanoma antigens, concomitant with laboratory studies to learn to enhance DC processing of tumor antigens, to evaluate the roles of distinct DC subsets and maturation states, and to observe DC function in tumors and lymph nodes in situ. This program emphasizes melanoma, because tumor-specific T cells are known for mice and humans, and it is now evident that DCs an present in vitro melanoma antigens derived from apoptotic cells. Documentation of tumor-specific immunity in humans has become more accessible with quantitative assays that are in place and include: binding of MHC tetramers, production of ELISPOTS, and recall assays to elicit specific killer T cells. The program will include dual center randomized trials. In the first we will compare two types of DC in eliciting immunity to melanoma peptides, and look for speaking of the immune response to other antigens, as an index of cross presentation in vivo. In the second, we will compare DCs loaded with peptides vs. dying tumor cells in expanding tumor specific CD4 and CD8 T cells. Shared ongoing core facilities for administration, DC production, and immune monitoring will energize and standardize interactions. Together, we hypothesize that DCs, nature's adjuvant, will enhance immunity to tumor antigens so that the clinical consequences for cancer vaccination and therapy can be pursued. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNODERMATOLOGICAL THERAPY OF SKIN CANCER Principal Investigator & Institution: Elmets, Craig A.; Professor and Chair; Dermatology; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2001; Project Start 06-JAN-1999; Project End 31-DEC-2003 Summary: Non-melanoma (basal cell and cutaneous squamous cell carcinomas) skin cancer and melanoma are common human malignancies whose growth is controlled at least in part by T-lymphocyte mediate immune responses. There is great interest in developing new modalities which will enhance and exploit this host defense mechanism for therapeutic benefit. We have observed that cutaneous squamous cell carcinomas and melanomas exhibit a profound reduction in tumor growth when treated with the bacterial super- antigen Staphylococcal enterotoxin B (SEB). The response is immunologic in nature and is highly specific for malignant tissue, both in vivo and in vitro. SEB may thus have great potential as a immunodermatologic therapy for skin cancer. In this proposal, we plan to investigate the hypothesis that the bacterial superantigen SEB causes selective destruction of non- melanoma and melanoma skin cancers by serving as a ligand between the tumor cell and cytotoxic T-lymphocytes. We will more fully assess the immunodermatologic potential of SEB as a therapy for skin cancer by studying the range of cutaneous tumors responsive to SEB immunodermatologic therapy. We will also assess the efficacy of mutants SEB as therapeutic agents in skin cancer in order to identify those regions of the molecule most important at causing regression of skin cancers. Studies will be performed to evaluate whether inhibition of tumor cell growth by SEB and T-cells is cytotoxic in nature. Experiments will be conducted to identify the molecule on cutaneous squamous cell carcinomas to which SEB binds that allows it to inhibit the growth of cutaneous tumors. We will be particularly interested in determining whether SEB binding to major histocompatibility
30
Melanoma
complex class I and class II molecules plays a role in the response. Because SEB limits the growth of malignant cells, but has little effect on keratinocytes from which these tumors are derived, we will investigate whether this is due to differential binding on SEB to tumor cells versus normal keratinocytes, differences in the expression of the adhesion molecule ICAM-1 on these two cell types, or to differences in the Fas pathway in normal versus malignant keratinocytes. Finally, experiments will be performed to precisely define the characteristics of the T-cell most effective at causing SEB-induced regression of cutaneous tumors. The ultimate goal of this proposal is to generate new knowledge that can be used to develop new and better strategies for the control of nonmelanoma and melanoma skin cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNOLOGICAL METASTASES
MODULATION
OF
OCULAR
TUMOR
Principal Investigator & Institution: Niederkorn, Jerry Y.; Professor; Ophthalmology; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2002; Project Start 01-JUL-1981; Project End 31-DEC-2006 Summary: (From the Applicant's Abstract): Uveal melanoma is the most common and malignant intraocular tumor in adults. Metastases appear in 19 percent to 35 percent of patients within 5 years of diagnosis of uveal melanoma. The liver is the primary organ for the development of metastases and up to 95 percent of the patients who die from uveal melanoma, have liver metastases. Although the treatment of primary uveal melanoma has improved substantially over the past two decades, there have been no significant advances in the management of metastases and as such, the five year survival time for uveal melanoma patients has not changed in over 25 years. Regretably, there still remains no effective treatment for uveal melanoma metastases. This Research Plan will address three specific aims relating to the immunobiology and therapy of liver metastases, the leading cause of morbidity and mortality in uveal melanoma patients. The proposed studies consider three hypotheses. The first hypothesis proposes that a component of the innate immune system, the natural killer (NK) cell repertoire, is instrumental in controlling metastases arising from intraocular melanomas. A corollary of this hypothesis is that successful uveal melanoma metastases employ a variety of escape mechanisms to thwart NK cell-mediated immune surveillance. The second hypothesis predicts that therapeutic strategies that stimulate NK activity will overcome the NK escape mechanisms of uveal melanomas and will culminate in reduced liver metastases and improved host survival. The third hypothesis predicts that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can be effectively used to treat uveal melanoma liver metastases. The specific aims for this project are: 1) Evaluate and characterize NK cell escape mechanisms employed by uveal melanoma cells; 2) evaluate NK cell-based immunotherapy; and 3) evaluate tumor necrosis factor-relatedapoptosis inducing ligand (TRAIL)based therapy. These studies will utilize a wellcharacterized mouse model that recapitulates the human counterpart. The long rang goal of this project is to design, develop, and evaluate novel immunotherapeutic modalities for the prevention and treatment of uveal melanoma metastases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNOTHERAPY OF MELANOMA WITH DENDRITIC-TUMOR HYBRIDS Principal Investigator & Institution: Shu, Suyu C.; Director; John Wayne Cancer Institute 2200 Santa Monica Blvd Santa Monica, Ca 90404
Studies
31
Timing: Fiscal Year 2002; Project Start 15-APR-2002; Project End 31-MAR-2007 Summary: (provided by applicant): In the John Wayne Cancer Institute, active immunotherapy of melanoma by allogeneic tumor cell (PMCV) vaccination has shown enhanced survival of patients who developed an immune response but only a fraction demonstrates the regression of established metastases. Alternatively, the therapeutic efficacy may be improved if isolated tumorimmune T cells are transferred to the tumorbearing host. We have identified that lymph nodes draining tumor vaccines contain T lymphocytes specifically sensitized to the tumor, but those cells require in vitro activation to differentiate into functional cells. We have designed a clinical protocol to treat patients with metastatic melanoma with such T cells. Although responses were observed in some patients, the majority did not seem to benefit. A theoretically attractive improvement for both active and adoptive immunotherapy will rely on targeted vaccine designs. To induce antigen (Ag)- specific immune responses, host Ag presenting cells (APC) play a pivotal role. Among various APC, dendritic cells (DC) seem to be most potent for eliciting T cell responses. The use of DC for stimulating antitumor immunity has been achieved by pulsing DC with peptides, protein, tumor lysates or RNA derived from neoplastic cells. A new approach is the generation of DCtumor fusion hybrids. Because of technical difficulties, attempts have been made to fuse cells by exposing them to electric fields. Recently, a clinical trial treating patients with metastatic renal cancer with electrofusion of allogeneic DC and autologous tumor cells demonstrated a high response rate (7/17). Fused hybrids should have the ability to elicit both MHC class I- and II-restricted responses by processing and presenting both known and undefined Ag. With this approach, it may be the technique rather than conceptual aspects that limit its transfer to clinic. In animal studies, we have demonstrated that a high fusion efficiency (~35%) by electrofusion. Using PMCV, preliminary results showed at least a 10% fusion rate. In this project, we propose to carry out Phase I/Ii clinical trials and address important questions regarding the biological and immunological functions of autologous DC-allogeneic tumor hybrids generated by electrofusions. The specific aims are: 1) To optimize electrofusion of autologous DC and allogeneic melanoma PMCV cells; 2) To characterize the functions of fused cells for Ag processing and presentation as well as MHC restriction; 3) To conduct Phase I/II clinical trials of immunotherapy of melanoma; 4) To analyze humoral and cellular immune responses of patients undergoing immunotherapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMPROVING RISK ASSESSMENT FOR MELANOMA Principal Investigator & Institution: Colditz, Graham A.; Professor of Medicine and Epidemiology; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: The overarching goals of this Project are (1) to utilize our epidemiological understanding of cutaneous melanoma in order to create clinical and population risk estimation and risk stratification and (2) to translate these modeling approaches into patient care in an active clinical setting We will explore different risk modeling approaches to better inform primary and secondary prevention strategies. This will lead t stratification for prevention trials, including chemoprevention when agents become available for clinical applications. Extensive epidemiological data from the Nurses' Health Study (121,700 women followed from 1976 to 2000), Health Professionals Followup Study (52,000 men followed from 1986 to 2000), and Nurses' Health Study II (116,000 women followed from 1989 to 2001) provide a rich resource on risk factors and the incidence of melanoma in over 230,000 women and 50,000 men. None of these cohorts
32
Melanoma
has funding to evaluate melanoma risk. Given the unique size and scope of these cohorts, we will examine the ability of risk models to classify individuals with regard to risk of melanoma, and we will evaluate if such a classification of risk can be clinically useful in determining primary prevention strategies and in directing the level of screening surveillance. Based on the above, our specific aims are as follows. We will construct statistical models for melanoma risk, incorporating traditional epidemiological risk factors to stratify population subgroups based on risk We will construct separate models for women (combining data from the HS and NHS II cohorts) and women. We will construct separate models for women (combining data from the NHS and NHS II cohorts) and men. We will evaluate the models with respect to both goodness of fit (i.e., predicting incidence in subgroups) and discriminatory accuracy at the individual level, and will evaluate the additional discriminatory accuracy gained by including additional risk factors, including genetic markers. Using results from Aims 1 and 2 above, we will evaluate the potential public health effectiveness, in terms of reduction in disease burden, associated with various high-risk and population-based primary and secondary prevention strategies. Using results from Aims 1 and 2 above, we will test the hypothesis the individual risk awareness will lead to risk-minimizing behaviors. We will perform these studies at the adult general dermatology clinics affiliated with Harvard Medical School Department of Dermatology (i.e. Massachusetts General Hospital, Brigham and Women's Hospital, Beth Israel Deaconess Hospital). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INCREASING EFFECTS OF INTERFERONS FOR MELANOMA Principal Investigator & Institution: Borden, Ernest C.; Director; Cleveland Clinic Foundation 9500 Euclid Ave Cleveland, Oh 44195 Timing: Fiscal Year 2002; Project Start 07-JAN-2002; Project End 31-DEC-2005 Summary: New therapies to eliminate melanoma must be identified both for the highrisk patient after surgery and for metastatic disease. Interferons (IFNs) have therapeutic activity in both clinical settings but little expansion has occurred in understanding of mechanisms underlying clinical effectiveness in melanoma -- or indeed other malignancies. Underlying clinical antitumor effects must be the potent and pleiotropic gene modulatory effects that occur at a transcriptional level. Utilizing oligonucleotide array analysis, over 100 genes that are induced by IFNs in a melanoma cell line have been identified. On an equimolar basis these genes are induced to a substantially greater extent by IFN-beta than by IFN-alpha2. Based upon the hypothesis that the antitumor effects of IFNs in melanoma may result from direct effects on tumor cells, apoptosis, an understudied effect of IFNs, is a focus of our studies. Induction of apoptosis, coupled with array studies, led to the protein TRAIL (TNF-Related Apoptosis Inducing Ligand) as a mechanism that in part accounts for melanoma cell death. In sensitive melanoma cell lines, IFN-beta, but not IFN-alpha2, induces caspase dependent apoptosis that was associated with TRAIL. Resistant melanoma cell lines are characterized by lack of proliferative inhibition or apoptosis induction by either IFN- alpha2 or IFN-beta and lack of TRAIL induction. The data further suggest that apoptosis induction is negatively influenced by NFkappaB (Nuclear Factor kappa B) activation by TRAIL. With a goal of understanding of IFNs as antitumor cytokines and using melanoma as a model, our working hypothesis is that genes and functional mechanisms, yet to be identified, contribute substantially to the antitumor effects of IFNs. Our estimates based upon genome size suggest that greater than 500 interferon- stimulated genes (ISGs) remain to be identified. The goals of the proposal are: 1) By assessment of sensitive and resistant melanomas to identify new genes that may contribute to mediating apoptosis response
Studies
33
and resistance in response to IFNs, 2) To define and confirm functional effects of the newly identified ISG, TRAIL, on IFN-induced apoptosis, 3) To determine how NFkappaB or other induced anti-apoptotic pathways influence actions of IFNs and TRAIL, and 4) As an effective inducer of of apoptosis in mice and of TRAIL, to conduct a Phase II trial of IFN-beta to identify disease response in metastatic melanoma. The data should contribute to understanding of IFNs effects in melanoma but also other neoplasms and to a beginning understanding of the therapeutic potential of TRAIL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INHIBITION OF MELANOMA METASTASIS BY ERISTOSTATIN Principal Investigator & Institution: Mclane, Mary Ann A.; Assistant Professor of Clinical Laborato; Medical Technology; University of Delaware Newark, De 19716 Timing: Fiscal Year 2001; Project Start 19-APR-2001; Project End 31-MAR-2003 Summary: Metastasis (i.e. tumor spread) is the major obstacle to cancer cure. The metastatic process consists of many steps. If this cascade of events is interrupted at any step, metastasis will not occur. Malignant melanoma cells interacted with their environment using the same repertoire of molecules (e.g. receptors) found on normal cells surfaces. Since cell-to- cell interactions occur at many pints of the cascade, blockade of receptor(s) on melanoma cells, through which they interact with other cells, represents a rational target for interruption of tumor spread. Eristostatin, am member of the disintegrin family of viper venom proteins, has been found to inhibit melanoma metastasis in vivo using immunodeficient mice. To date, the basis for eristostatin's antimetastatic effect remains unknown. The long term objective of this research is to identify molecular mechanisms by which melanoma metastasis may be inhibited. The specific goal proposed here is to investigate hoe eristostatin inhibits experimental melanoma metastasis by pursuing three specific aims: i) Create a panel of eristostatin mutations designed to alter single amino acid residues along its entire length. ii) Characterize the interactions of eristostatin and its mutants with four melanoma cell lines possessing distinct combinations of well-defined surface receptors. iii) Identify the structural sequence within eristostatin which is most critical for its anti-metastatic ability. Recombinant eristostatin mutations will be created by alanine scanning mutagenesis, and made as bacterial fusion proteins with glutathione-S transferase. These purified mutants will be used in a series of functional assays with four metastatic, human melanoma cell lines. We will identify the specific molecule with which eristostatin interacts on each type pf melanoma cell through crosslinking and immunological techniques. To determine which residue(s) of eristostatin are responsible for its cellular interactions, each mutant will be compared to wild type eristostatin's activity in cellular assays. Those mutants which show the greatest difference in cellular interactions will be used in experimental metastasis assays. After I.V. injection of immonodeficient mice with melanoma cells and mutated eristostatin, mice will be observed for 4 weeks, and then necropsied. Metastatic potential will be assessed by counting lung metastases. Cryosections of how lungs will be evaluated using immunohistochemical stains. Taken together, these studies will provide insights into how one naturally occurring protein possesses the "right fit" to bind melanoma cells and block their metastatic ability. This information will, in turn, lead to a rational design of therapeutic agents which would target these cells and triumph over tumor spread the major obstacle to cancer cure. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
34
Melanoma
•
Project Title: INTRACELLULAR MATURATION
PH
HOMEOSTASIS
AND
TYROSINASE
Principal Investigator & Institution: Trombetta, Eduardo Sergio.; Associate Research Scientist; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: The goal is to examine the role of organellar acidification in tyrosinase (TYR) activation, stabilization and transport through the secretory pathway. Recent findings that the level of pigmentation in melanocytes negatively correlates with acidic intracellular organelles, leading to increasingly more severe inactivation of TYR, its retention in a pre- Golgi compartment and subsequent degradation. Furthermore, we have recently found that some amelanotic melanoma cells have a higher cytosolic PH, which together with a lower organellar PH are reminiscent of the intracellular PH characteristic of tumor cells refractory to chemotherapy. Therefore, it is possible that alterations in intracellular PH homeostasis may cause not only TYRE inactivation in amelanotic melanomas, but may also underlay other phenotypes, such as immunogenicity of melanosome associated proteins, drug resistance, and possibly antiapoptotic mechanisms in melanoma. We will address the role of intracellular PH in TYR biogenesis by the following assays: First, we will determine the subcellular localization of TYR in amelanotic melanoma cells before and after TYR activation with acidification inhibitors. Second, we will measure the PH in the cytosol and in diverse intracellular organelles in melanocytes defective in P-protein, in which a role for organelle PH was implicated. The P-protein is a putative transporter, proposed to be the "guardian" of melanosomal PH, whose dysfunction causes misrouting of TYR to other sites, including the plasma membrane. These studies will test the hypothesis that variable intracellular PH homeostasis is the cause for variability in the levels of pigmentation between these cell types. Specific aim #1: To evaluate the intracellular location of TYR in different cell types and conditions. The steady state subcellular localization of epitope-tagged location of TYR in different cell types and conditions. The steady immunogold electron microscopy and cell fractionation, to understand the mechanism by which intracellular PH affects TYR maturation. Specific aim #2: To visualize the intracellular distribution of chemotherapeutic drugs and acidic compartments in living melanocytes cells. This will provide a comparative overview of the intracellular PH in melanocytes and amelanotic melanomas. This studies will be complemented by those in aim #3. Specific aim #3: To evaluated the pH in the cytosol and selected intracellular organelles in melanocytes defective in P-protein. PH sensitive probes will be targeted to specific intracellular compartments and will be used to specifically determine the PH in the cytosol, endoplasmic reticulum (ER), Golgi and lysosomes/melanosomes. This information will be correlated with TYR activation under different conditions that simultaneously induced alkalization and activation of TYR to determine how inactivation of wild type TYR in melanomas correlate with alterations in intracellular PH. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INVOLVEMENT OF MGLUR1 IN MOUSE MELANOMA CELLS Principal Investigator & Institution: Marin, Yari E.; Chemical Biology; Rutgers the St Univ of Nj New Brunswick Asb Iii New Brunswick, Nj 08901 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): Normal neuronal cells express the metabotropic glutamate receptor 1 (mGluR1), a G protein coupled seven transmembrane domain receptor, mGluR1 can be activated by its natural ligand, glutamate, the major
Studies
35
neurotransmitter in the mammalian central nervous system. Targeted ectopic expression of this receptor to melanocytes transforms the cells in vivo giving rise to melanoma in mice. Studies of the signaling pathways activated by mGluR1 in melanocytes can give insights into mechanisms and molecular markers of melanoma which may be targets for therapeutic approaches. Preliminary data from gene array analysis and DNA-protein binding assays using tumor cell lines derived from these tumor-bearing transgenic mice suggest that the transcription factor nuclear factor kappa B (NF-kappaB) and other genes in this pathway may be involved in the signal transduction events activated by mGluR1. NF-KappaB has been shown to promote the transcription of anti-apoptotic genes, and in many cases it is constitutively activated in tumor cells. We also have preliminary data showing that these tumor cell lines are capable of releasing the natural ligand of mGluR1, glutamate, into the growth media. The aims of these studies are to determine if the release of glutamate by these tumor cells is able to activate mGluR1 and lead to NF-KappaB activation. We will also investigate some of the upstream kinases that may mediate the mGluR1 triggered activation of NF-KappaB in our system. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: L1 CAM AND MELANOMA PROGRESSION AND ANGIOGENESIS Principal Investigator & Institution: Montgomery, Anthony M.; Pediatrics; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 92093 Timing: Fiscal Year 2002; Project Start 01-MAR-1996; Project End 31-DEC-2002 Summary: (adapted from the investigator's abstract) The major objective of this proposal is to define the role of the human neural cell adhesion molecule L1-CAM (L1) in the progression and neovascularization of human malignant melanoma. Despite widespread expression of this CAM on malignant melanoma, little is known of its function with respect to tumor progression. Two central hypotheses will be tested. First, that L1 ligation will directly influence tumor progression by affecting melanoma cell aggregation, survival, proliferation and translocation. Second, that L1 will regulate tumor growth and metastasis by inducing tumor neovascularization or angiogenesis. These hypotheses are primarily based on two novel findings presented in this proposal. First, that L1 can function as a heterophilic ligand for alphavbeta3; an integrin closely associated with melanoma progression and second that shet L1 polypeptides can induce a significant angiogenic response. The specific aims are three-fold. First, they will test the hypothesis that as a result of homophilic or heterophilic ligation, L1 will regulate melanoma cell behavior central to tumorigenicity, including adhesion, migration, survival, and proliferation. This will be assessed by using purified native L1 and defined recombinant L1 fragments. These fragments will allow a determination of those molecular domains or regions that are important for specific tumor cell responses. Second, the focus will be on defining L1- mediated interactions that will influence tumor progression or metastasis in the host, including homotypic melanoma interaction and heterotypic interactions with vascular cells and extracellular matrix (ECM). The consequences of L1 shedding will also be investigated with emphasis on inhibition of melanoma aggregation and modification of ECM to promote attachment and migration. Third, they will determine the role of L1 in melanoma neovascularization or angiogenesis. In this regard, they will first substantiate the hypothesis that L1 shed by melanoma cells can induce a significant angiogenic response and will, therefore, potentiate tumor growth and hematogenous metastasis. As a further objective of this aim, an attempt will be made to define the mechanism by which L1 induces an angiogenic response. Among other possibilities tested, it will be determined whether L1 is angiogenic by virtue of its ability to interact with the integrin alphavbeta3 expressed
36
Melanoma
on host vasculature. Finally, they will further assess the significance of a preliminary observation reported in this proposal that describes the expression of L1 on angiogenic vessels. Achieving the objectives of this proposal should significantly further the understanding of the role of the L1 cell-adhesion molecule in the progression of highly metastatic neural crest derived tumors; a role that to date has remained largely unresolved. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MAPPING MELANOMA METASTASIS SUPPRESSOR GENE(S) Principal Investigator & Institution: Miele, Mary E.; Medical Technology; University of Delaware Newark, De 19716 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: (Adapted from the investigator's abstract) As metastasis (i.e., tumor spread) is the most life-threatening complication of cancer. Identification of genes that regulate the spread of cancer is of utmost importance to reduce cancer deaths. Malignant melanoma serves as a good in vivo model for study of the metastatic process. Understanding the genetic changes in melanoma cells that are responsible for its metastatic phenotype is crucial for improvements in melanoma treatment and survival, and may relate to other solid tumor types as well. The long-term goal of this research is to identify the gene on chromosome 6 (#6) that regulates metastatic potential in cutaneous malignant melanoma. Transfer of a normal copy of #6 into human melanoma cell lines that form tumors and metastasizes in immunodeficient mice results in suppression of tumor spread (i.e. metastasis) without reducing tumor formation. These data suggest that a metastasis-suppressor gene (MSG) is located on #6. More recently, the location of the MSG has been narrowed to 6q16.3-q23 ( about40Mb) by similar studies using #6 fragment. Presently our laboratory has hybrid cells that contain a transferred #6 deleted at 6q21 ( about4Mb), a region frequently lost in many types of advanced cancers. These cells await evaluation in metastasis assays. Thus, the first specific aim is to narrow the region on #6 that encodes the metastasis-suppressor gene by evaluating hybrid melanoma cell lines with a transferred #6 deleted at 6q21 in metastasis assays. The second specific aim will be to further refine the location of the melanoma suppressor gene by identifying BAC, PAC, and/or YAC clones that span the region located at 6q16.3-q23. Selecting overlapping PACs and BACs that cover the region implicated in metastasis suppression will be introduced into the melanoma cell line. Transfected clones will be monitored for suppression of metastasis in immunodeficient mice, These studies will narrow the region of the MSG to <1Mb, which will facilitate its isolation by a combination of cloning techniques. Identification of this gene will shed light on steps in the metastatic process that can be targeted for therapeutic intervention. Gene therapies or novel agents may be designed to restore regulation of cell growth to metastatic cells. Expression of the MSG might be used as a marker to monitor response or to predict patient outcome. In addition, mutational analysis of the gene may provide diagnostic clues that would aid in selection of appropriate treatment regimens that would improve melanoma survival. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MELANOMA AND ALLELIC VARIATION IN THE MCIR GENE Principal Investigator & Institution: Kanetsky, Peter A.; Assistant Professor; Biostatistics and Epidemiology; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104
Studies
37
Timing: Fiscal Year 2001; Project Start 06-SEP-2000; Project End 31-AUG-2005 Summary: (Applicant's Description) One of my academic career goals is to develop molecular and genetic epidemiologic research to identify etiologic factors associated with pigmented lesions, including cutaneous malignant melanoma and multiple primary melanoma (MPM). Determination of susceptibility genes for melanoma can facilitate identification of those at increased risk for disease and may result in increase public and individual efforts of prevention and early detection. The potential impact of these measures is great, as melanoma incidence has reached epidemic proportions and mortality due to melanoma has slowly increased over the past decades. The Preventive Oncology Academic Award will give me an opportunity to become a competent melanoma molecular epidemiologist. To this end, I will advance my academic understanding of melanoma through further education in the basic sciences, molecular biology/epidemiology, genetics, and clinical decision making. Practical experience will be gained through participation in molecular laboratory biology, with a focus on methodologies used in molecular epidemiology. Two research projects are proposed to explore the association of a candidate susceptibility gene and development of melanoma. Mutations in the candidate gene of interest, the melanocortin-1 receptor (MC1R), may affect melanin synthesis, resulting in an increased potential for cellular DNA damage that may lead to melanocytic carcinogenesis. The goals of the first study are i) to determine the number and types of gene variants among persons with MPM and single cutaneous melanoma (SCM), and ii) to test whether these mutations play a role in the subsequent development of MPM. The results will contribute greatly to the epidemiologic literature on candidate susceptibility genes associated with melanoma and will help focus primary and secondary prevention for persons at increased risk for secondary, primary melanomas. The second project evaluates whether allelic variants in the MC1R gene explain the pattern of melanoma in families prone to melanoma. Result from this project may provide valuable insight into the genetic predisposition to melanoma seen in some families, and may lead to more efficient mechanisms of primary prevention and clinical follow-up within these families. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MELANOMA CELL SURFACE PROTEOGLYCANS IN METASTASIS Principal Investigator & Institution: Mc Carthy, James B.; Professor; Lab Medicine and Pathology; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: (Adapted from the investigator's abstract) Melanoma chondroitin sulfate proteoglycan (MCSP), also known as high molecular weight melanoma associated antigen (HMW-MAA) is large, highly antigenic cell surface proteoglycan that is dramatically upregulated in melanoma. MCSP is being actively pursued as a target for melanoma vaccine development due to its restricted expression and antigenic properties. Despite its potential clinical importance, relatively little is known about the role of MCSP in melanoma progression. Previous studies have implicated MCSP in adhesion, motility, or cellular growth control. He presents data to demonstrate that inhibition of MCSP expression by anti-sense oligonucleotides inhibits tumor invasion and growth in soft agar in vitro. He has demonstrated that MCSP functions as an adhesion molecule, in part by enhancing the activity of a4b1 integrin, a mediator of tumor invasion and arrest. In addition, he has identified a novel signaling pathway stimulated by MCSP. Activation of MCSP leads to the rapid association and tyrosine phosphorylation of p130cas, an adapter protein implicated in tumor motility and
38
Melanoma
invasion. This signaling pathway also involves the association of MCSP with cdc42, a rho-family GTPase that mediates filopodial formation, cell motility and growth. Furthermore, Ack-1, a tyrosine kinase that associates with active (i.e., GTP bound) cdc42, is required for MCSP induced tyrosine phosphorylation of p130cas. Collectively the data are consistent with a model in which MCSP enhances tumor growth and invasion by sequestering intracellular components of a signaling complex in response to an external stimulus. In this application he will further define that signaling complex and study its importance for melanoma growth, invasion and metastasis. Additionally, although the MCSP sequence is published, it has not previously been cloned. He has recently amplified the full-length coding sequence for MCSP by RT-PCR of human melanoma mRNA and are in the process of expressing it in transfected melanoma cells which lack MCSP. This clone will enable them to examine the structural and functional relationships between MCSP, its extracellular stimuli, and its intracellular signal transduction. He proposes three specific aims: 1. To evaluate the importance of MCSP expression and function in the growth, invasion and metastasis of malignant melanoma cells. 2. To delineate the mechanism of Ack-1 in MCSP induced tyrosine phosphorylation of p130cas and to study this mechanism in the survival, growth and metastasis of malignant melanoma cells. 3. To define functional domains of the MCSP core protein required for signaling and melanoma growth, invasion and metastasis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MELANOMA CHEMOPREVENTION Principal Investigator & Institution: Dellavalle, Robert P.; Dermatology; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): The incidence of cutaneous malignant melanoma is rising faster than any other cancer in the US. 1 in 74 Americans will develop melanoma, more than 45,000 cases will be diagnosed, and more than 7,500 Americans will die from melanoma this year. Effective prevention of melanoma will not only save lives, but will also decrease the estimated one billion dollars spent annually treating melanoma in the US. There is currently no recognized chemoprevention for melanoma. Two large, randomized, placebo-controlled clinical trials, the VA-HIT Study utilizing gemfibrozil, and the AFCAPS Study utilizing lovastatin, have each reported an association of lipidlowering medication therapy with statistically significant lower melanoma incidence rates. Lovastatin inhibits melanoma cell growth in tissue culture, and mice Jed lovastatin develop lower lung metastases following tail vein injection with mouse B16 melanoma cells. More recently low concentrations of atorvastatin have been reported to specifically induce apoptosis and inhibit migration of human A375 melanoma cells but not cultured melanocytes. To investigate the unconventional hypothesis that lipidlowering medications might prevent melanoma, a case-control study will be conducted utilizing Veterans Administration (VA) databases to answer the following question: Do persons who have developed cutaneous malignant melanoma have a history of less lipid-lowering medication exposure than persons who are spared the disease? The answer to this question will help determine whether more expensive and labor intensive randomized prospective clinical trials of potentially teratogenic lipid-lowering medications should be initiated in persons at high risk of developing melanoma. Robert Dellavalle, MD, Ph.D., is an Assistant Professor of Dermatology at the University of Colorado Health Sciences Center and a staff dermatologist at the Denver VA medical center He is committed to a career in academic dermatology and public health. His
Studies
39
current career goals are completing a Masters of Science in Public Health and becoming an independent researcher in skin cancer prevention and control. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MELANOMA CONTROL FOR SIBLING OF MELANOMA PATIENTS Principal Investigator & Institution: Gilchrest, Barbara A.; Professor and Chair; Dermatology; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118 Timing: Fiscal Year 2001; Project Start 10-APR-1998; Project End 31-JAN-2004 Summary: With low cost screening and preventive procedures readily available, no one should die of cutaneous melanoma. Promoting melanoma control for at risk populations through regular skin cancer screening and sun protection practices should counter this modern cancer epidemic. Siblings (and other first-degree relatives) of melanoma patients have a two - eight fold elevated relative risk of developing melanoma themselves but have suboptimal knowledge of their risk and limited practice of screening and prevention measures. To date, no intervention protocols have targeted this high risk sibling group, a population estimated to be up to three-quarters million or more Americans. The investigators propose a randomized trial testing personalized telephone counseling intervention support and screening (PERTCISS) that delivers melanoma risk information to siblings and promotes screening and prevention practices. They propose to intervene at a time of a new diagnosis of melanoma in a family member, capitalizing on this teachable moment to reach siblings. They will randomize 450 adult siblings (New England residents) of newly diagnosed melanoma patients to PERTCISS or standard care (SC). The specific aims are to determine, in siblings, the impact of PERTCISS compared to SC on melanoma screening and prevention practices, as well as the knowledge and attitudes that mediate and motivate these practices. They hypothesize that, compared to those in SC, siblings randomized to PERTCISS will demonstrate: 1) Higher levels of three practices: a) physician skin cancer screening examinations, b) skin self-examination for melanoma, c) sun protection practices; and 2) Higher levels of knowledge about melanoma risk and improved attitudes about early detection and prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MELANOMA NRAS/BRAF MUTATIONS: A POPULATION-BASED STUDY Principal Investigator & Institution: Thomas, Nancy E.; Dermatology; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2003; Project Start 05-AUG-2003; Project End 31-JUL-2008 Summary: (provided by applicant): Melanoma, which is rapidly increasing in incidence, remains a potentially fatal disease with poor medical treatment options and controversial methods of prevention. Because of the increasing burden of this disease and its lethality, improved methods of prevention, early diagnosis and treatment are expected to be of increasing importance. NRAS and BRAF, mediators in the RAS-RAFMEK-ERK-MAP cell signaling pathway, are the most commonly mutated oncogenes thus far described for melanoma. However, despite the identification of these mutations in primary human melanomas, the frequency and mutational spectrum of NRAS and BRAF mutations in melanoma have not been fully characterized and there is a critical gap in the knowledge base regarding the association of these mutations with heterogeneity, precursor lesions, risk, and prognosis in melanoma. The specific aims of this study are to: (1) determine the population-based frequency and mutational
40
Melanoma
spectrum of NRAS and BRAF somatic alterations in primary cutaneous invasive melanoma and their associations with histologic subtype and potential precursor lesions, and (2) determine associations between NRAS and BRAF mutational phenotypes and known prognostic indicators and risk factors. For this study, a group of approximately 300 consecutive patients with malignant melanoma in North Carolina in the year 2000 has been assembled. Complete epidemiologic data, pathology, and tumor blocks have been obtained for these patients. NRAS and BRAF somatic mutations will be detected and characterized using the highly sensitive technique of single strand conformational polymorphism (SSCP) analysis combined with direct sequencing of PCR products. The population-based frequency of these mutations will be determined and compared between pathologically distinct subtypes of melanoma (superficial spreading, lentigo maligna, nodular, and acral lentiginous). In melanoma samples associated with a nevus, this component will be analyzed separately for mutations using laser capture microdissection. Mutational phenotype will be associated with subtype, potential precursor lesions, risk factors, and prognostic indicators. The data derived from this study is expected to clarify the role of NRAS and BRAF in the development, progression and heterogeneity of melanoma, ultimately leading to better prevention, classification and treatment. Elucidation of how these mutations might arise in relationship to environmental and hereditary factors should result in more evidence-based recommendations for risk factor avoidance. In addition, understanding how mutations arise in relationship to precursors should provide information regarding which potential precursors should be removed. This study is also expected to lead to identification of new hemotherapeutic targets and more efficient testing of inhibitors for NRAS and BRAF signaling, which have recently been developed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MELANOMA T CELL DEFINED ANTIGEN IDENTIFICATION Principal Investigator & Institution: Hogan, Kevin T.; Surgery; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (provided by applicant) Vaccination with antigenic peptides that stimulate a melanoma-specific cytotoxic T lymphocyte (CTL) response is a promising approach to the treatment of melanoma. The work proposed here is predicated on the hypothesis that T cell-mediated immunotherapy will be most successful when: (i) multiple peptide epitopes derived from different source proteins are presented by the same MHC molecule: and (ii) peptide epitopes are presented on multiple MHC molecules within the same individual. Immunization with peptides derived from multiple source proteins rather than a single source protein should minimize the probability that a gene mutation or deletion will result in immune escape, while targeting peptide epitopes to multiple class I MHC molecules should minimize the likelihood that mutation or loss of a single class I gene will result in immune escape, and at the same time broaden the percentage of the population that can receive treatment. Therefore, the overall objective of the research proposed here is to expand the available repertoire of melanoma-derived peptide antigens, both with respect to their absolute number and the range of MHC molecules on which they can be presented, with the ultimate goal (although beyond the scope of this proposal) of using the peptides as a vaccine for the treatment of melanoma. The specific aims of this research proposal are to: (1) determine if the utility of the known class I MHC-restricted melanoma epitopes can be expanded by first determining if they are naturally processed and presented by other members of the same class I MHC supertype family, and secondly by asking if the complexes are capable of stimulating a
Studies
41
melanoma-specific CTL response; (2) utilize SRM scanning mass spectrometry to identify new CTL epitopes derived from gp 100, tyrosinase, MART-1, TRP- 1, TRP-2, MC1R, MAGE-3, and MAGE-12; (3) determine the extent to which the gplOO, tyrosinase, MART-l, TRP-1, TRP-2, MC1R, MAGE-3, and MAGE-12 melanoma antigens give rise to HLA-A1, A2, A3, B7, or B8 MHC associated epitopes that can be recognized by melanoma-specific CTL; and (4) identify and characterize novel epitopes recognized by melanoma-specific CTL. The methods employed in this proposal will involve a unique combination of cellular immunology and mass spectrometry which will allow for the identification of antigenic peptides both with and without pre-existing CTL. The successful completion of this research should impact on melanoma therapy by increasing the number of available antigens for vaccination, as well as by increasing the percentage of the population that can avail themselves of this form of treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MENTORED DEVELOPMENT AWARD
PATIENT-ORIENTED
RESEARCH
CAREER
Principal Investigator & Institution: Florell, Scott R.; Dermatology; University of Utah Salt Lake City, Ut 84102 Timing: Fiscal Year 2003; Project Start 15-FEB-2003; Project End 31-JAN-2008 Summary: (provided by applicant): The goal of this project is to determine the role of p16, a tumor-suppressor gene in the retinoblastoma cell-cycle regulation pathway, in familial melanoma kindreds. Malignant melanoma is the most lethal of the skin cancers, and unlike most malignancies, often affects younger patients in their third and fourth decades. Several risk factors have been associated with melanoma, including sun exposure, genetic predisposition, total number of nevi present on an individual, and characteristics of nevi. The overall proportion of cutaneous melanoma attributable to genetic predisposition is reported to be about 10- 15%, but evaluation of cancer incidence data from the Utah Population Database suggests that the fraction of melanoma occurring in a familial setting may be as high as 30%. The applicant proposes to re-examine members of Utah melanoma kindreds, first studied 15 years ago at the UUSM, that helped establish the presence of a melanoma susceptibility locus on 9p21 and later confirm the association of p16 mutations with familial melanoma. A five-year mentored program is proposed to investigate the global hypothesis that carriage of a germline p16 mutation results in measurable clinical, histologic, and cellular changes that lead to familial susceptibility to melanoma. This program will incorporate both didactic and research training and will be guided by a research oversight committee composed of four established scientists at the UUSM and the Huntsman Cancer Institute. Three specific aims are proposed. First, clinical differences between carriers and non-carriers of a p16 mutation will be examined in the Familial Melanoma Research Clinic (FMRC) at the Huntsman Cancer Institute. Kindred members studied 15 years ago will be re-examined to measure differences in photodamage, number of nevi, size of nevi, characteristics of nevi, and distribution of nevi among p16 carrier and noncarrier kindred members. Second, I will determine whether p16 mutation carriage results in decreased senescence or apoptosis of nevus cells utilizing B-galactosidase levels and TUNEL staining, respectively. Third, I will determine whether nevi and melanomas from p16 mutation carriers have acquired additional mutations that could lead to increased risk of malignant transformation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
42
Melanoma
•
Project Title: METABOLIC IMMUNOTARGETING
ENGINEERING
OF
CANCER
FOR
Principal Investigator & Institution: Guo, Zhongwu; Chemistry; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: (provided by applicant) Oncogenic transformations are closely correlated with the change of glycosylation patterns of cell surfaces, and the aberrant carbohydrates expressed on tumors, which are called tumor-associated carbohydrate antigens (TACAs), are important targets for the development of cancer vaccines that can be used for cancer diagnosis and therapy. However, the problem of immunotolerance to TACAs has severely hindered further progress in the area. To solve this problem and to develop new, effective cancer vaccines, this project will exploit a new strategy that is based on modified TACAs and metabolic engineering of cancers. First, a TACA on cancer cells will be metabolically modified by treating them with an artificial derivative of a monosaccharide that can be taken as a precursor by cancer cells to biosynthesize a neoantigen - an artificially modified analog of the TACA. The metabolic engineering of cancer takes the advantage of the remarkable flexibility of carbohydrate biosynthetic machineries. Then, specific monoclonal antibodies (mAbs) will be used to selectively target tumor cells labeled by the neoantigen. The mAbs in return can be prepared with a synthetic vaccine made of the neoantigen. As vaccines made of artificial carbohydrates are potentially more immunogenic than those made of the natural TACAs and the metabolic engineering can specifically mark cancer cells, effective vaccines may be easily composed from modified TACAs and the new strategy will potentially solve the problem of immunotolerance to TACAs. The metabolic modifying targets of this project are sialyl TACAs. Melanoma is employed as the tumor model, and GD3 and GM3 on its cells are the specific targets. The N-modified analogs of mannosamine and sialic acid will be used as the precursors, and the neoantigens expressed on melanoma will then be the N-modified derivatives of GD3 and GM3. The aims of this project are: 1)to find the effective precursors for metabolic engineering of melanoma via studying the bioavailability of various precursors to the enzymes involved in the biosynthesis of sialyl TACAs and to melanoma cells; 2) to find the effective vaccines that can provoke specific immune responses to the neoantigens via studying the conjugates of various Nmodified GD3 and GM3; 3) to illustrate the new strategy through specific immunotargeting of metabolically engineered melanoma. This research will eventually establish a proper combination of the precursor and vaccine. As the overexpression of sialic acid is found in various tumors and sialic acid is a shared feature of many TACAs, the principles established herein may be of wide applicability. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MICROCIRCULATION OF UVEAL MELANOMA Principal Investigator & Institution: Folberg, Robert; Fc Blodi Professor; Pathology; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2003; Project Start 01-APR-1994; Project End 31-MAR-2008 Summary: (provided by applicant): Uveal melanomas are both sight and life threatening. Radiation therapy and enucleation are equally limited in preventing metastasis, and there is no effective treatment for metastatic uveal melanoma. There are no lymphatics in uveal melanomas: these tumors spread exclusively by a hematogenous route. The uveal melanoma microcirculation is heterogeneous, including incorporated pre-existing vessels, mosaic vessels, angiogenic vessels, and perfusable extra-vascular
Studies
43
matrix patterns (EMPs) now regarded as a "fluid conducting meshwork". The presence of looping and interconnected EMPs in primary melanomas is strongly associated with death from metastases: the primary tumors of 88% of patients dying of metastatic uveal melanoma contain EMPs which are also present in all sites of metastatic uveal melanoma. EMPs are generated in vitro by aggressive uveal melanoma cells that are embedded in matrix in the absence of endothelial cells and fibroblasts; non-aggressive melanoma cells do not generate EMPs, regardless of matrix conditions, addition of soluble growth factors and hypoxia. EMPs connect to tumor blood vessels and conduct plasma in animal models and human tissues. Preliminary data indicate that the 3dimensional distribution of perfused EMPs may provide a greater surface area exposure to plasma and therapeutic agents than vessels. We propose in the first specific aim to compare the distribution of plasma in EMPs with blood vessels in an orthotopic animal model and in human tissues using novel 3-dimensional visualization techniques. In the second aim, we take advantage of the fact that EMPs are generated by aggressive uveal melanoma cells only when these cells are embedded in thick matrix. By growing aggressive uveal melanoma cell lines under conditions permissive and not permissive of EMP formation, we can compare differential gene expression regulating EMP formation. By validating expression of these discriminating genes in human primary uveal melanoma tissues with EMPs from patients who have died of metastatic melanoma, and in metastatic uveal melanoma tissues, we can identify novel molecular targets for the treatment of aggressive primary uveal melanomas and their metastases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR EPIDEMIOLOGY OF NON-MELANOMA SKIN CANCER Principal Investigator & Institution: Nelson, Heather H.; Cancer Cell Biology; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02460 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-JUL-2003 Summary: Non-melanoma skin cancer is the most prevalent malignancy in the US, resulting in significant morbidity and health-care expense. Epidemiologic investigations have identified exposure to ultraviolet radiation as the primary risk factor for this disease; other environmental exposures that contribute to risk include ionizing radiation, arsenic, polycyclic aromatic hydrocarbons, and chronic immunosuppression. Host factors associated with increased risk for non-melanoma skin cancer include increasing age, male gender, and sun sensitive skin type. Basal cell and squamous cell carcinomas have been shown to contain alterations in the p53 gene, and recent work has identified a gene on chromosome 9q22, ptch, that is hypothesized to be critical in basal cell carcinoma tumorigenesis. These findings, while informative, are derived from relatively small, selected groups of patients and reflects the paucity of population-based molecular epidemiology for this disease. We propose to expand a large, well-established case-control study of non-melanoma skin cancer in New Hampshire to include investigation of genetic susceptibility. The project will focus on genes that potentially modify ultraviolet radiation exposure, including polymorphisms in the glutathione Stransferases (GSTM1, GSTT1, and GSTP1) and the newly identified variants in DNA excision repair genes (ERCC2/XPD, and XPF). In addition, we will collect tumor specimens from cases for characterization of mutations at p53 and 9q22/ptch. We will determine mutation spectra examine associations of mutation with carcinogenic exposures and patient traits, and refine a novel model of skin tumorigenesis. These studies will increase our understanding of host susceptibility to non-melanoma skin
44
Melanoma
cancer and advance current models of skin carcinogenesis through identification of patterns of gene inactivation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR MECHANISMS OF MELANOMA INVASIONS Principal Investigator & Institution: Chen, Wen-Tien; Professor; Medicine; State University New York Stony Brook Stony Brook, Ny 11794 Timing: Fiscal Year 2001; Project Start 01-JUL-1984; Project End 31-JAN-2004 Summary: The metastatic potential of tumor cells is the most important determinant for the prognosis of neoplastic disease. Among the molecular steps required for successful metastasis are several discrete events that involve the invasion of tumor cells through connective tissue barriers. Cell invasiveness concerns adhesion to and proteolysis of extracellular matrices and basement membranes, as well as cell motility. This proposal focuses on plasma membrane-associated proteases and adhesion molecules of human malignant melanoma cells that are important in mediating the invasiveness and metastatic potential of these cells. Recent work from this laboratory identifies several novel membrane proteases from human malignant melanoma cells, chicken embryonic cells, chicken transformed cells, and chicken embryos. Unique cell surface structures called invadopodia are present on cells expressing the malignant phenotype and have been shown to be involved in the invasiveness of cells. The invadopodia are sites of active tyrosine-phosphorylation, localization of beta1 integrins, and active degradation of the extracellular matrix by membrane proteases. The goals of this proposal are (1) to determine the biochemical nature of membrane proteases by the combined approaches of protease activity assays, cellular localization by monoclonal antibody production, sub-cellular fractionation, inhibitor- and antibody-affinity chromatography, protein biochemistry including microsequencing, and molecular cloning, (2) to determine how membrane proteases interact with other proteases to activate degradation, and their role in the expression of cell invasiveness, (3) to investigate the control mechanisms of cell invasion, particularly focusing on the direct or indirect interaction of membrane proteases with putative motility factors including the laminin A chain peptide, autocrine motility factor, acidic fibroblast growth factor, and interleukin-I during the induction of invadopodia and with the human integrins that localize to invadopodia during the stabilization of invasion-associated membranes, and (4) to determine the expression and localization of protease and adhesion molecules in experimental invasion and metastasis models and human tumors by scanning confocal microscopy and immuno-electron microscopy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR PATHOGENESIS OF MALIGNANT MELANOMA Principal Investigator & Institution: Chin, Lynda; Assitant Professor of Dermatology; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 01-AUG-1998; Project End 31-JUL-2003 Summary: Genetic basis of malignant melanoma is poorly understood. Progress in our understanding of the pathogenesis of malignant melanoma and in the design of therapeutic modalities has been significantly hampered by the lack of a bona fide animal model. In this proposed study, transgenic and knockout mouse technology will be utilized to construct a mouse model for malignant melanoma. Commonly encountered melanoma-associated genetic lesions will be analyzed in vitro to dissect their molecular functions and their causal roles in disease will be validated in vivo. Specifically, I will
Studies
45
focus on the differential roles of p15 INK4b, P16INK4a and p19ARF as well as activated H-rasva112 in development of malignant melanoma. My working hypothesis is that loss of both gene products of the INK4a gene, (namely p16INK4a and p19ARF), are important, but not sufficient, in development of malignant melanoma, that p15INK4b does not play a key role in melanoma pathogenesis, and that additional genetic events such as RAS activation may be necessary to achieve full malignant transformation of melanocytes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: METASTASIS
MOLECULAR
REGULATION
OF
HUMAN
MELANOMA
Principal Investigator & Institution: Singh, Rakesh K.; Pathology and Microbiology; University of Nebraska Medical Center Omaha, Ne 681987835 Timing: Fiscal Year 2001; Project Start 01-APR-1998; Project End 31-MAR-2003 Summary: The major goal of our research is to define the mechanism(s) that regulate the process of metastasis, and use this knowledge to design innovative hypothesis-based therapies. Metastasis is a highly selective process that is regulated by multiple interrelated mechanisms whose outcome is dependent upon both the intrinsic properties of tumor cells and the host response. Signals from autocrine or paracrine pathways, alone or in combination, may regulate tumor growth and metastasis with the eventual outcome dependent on a balance of stimulatory and inhibitory factors. Recent data from our laboratory demonstrate that the organ microenvironment can modulate gene expression of growth and angiogenic factors in tumor cells in an organ site specific manner. Our analyses of different human metastatic melanoma cell variants demonstrated a direct correlation between the levels of interleukin-8 (IL-8) mRNA expression and protein secretion with metastatic phenotype in nude mice. Preliminary data from our laboratory and others suggest that IL-8 is an obligate autocrine growth, motility and angiogenic factor for melanoma cells. In this application we propose to test the hypothesis that autocrine production of IL-8 and its receptors and their regulation by organ specific cytokines are important determinant in melanoma growth and metastasis. Three specific aims will be pursued: First, we will determine the functional significance of the autocrine production of IL-8 and its receptors on the expression of cellular phenotypes associated with melanoma growth and metastasis. Second, we will analyze whether the organ microenivronments can differentially modulate the expression of IL-8 and its receptors in metastatic melanoma cells. Third, we will determine whether the expression of IL-8 correlates with the clinical grade of human melanoma tumor specimens. The knowledge gained from this research will extend our basic and clinical understanding of the mechanism(s) regulating the process of melanoma tumor growth and metastasis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOUSE MODEL OF MALIGNANT MELANOMA Principal Investigator & Institution: Depinho, Ronald A.; Professor; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-MAR-2004 Summary: The significance and impact of melanoma as a disease entity can not be understated. Despite the long history of clinical and molecular efforts directed towards this disease, surprisingly little is known about the precise genetic lesions leading to melanoma and even less is known with regard to how these few genetic lesions relate to
46
Melanoma
disease classification or progression. Significant progress on both the basic and clinical fronts could be achieved through the production of an accurate mouse model of malignant melanoma that faithfully reproduces disease progression on the pathological and molecular levels. This proposal attempts to refine and validate further an established mouse model of cutaneous melanoma. To achieve this goal, mice will be engineered to possess several genetic lesions commonly observed in human melanomas, including activated MET, EGF receptors as well as disruption of the p16INK4a, PTEN and possibly Mxi1 genes. Evolving gene expression patterns and genomic changes at various tumor stages will be extensively cataloged as a means of validation. This refined model of melanoma should serve to advance our understanding of melanoma biology as well as to provide a system for melanoma gene discovery. The latter will include a combination of CGH, genome wide LOH, genetic mapping of susceptibility loci and candidate gene mutational analyses. The use of these melanoma mice in preclinical testing are outlined as well. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GMCSF Principal Investigator & Institution: Slingluff, Craig L.; Professor of Surgery Chief, Division Of; Surgery; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2003; Project Start 05-AUG-2003; Project End 31-JUL-2005 Summary: (provided by applicant): The majority of shared melanoma antigens identified thus far can be divided into two groups; 1) melanocyte differentiation proteins (MDP) and 2) cancer-testis antigens (CTA). Generally, both types of proteins are encoded by non-mutated genes, which lack tumor-specific mutations. Therefore, epitopes derived from these molecules could be useful in a vaccine for a large population of melanoma patients. Interestingly, MDP and CTA are differentially expressed in various stages of melanoma. Generally, the expression of MDA decreases in more metastatic lesions, whereas the expression of CTA increases in metastatic lesions. Thus, metastatic tumors contain a heterogeneous population of cells with respect to protein expression, Based on the emergence of metastases that have lost expression of target antigens vaccines that incorporate single melanoma derived epitopes may be inadequate in generating a complete immune response against the tumor. Ideally, a polyvalent vaccine that incorporates epitopes derived from both groups of antigens should compensate for the differential display of melanomaassociated antigens. Preliminary data from an ongoing vaccine trial at the University of Virginia (UVA-Me139) support the safety and immunogenicity of a vaccine strategy incorporating 12 melanoma peptides. This 12-peptide preparation will be used in the currently proposed study. Granulocyte-macrophage colony stimulating factor (GM-CSF) has been included in our vaccine regimens as a local cytokine adjuvant. The rationale for inclusion of GM-CSF is based on substantial murine and human data, but other studies with Montanide ISA-51 adjuvant alone have been demonstrated immunogenicity in the absence of GMCSF. In the present study, we propose to test the hypothesis that the GMCSF included in this regimen contributes to a heightened cellular immune response compared to vaccination in Montanide ISA-51 adjuvant alone. A second question being addressed in this study is the immunologic consequences of vaccination in more than one injection site. In the following study, we propose a 2-by-2 design to address both questions. The primary goals are to estimate: (1) whether GM-CSF administered locally changes the immunogenicity of vaccination with multiple synthetic melanoma peptides
Studies
47
in an emulsion with incomplete Freund's adjuvant, (2) whether vaccination at two extremity sites induces different immunogneicty than vaccination at a single site. Secondary goals are to obtain preliminary data on (3) whether booster vaccination every three months may maintain immune responses to a peptide vaccine, and (4) whether celluar immune responses to a 12-peptide vaccine may correlate with clinical outcome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTIMERIC LIGANDS FOR TARGETING OF MELANOMA Principal Investigator & Institution: Gillies, Robert J.; Professor; Biochemistry; University of Arizona P O Box 3308 Tucson, Az 857223308 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): The goal of the proposed work is to develop platform targeting agents for imaging and, eventually, therapy of metastatic melanoma. These agents are heteromultimeric ligands directed against combinations of cell surface receptors or epitopes. Prior work by our team and others has shown that homomultimers of ligands bind with significantly higher affinity compared to their component monomers through a process known as cooperative affinity. The current research extends this observation to the use of heteromultimers. The composition of the multimers will be driven by DNA array and monomer ligand binding data, They will have advantages over agents directed against single epitopes by not relying on a single overexpressed cell surface protein. They will have advantages over other multifunctional agents in that they are produced via convergent synthesis and the multimer will be relatively small. Two hypotheses drive this work. 1) Heteromulfimeric ligands directed against combinations of cell surface proteins will bind with higher affinity and apparent cooperativity compared to individual monomers. 2) Combinations of expressed cell surface proteins can uniquely define individual cell types. The two aims of the proposed work follow these two hypotheses. Aim 1 will use a model system comprised of four well-defined ligand-receptor combinations. This system will be used to determine the optimum linker spacing and rigidity, the optimal avidity of the monomeric units, the in vitro binding curves and the in vivo biodistribution characteristic. Aim 2 will screen the expression patterns of 209 cell surface proteins associated with metastatic melanoma. This screen will use a custom DNA array, which will generate comprehensive data sets to identify potential targets. These data will be used to compare patterns of expression in melanoma cells from established and low passage primary cultures, to libraries ofmRNA from normal human tissues. These will be confirmed by RT-PCR, and by binding assays using bona fide agonists. At the end of Aim 2, the two aims will converge in the design of multimeric ligands that will specifically recognize metastatic melanoma for eventual use in detection, diagnosis and treatment of this terminal cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NON-INVASIVE BRESLOW THICKNESS MEASUREMENT FOR MELANOMAS Principal Investigator & Institution: Elbaum, Marek; Electro-Optical Sciences, Inc. 1 Bridge St Irvington, Ny 10533 Timing: Fiscal Year 2001; Project Start 19-APR-2001; Project End 31-JUL-2001 Summary: (Verbatim from the Applicant's Abstract): The aim of the proposed effort is to demonstrate the feasibility of an innovative method for in vivo preoperative evaluation of malignant cutaneous melanoma. This method will analyze images of melanomas in
48
Melanoma
the visible and near infrared acquired with a multispectal digital dermoscope, MelaFind(tm), developed by Electro-Optical Sciences, Inc., for automatic detection of cutaneous melanoma. The method will meet the following goals: (1 ) reliable in vivo differentiation of invasive from in situ melanomas; (2) in vivo estimation of Breslow thickness for invasive melanomas with an accuracy not worse than that of the standard histological determination. Breslow thickness is one of the most important predictors of the prognosis of cutaneous melanoma. It is also used to decide on surgical management as well as work-up and follow-up strategies for melanoma patients. Thus the proposed method has the potential to improve the care of melanoma patients and to reduce the cost of health care by reducing the number of re-excisions of the tumor. The feasibility of the method will be demonstrated in Phase I. In Phase II, a software package (MelaMeter) for noninvasive Breslow thickness measurement, will be developed and tested with MelaFind (tm). PROPOSED COMMERCIAL APPLICATION: The proposed product is a practical hand-held and portable instrument that will perform two functions: 1) differentiation between invasive and in situ melanomas and 2) estimation of Breslow thickness. This product has the potential of benefit 100,000 new melanoma patients each year in the U. S. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NUCLEOTIDE EXCISION REPAIR IN CUTANEOUS MELANOMA Principal Investigator & Institution: Tsao, Hensin; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2008 Summary: (provided by applicant): The incidence of cutaneous melanoma (CM) has dramatically increased over the past several decades. Like other cancers, melanomas most likely result from an interaction between environmental carcinogens, such as ultraviolet radiation, and genetics. Evidence so far suggests that mutations in growth regulatory genes, such as RAS and INK4alpha, contribute to the development of CM. Less understood, however, is the role of DNA repair in melanoma tumorigenesis. Defects in nucleotide excision repair (NER), as seen in the clinical disorder xeroderma pigmentosum, lead to a greatly exaggerated risk of developing CM. The mechanism, however, underlying this clinical observation is largely uncharacterized. The long-term objective of this project is to understand the role of nucleotide excision repair in the pathogenesis of cutaneous melanoma. Specifically, the proposed studies will evaluate if (1) ongoing NER is critical in restricting spontaneous melanoma tumor growth; (2) novel targets for mutation in addition to RAS and INK4alpha emerge in the absence of NER; (3) loss of INK4alpha disrupts the UV response in NER-deficient cells. To test these hypotheses, the Candidate will use murine models to (I) examine, in vivo, the biological consequence of NER loss on the formation of melanomas and (II) characterize, in vitro the impact of INK4alpha loss on the UV-response in NER-deficient murine embryonic fibroblasts (MEFs). A more thorough understanding of the DNA repair mechanisms could lead to better strategies for prevention and therapy. Dr. Tsao received both his M.D. and Ph.D. from Columbia University. After completing a residency in Dermatology, he returned to the laboratory in order to focus on human melanoma genetics. With the proposed studies, he is taking a dramatic departure from previous studies and immersing himself in mice cancer genetics. Dr. Tsao is an Assistant Professor of Dermatology at Harvard Medical School and an associate physician at the Massachusetts General Hospital Melanoma Center. Dr. Tsao is committed to the study of cutaneous melanoma and the career development activities outlined in this application will allow him to become fully independent.
Studies
49
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OCULAR MELANOMA Principal Investigator & Institution: Simpson, E Rand.; Director / Associate Professor; Ontario Cancer Institute 610 University Ave Toronto, Timing: Fiscal Year 2001; Project Start 01-SEP-1986; Project End 31-JAN-2004 Summary: The Collaborative Ocular Melanoma Study is a multicenter, randomized, controlled clinical trial designed to compare the efficacy of enucleation vs. irradiation in the treatment of eyes with choroidal melanoma. Candidates for the study will be newly diagnosed cases with choroidal melanoma in one eye greater than 3 mm in height and up to 18 mm by 8 mm in size and with no evidence of metastatic disease. Informed consent will be obtained from all patients prior to randomization. The outcome of primary interest is death from all causes. Secondary outcomes will include death from cancer, whether metastatic or not, diagnosis of other tumors, and preservation of vision. Complications of irradiation and changes in visual acuity will be documented and monitored carefully throughout follow-up. Standardized clinical and data collection procedures will be employed, and standardized forms will be used in all centers. Central training and certification of all study staff will be required. The study will be conduced in cooperating clinics located throughout the United States. The study will be directed by an Executive Committee consisting of 12 to 15 study investigators and a Steering Committee to deal with day-to-day operational decisions. An independent Data and Safety Monitoring Committee will be responsible for assuring the ethical conduct of the study and for reviewing the accumulating data on a regular basis for evidence of adverse or beneficial effects of therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PEPTIDE AND APC BASED MELANOMA VACCINE Principal Investigator & Institution: Mukherji, Bijay; Professor of Medicine; Medicine; University of Connecticut Sch of Med/Dnt Bb20, Mc 2806 Farmington, Ct 060302806 Timing: Fiscal Year 2001; Project Start 01-SEP-1993; Project End 31-DEC-2002 Summary: The major objective of this proposal is to develop a more effective form of active specific immunization with a vaccine made from synthetic peptides loaded on to dendritic cells in the human melanoma model. We have shown that a peptide and antigen presenting cell-based vaccine can induce a peptide specific and autologous melanoma reactive cytolytic T lymphocyte (CTL) response in melanoma patients. We have observed that in vitro stimulation of PBL from the immunized patients led to the rapid generation of peptide specific CTL, the CTL activities, however, often precipitously declined after repeated stimulation with the development of a Th2 type response. There was preliminary evidence of apoptosis in the process. These suggest that in vivo expansion of antigen specific CTL might also be regulated by a Th2 type response or through activation induced cell death (AICD). Hence, the proposed study will examine the mechanism of the decline of the CTL response with particular reference to the role of the Th2 cells and the role of AICD. Further, we shall test the hypothesis that a more effective peptide/APC-based immunization can be achieved with a number of innovations to the approach (such as by using dendritic cells, higher peptide loading, a different format of immunization consisting of priming and boosters, pretreating with cyclophosphamide to block the Th2 response, and using the type 1 cytokine IL-12 to induce a Th1 response). The study will be carried out with a clinical trial that will include these new approaches coordinated with extensive laboratory evaluations of the
50
Melanoma
biologic response to test whether or not a Th1 type response can be induced, CTL response can be amplified, and memory response can be generated. The trial will be carried out with a vaccine made of DC (cultured in GM-CSF and IL-4) loaded with the HLA-A1 or - A2 determined peptides encoded by the following genes: MAGE-1, MAGE- 3, MART-1/Melan A. Thus, melanoma patients, who are HLA-A1 or HLA-A2 positive and whose melanomas express the above genes, will be primed with the vaccine and then given several boosters with a single low but biologically active dose of Interleukin-12 and a single injection of cyclophosphamide 3 days before immunization. A skin test with the naked peptide will be done after each vaccination and extensive analyses of the host immune responses in the draining lymph nodes, in tumors, and in circulation will be performed to determine whether or not the new approach could induce a Th1 type response and amplify specific CTL response and activate memory response. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PERCEPTION OF GENE-ENVIRONMENT CANCER RISKS IN MELANOMA Principal Investigator & Institution: Hay, Jennifer L.; Instructor; Sloan-Kettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2003; Project Start 08-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): The overall goal of this career development application is to launch an independent research program on perception of geneenvironment cancer risks. There is mounting evidence that common genetic polymorphisms can either accentuate or attenuate environmental risks, such as smoking and sun exposure, and that these interactions are a primary etiological pathway to carcinogenesis. In the coming years, it is likely that a growing number of individuals will receive probabilistic information concerning genetic and environmental cancer risk factors. The number of individuals who are affected will exceed those with uncommon, highly penetrant single-gene mutations. Existing research on cancer risk communication targeted to those with single risk factors, such as genetic mutations alone, or lifestyle risk factors alone, do not adequately address the potential challenges and prevention opportunities presented by our increasingly comprehensive understanding of environmental and genetic risk interactions. Gene-environment interactions are implicated in the etiology of a number cancer sites. Melanoma will provide the paradigm for study in this application because of the evidence for gene-environment etiology, rising incidence rates, and promise of behavioral prevention. Given the current absence of identified germ line mutations, studying first-degree relatives of melanoma patients will provide a vehicle in the proposed studies to examine the role of geneenvironment risk perceptions and both skin cancer screening and sun protection behavior. Study I is a qualitative interview study of risk perceptions among first-degree relatives of melanoma patients. Study II is a prospective assessment of risk perceptions, skin cancer screening, and sun protection behaviors among first degree-relatives of recently diagnosed melanoma patients. Through intensive interaction with multidisciplinary colleagues, formal epidemiology coursework, teaching, and research, this career development award will establish my multidisciplinary research skills at the interface of genetic epidemiology and behavioral science, and position me to establish novel theory and measurement strategies for the role of risk perceptions of geneenvironment interactions, and ultimately to develop communication models of geneenvironment cancer risks which will be applicable to other cancer sites. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
51
Project Title: PILOT--CUTANEOUS ONCOLOGY Principal Investigator & Institution: Johnson, Timothy M.; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2001; Project Start 30-SEP-1988; Project End 31-MAY-2006 Summary: The Cutaneous Oncology Program was initially established as a developmental program and achieved full programmatic status in 1996. Its mission is to utilize knowledge gained from basic, preclinical, and clinical research endeavors to improve the overall care of patients with skin cancer. We believe that understanding the biology of melanoma and non-melanoma skin cancers will drive future innovations in prevention, diagnosis, and treatment. The program now consists of 15 investigators from 9 Departments, with over $3.2 million dollars in annual direct funding for basic and clinical research activities. Basic research efforts are focused on areas that have relevance to all forms of cutaneous neoplasia, including the investigation of molecular, biochemical, cellular, and tissue alterations driving the development and progression of skin cancer. A major new initiative is aimed at developing mouse models of human skin cancer for basic and preclinical studies. The clinical research program has made important advances using innovative, immune-based therapies for melanoma. Given the importance of early detection, additional efforts in melanoma are focused on the development of improved patient-education materials, while other work is aimed at better understanding the psychosocial and behavioral repercussions of being diagnosed with melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA Principal Investigator & Institution: Bystryn, Jean-Claude; Professor; Dermatology; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2001; Project Start 12-SEP-2001; Project End 31-AUG-2005 Summary: Our goal is to develop a potent adjuvant that can strongly, but safely, boost the immunogenicity of cancer vaccines. The proposal is based on recent observations that IL-2 and GM-CSF can individually increase the immunogenicity of vaccines, and that the adjuvant activity of each cytokine is markedly increased by co-encapsulating the cytokine into liposomes together with the vaccine. As each cytokine upregulates vaccine immunogenicity by different mechanisms, the combination of both cytokines should result in a particularly potent adjuvant. To test this hypothesis, we propose to conduct a randomized phase II trial to examine: 1) Whether IL-2+GM-CSF co-encapsulated into liposomes together with a melanoma vaccine can increase vaccine-induced cellular immune responses more strongly than either cytokine alone. Patients with resected AJCC stage III melanoma who are HLA-A2(+) will be randomized to treatment with a polyvalent, shed melanoma antigen vaccine encapsulated into lipsomes together with IL-2 or GM-CSF, or with both cytokines. The magnitude of vaccine-induced CD8+ T cell responses to A-2 restricted peptides derived from MAGE-3, MART-1, gp100, tyrosinase and TRP-2 will be measured by ELISPOT at baseline and at fixed intervals following immunization. 2) Whether IL-2+ GM-CSF lipisomes can enhance vaccine-induced antibody responses more strongly than either cytokine alone: Vaccine-induced antibody responses in the 3 groups of patients will be measured to individual melanoma antigens by Western immunoblotting. 3)The safety of this treatment/ Side effects will be followed by standard procedures. Major strengths of this proposal are that we have already demonstrated that IL-2 liposomes and GM-CSF liposomes are individually
52
Melanoma
potent vaccine adjuvants in humans, that we have determined the optimal doses of each cytokine that maximally enhance vaccine-induced immune responses when encapsulated into lipsomes, that we have developed assays that are sufficiently sensitive to measure vaccine-induced CD8+ T cell and antibody responses to individual melanoma antigens, and that the vaccine contains multiple melanoma antigens so that the adjuvant activity of IL-2 + GM-CSF liposomes with different antigens can be evaluated. Successful completion of this work will provide a new method to increase the effectiveness of melanoma vaccines, and may lead to an improved treatment for the primary and secondary prevention of this cancer. More broadly, it may provide a general method of potentiating the immunogenicity of vaccines against other cancers and to infectious diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROGNOSTIC MARKERS FOR ASSESSMENT OF TREATMENT EFFICACY OF MELANOMA Principal Investigator & Institution: Hoon, Dave S B.; Director of Molecular Oncology/ Member; John Wayne Cancer Institute 2200 Santa Monica Blvd Santa Monica, Ca 90404 Timing: Fiscal Year 2002; Project Start 15-APR-2002; Project End 31-MAR-2007 Summary: (provided by applicant): One of the major problems in managing malignant melanoma is predicting the course of disease progression after removal of the primary tumor. Our main hypothesis is that molecular markers can be used for analysis of tumors and blood as surrogates to predict disease progression and outcome, and treatment efficacy well in advance of clinicopathological events. Malignant melanoma progression occurs from accumulation of multiple genetic aberrations that result in progressive genetic instability. In order to translate the detection and prognostic value of these changes efficiently, analysis must be conducted on specimens from well-defined retrospective and prospective clinical trials. Validation of the molecular results will allow better disease stratification and management of malignant melanoma. In the previous grant period we developed multimarker RTPCR assays to identify blood prognostic molecular markers (PMMs) and demonstrated that they could be useful as potential surrogates of subclinical disease progression, and to predict disease recurrence. We will continue to develop new informative PMMs for blood in this proposal. Our hypothesis is that quantitative levels of PMMs which include melanomaassociated antigens (MAAs) and cellular physiologic factors influencing tumor progression/metastasis in melanoma tumors can also be used as surrogates of disease outcome and the efficacy of active-specific immunotherapy (vaccine). Our hypothesis is that DNA markers in primary and metastatic melanoma can also be used as PMMs. We have identified several DNA markers that have shown potential clinicopathological utility. In this renewal we will focus on assessing paired primary/metastatic melanomas to develop different types of PMMs to complement the blood RT-PCR assay as correlates to disease progression and outcome, and treatment failure. The Aims of the project are as follows: 1) Development and assessment of new mRNA PMMs for assessing melanoma patients' tumor and blood; 2) Development and assessment of DNA markers in melanoma tumors as prognostic indicators of disease progression and outcome; and 3) Validation of the clinical and pathological utility of RNA and DNA molecular markers in melanomas from patients entered in the multicenter PMCV Phase III clinical trial. The Aims will take advantage of the JWCI's large melanoma patient referral and comprehensive follow up to provide resources to develop and assess PMMs. The Aims will also take advantage of the randomized multicenter vaccine trial's archived and prospectively collected specimens to validate the PMMs. Identification of
Studies
53
molecular markers for melanoma at different stages of disease progression will allow us to develop an "applicable" molecular progression model to aid in management decisions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MELANOMA
PROGNOSTIC
MARKERS
FOR
PRIMARY
CUTANEOUS
Principal Investigator & Institution: Pinkel, Daniel D.; Professor; Cancer Center; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2002; Project Start 01-MAY-2002; Project End 31-MAR-2007 Summary: (provided by applicant) Cutaneous melanoma presents a significant health problem in Western Europe, Australia, and the United States. Americans in the United States currently have approximately a 1 in 75 lifetime risk developing this disease. If melanoma is not excised before it metastasizes the prognosis is poor. Recent evaluation of adjuvant treatments such as interferon alpha indicate the ability to prolong survival in patients with occult metastases, so identification of these patients is highly important. The goal of this proposal is to develop DNA copy number and gene expression markers in the primary tumor that will improve the ability to determine if clinically significant metastasis has occurred by the time of diagnosis. Sentinel lymph node (SLN) biopsy, coupled with several other characteristics of the primary tumor such as thickness and ulceration, are currently the best prognostic indicators. The finding of malignant cells in a sentinel node is a definite sign that the disease has begun to spread. but negative nodes do not guarantee a good outcome. A substantial proportion of all cases of metastatic melanoma come from patients who were SNL- at diagnosis. Thus improving the ability to determine which patients were at elevated risk of progression would have substantial medical benefit. In this project we w ill study primary tumors and corresponding metastases from a cohort of 700 patients that underwent SLN biopsy at UCSF, and an additional set of 100 primary tumors of Acral Lentiginous Melanoma (ALM), to detect DNA copy number changes and gene expression changes that distinguish primary tumors that metastasize from those that do not. Screening for DNA copy aberrations will be performed using array comparative genomic hybridization (array CGH) which has recently been developed in our laboratories. Candidate genes will be identified based on the copy number aberrations, and the prognostic power of the expression levels of these candidates will be evaluated. Using an independent set of tumors from the SLN cohort, we will validate the ability of these markers to: 1) distinguish patients that develop metastases from those that do not, and 2) to distinguish patients with negative sentinel nodes that develop metastases from those with negative nodes that remain disease free. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: QUALITY OF LIFE--THE COLLABORATIVE OCULAR MELANOMA STUDY Principal Investigator & Institution: Melia, B. M.; Ophthalmology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 01-AUG-1994; Project End 31-JUL-2005 Summary: The Collaborative Ocular Melanoma Study (COMS) is a set of randomized clinical trials sponsored by the National Eye Institute and designed to evaluate the role of radiotherapy in the treatment of choroidal melanoma. The primary COMS trial will determine whether enucleation or radiotherapy without enucleation provides patients
54
Melanoma
with the longest remaining lifespan. The two treatment approaches under investigation, enucleation versus radiation therapy, are likely to have different psychological and physiological effects on the patients receiving them. In addition to consideration of any survival difference between treatment approaches, the impact of the treatments on the patient's quality of life will be an important consideration in determining the best form of therapy. The COMS does not currently incorporate measures of the disease impact on quality of life, with the exception of an assessment of visual acuity. The purpose of the proposed study is to address the issues of quality of life and the psychological and physical impact of treatment in patients with choroidal melanoma using the existing framework of the COMS. Specifically, the study will: 1. estimate baseline quality of life and its changes over time in choroidal melanoma patients from enrollment into the COMS, with follow-up for 5 years; 2. compare baseline quality of life and its changes over time in patients randomized to receive radiotherapy versus enucleation; 3. and compare quality of life cross-sectionally according to treatment assignment in patients previously enrolled in the COMS. To achieve these aims, a health-related quality of life instrument, the SF-36 Health Survey, and a visual functioning assessment instrument, the Activities of Daily Vision Scale, will be incorporated into the patient evaluations performed at baseline and during follow-up for the COMS. This study will provide valuable information about the how patients with choroidal melanoma experience the disease and its treatment. Future patients will benefit from these results, which will help them balance the trade-offs between quantity and quality of life related to choice of treatment for this disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF EXPRESSION OF MGSA/GRO GENES IN MELANOMA Principal Investigator & Institution: Richmond, Ann A.; Professor; Cell and Developmental Biology; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917 Timing: Fiscal Year 2001; Project Start 01-FEB-1993; Project End 31-JAN-2003 Summary: The chemokines, MGSA/GRO and IL-8, are constitutively expressed in melanoma and appear to play a causal role in melanoma tumor progression. Evidence to date points to a transcriptional deregulation of the MGSA/GRO chemokine, partly through an endogenous activation of the transcription factor, NF- kappaB. An immediate upstream regulatory region (IUR) is located adjacent to the NF-kappaB element and in CAT reporter assays, mutation of this element drastically decreases basal transcription. The IUR element, TCGAT, binds three proteins, approximately 100, 40 and 22kD, and the binding of these proteins cannot be eliminated or supershifted in electrophoretic mobility shift assay by antibodies to other potentially relevant transcription factors. Preliminary data point to a potential interaction between the NFkappaB and the novel IUR binding proteins. There are four specific aims for this proposal: 1) to characterize the process by which NF-kappaB is constitutively activated in Hs294T melanoma cells and determine whether NF-kappaB activation contributes to the endogenous transcription of MGSA/GRO in melanoma; 2) to purify, sequence and clone the proteins which bind to the immediate upstream region (IUR) of the MGSA/GROalpha gene enhancer, and to determine if these factors contribute to MGSA deregulation in melanoma; 3) to characterize the prevalence or coordinate deregulation of CXC chemokines in malignant melanoma; and 4) to determine whether overexpression of the mouse homolog of MGSA in normal melanocytes is associated with tumor formation in vivo, a transgenic model will be developed. Expression of the
Studies
55
mouse homolog of MGSA/GRO, MIP-2, will be directed by the tyrosinase promoter which will result in melanocyte specific expression. We will treat the transgenic mice with chemical carcinogens and uv irradiation to determine how continued expression of these chemokines effects melanocyte response to agents involved in tumor initiation/progression. These experiments should provide important new information about the mechanism by which deregulation of the expression of chemokines chemotactic occurs and this is key to understanding how to suppress these mediators of tumorigenesis and chronic inflammatory response. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLES OF NITRIC OXIDE AND OXYGEN IN OCULAR MELANOMA Principal Investigator & Institution: Braun, Rodney D.; Anatomy and Cell Biology; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2001; Project Start 01-FEB-1998; Project End 31-JAN-2003 Summary: (Adapted from applicant's abstract): Choroidal melanoma is the most common primary ocular cancer among the adult population. It is an important disease, because treatment may destroy vision in the affected eye and the tumor can metastasize. Its treatment is very controversial and is currently the subject of a major NEI clinical trial. Enucleation is a common treatment, but there has only been recent emphasis to develop eye-sparing therapies. Unfortunately, these newer treatments have been only marginally successful in eradicating the tumor while sparing vision. The ultimate goal should be to improve therapy so that safer, more efficacious treatments can be applied sooner in the course of the disease. The ability to treat sooner and more aggressively may ultimately enhance patient survival. Some eye-sparing therapies (e.g., radiation therapy, photodynamic therapy, and immunotherapy) are dependent on oxygen, yet virtually nothing is known about the physiology of this tumor, including mechanisms for blood flow control. In other areas of cancer research, there has been recent interest in the modulation of nitric oxide (NO) to modify tumor blood flow and oxygenation to improve treatment. One major drawback of these strategies, however, is that NO modulators must typically be given systemically, and side effects may limit their clinical application. Since choroidal melanomas are often accessible to treatment using an episcleral approach, the utilization of compounds associated with NO to locally manipulate the microenvironment of this tumor is especially appealing, since systemic treatment can be avoided. The purpose of the proposed study is to test hypotheses relating to the effects of NO on blood flow and oxygenation in human choroidal melanoma growing in the choroid of the athymic rat. The hypotheses to be tested are that (1) NO synthetase (NOS) is expressed in human choroidal melanoma parenchyma and/or vasculature, (2) NO plays a role in regulating microvascular blood flow in human choroidal melanoma and (3) human choroidal melanoma in vivo has areas in which the oxygen tension is low (hypoxia) and the oxygenation of the tumor is dependent on NO availability. The results of these studies could lead to development and testing of new therapies for choroidal melanoma, based upon selective, local delivery of agents which modulate NO availability and modify tumor blood oxygenation, thereby enhancing the effectiveness of treatments directed toward salvage of the affected eye. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
56
Melanoma
•
Project Title: SENSITIZATION TO THERMORADIOTHERAPY IN HUMAN XENOGRAFTS Principal Investigator & Institution: Leeper, Dennis B.; Professor; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2003; Project Start 15-JUL-2003; Project End 31-MAR-2007 Summary: Project 1 serves the program by testing the hypothesis that acute acidification by lactic acidosis will enhance thermosensitization and selectively sensitize melanoma xenografts to radiotherapy. Protocols were established for acute acidification to less than or equal too pH3 6.3 and oxygenation of melanoma has uniquely high activity of H+ linked monocarboxylate transporters (MCT, a.k.a. lactate symport) that are the major membrane proton exchange. Although thermosensitization by acidification was demonstrated, radiation must be combined with hyperthermia to achieve local control. Five specific aims will test the hypothesis and investigate mechanisms of melanoma acidification. Aim 1 will investigate inhibition of mitochondrial respiration by metaiobenzylguanidine (MIBG) on melanoma acidification and oxygenation for sensitization to thermoradiotherapy. Variation in glycolytic/respiratory ratio among frozen melanoma biopsy cell suspensions will indicate relative susceptibility to MIBG. Aim 2 will investigate inhibition of the MCT either by alpha-cyano-4-hydroxy-cinnamic acid (CNCn) or by Ionidamine on acidification of melanoma and sensitization to thermoradiotherapy. The activity of the plasma membrane MCT among stored melanoma biopsy cell suspensions will indicate relative susceptibility to CNCn or Ionidamine. Aim 3 will identify the utility of combining MIBG and CNCn as a cocktail to acidify and oxygenate all melanomas. Melanomas with high rates of respiration will be sensitive to MIBG, and those with high rates of glycolysis sensitive to CNCn. In each protocol excess glucose must be combined with inhibitors to fuel lactate production. Two different F2 melanomas xenografts in nude mice will be studied that differ in vascularity, radiation sensitivity and expression of heat shock proteins. Tumor growth delay will be compared with tibial bone marrow toxicity to establish therapeutic gain. Cellular radiation response parameters in vitro will be determined in Project 3. Project 1 provides mice with melanoma xenografts to Project 2, so that together with Core A, biological endpoints can be investigated to predict response of melanomas and normal tissues to treatment pH9, pHi, 23Nai, pO2, oxygen consumption, bioenergetics and blood flow. Aim 4 supports Project 3 to determine the effect of acute acidification on apoptosis and the relationship with hyperthermia-induced upregulation of hsp70 in DB1 xenografts grown up from cell stably transfected with the gene for enhanced green fluorescent protein (egfp) under control of the hsp70 promoter. Aim 5 with Project 3 supports Project 4 to confirm whether nucleolin translocation is a determinant of heat response in vivo by measuring nucleolin movement from the nucleolus into the nucleoplasm in DB-1 xenografts as a function of acidification during hyperthermia. Acute tumor acidification will have the clinical effect of increased tumor temperature with additional benefit from increased tumor oxygenation. These results will help direct a Phase I/II trial conducted by Dr. Douglas Fraker, Univ. of Penn. To demonstrate the effects of acidification of melanoma response to limb perfusion with melphalan at 42 degrees Centigrade. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SIGNALING PATHWAYS FOR UV-INDUCED MELANOGENIC RESPONSES Principal Investigator & Institution: Abdel-Malek, Zalfa A.; Research Professor; Dermatology; University of Cincinnati 2624 Clifton Ave Cincinnati, Oh 45221
Studies
57
Timing: Fiscal Year 2003; Project Start 01-APR-1998; Project End 31-MAR-2008 Summary: (provided by applicant): In human skin, epidermal melanocytes play a crucial role in photoprotection mainly due to their ability to synthesize melanin. Melanocytes have an extremely low proliferative capacity, thus their survival in the epidermis is crucial for cutaneous photoprotection. However, it is becoming clear that the risk for skin cancer is not simply determined by melanin content in the skin, but rather by the ability of the metanocyte to maintain genomic stability in the face of exposure to ultraviolet radiation, to prevent malignant transformation into melanoma. Endothelin-1 (ET-1) and alpha-melanocyte stimulating hormone (alpha-MSH) are two epidermal factors whose synthesis is stimulated by UV exposure. Both factors enable human melanocytes to overcome UV-induced G1 arrest and stimulate melanogenesis. Recently, we demonstrated that ET-1 and apha-MSH increase the survival of UVirradiated melanocytes by inhibiting apoptosis. We found that cultured human melanocytes that express loss-of-function mutations in the melanocortin 1 receptor, the receptor for alpha-MSH, have increased susceptibility to killing by UVR. We attribute this increased sensitivity to UV exposure to extensive DNA damage that overwhelms the repair capacity of those cells, and to inability to fully activate survival pathways. These mutations have been associated with poor tanning ability, and increased risk for melanoma and non-melanoma skin cancers, independently of skin or hair color. We hypothesize that ET- 1 and alpha-MSH promote human melanocyte survival by inhibiting apoptosis and reducing the extent of UVB-induced DNA damage. We propose to investigate the ability of ET-1 and/or a-MSH to limit the extent of UVBinduced DNA damage and/or to enhance the rate of DNA repair. We will also determine the capacity of ET-1 and alpha-MSH to activate the Akt/PKBdependent survival pathway. Activated Akt/PKB is known to inhibit apoptosis by phosphorylating and inactivating its substrates Bad and caspase 9, and by activating NFkB and CREB. Additionally, we plan to elucidate whether the survival effects of ET-1 and/or alphaMSH involve activation of the transcription factor Mitf, which upregulates Bcl2 expression, by modulating the activities of ERK1/2, p38 and JNK/SAPK, and CREB in UVB-irradiated melanocytes. Determining the differences in the ability of melanocytes from different pigmentary phenotypes to respond to survival factors is significant for assessing the magnitude of the cytotoxic and genotoxic effects of UVR in the skin. Also, assessing the differential sensitivity to the survival effects of a-MSH and ET-1 can be used as a reliable marker for determining individual risk to skin cancer, particularly melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SLC AND DENDRITIC CELLS IN ANTITUMOR IMMUNITY & THERAPY Principal Investigator & Institution: Mule, James A.; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2001; Project Start 30-SEP-1992; Project End 31-MAR-2006 Summary: In order to develop new and more effective immune-based cancer treatments, relevant, small animal models continue to play a necessary role in understanding the underlying biology of such therapies, which are designed to modulate the immune system to recognize a neoplasm as "foreign". We have shown that murine tumor lysatepulsed dendritic cells (TP-DC) can elicit tumor-specific T cell reactivities in vitro and in vivo. This observation has been made in a variety of histologically-distinct murine tumors, including sarcoma, carcinoma, and melanoma. We have further shown that synegeneic hosts can be effectively immunized in vivo to reject aggressive, weakly-
58
Melanoma
immunogenic sarcomas, a breast carcinoma, and a poorly-immunologic subline of the B16 melanoma by immunization with TP-DC, which is dependent upon host-derived CD8+ and CD4+ T cells. TP-DC treatments can also result in regression of both established subcutaneous tumor nodules and lung metastases., which can be further enhanced by the systemic administration of IL-2. The experimental studies outlined in this application are designed to continue our preclinical efforts to generate more potent immunization strategies against cancer based on potent antigen-presenting DC. We will now extend our efforts on novel approaches to use TP-DC in the setting of a powerful chemoattractant cytokine, denoted secondary lymphoid tissue chemokine (SLC). The rationale for doing so is based on our recent data demonstrating that SLC is a unique, potent chemokines selective for the recruitment of naive T cells and immature DC. It is our hypothesis that concomitant expression of SLC at the immunization site of TP-DC will result in increased tumor reactivity through elevated levels of host immune cell recruitment and activation. We propose the following Specific Aims: 1. To evaluate the efficacy of SLC to attract T cells and DC to primary immunization sites in vivo; 2. To evaluate the capacity of immunization of tumor-bearing mice with SLC gene-modified TP-DC to mediate a therapeutic anti-tumor response in vivo; 3. To determine the mechanism of tumor response in mice immunized with SLC gene- modified TP-DC; 4. To evaluate the combination of SLC and additional recombinant cytokines to enhance therapeutic efficacy in vivo; and 5. To evaluate the clinical use of SLC in the treatment of patients with advanced melanoma. The range of therapeutic strategies will be tested and compared in settings of minimal and advanced disease states. The overall goal of our research effort will be to develop and optimize a new strategy that combines a chemokine with DC-based vaccine approaches for the treatment of cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SPORE IN SKIN CANCER Principal Investigator & Institution: Kupper, Thomas S.; Professor and Chair; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2006 Summary: In this proposal, we seek to establish a Specialized Program of Research Excellence (SPORE) in Skin Cancer at Harvard University and Brigham and Women's Hospital, within the newly configured Dana Farber Harvard Cancer Center. The DanaFarber Harvard Cancer Center SPORE includes investigators from Harvard Medical School and School of Public Health, as well as the Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Children's Hospital Medical Center, Dana- Farber Cancer Institute, and the Massachusetts General Hospital. These institutions have come together around the theme of translational research in melanoma and cutaneous oncology Five Projects, five Shared Resources (Cores), a Developmental Program, and a Cancer Development Program are proposed. Project 1 will translate epidemiologic findings into the Development of improved risk models for melanoma; once developed, these will be validated across a large patient population. Project 2 employs the power of whole genome transcriptional profiling with the ultimate goal of improving our ability to diagnose and predict the biological course of primary melanoma. Project 3 tests the hypothesis that cutaneous T cell lymphoma is a malignancy of a population of memory T cells that normally performs immunosurveillance of the skin, and seeks to identify new targets for therapy. Projects 4 and 5 are exciting translational clinical trials. In Project 4, two diametrically different dendritic cell vaccination strategies are directly compared, using novel immunological endpoints. In Project 5, biochemotherapeutic approaches are employed to treat metastatic melanoma. Immunologic monitoring will
Studies
59
be performed again with the goal of improving therapy for melanoma patients. These five Projects are integrated by five Cores. The Biostatistics Core provides expert consultation to each study while the Tissue and Pathology Core provides controlled and organized access to tissue vital for these projects. An assessment of immunologic endpoints. The Clinical Data Management Core provides a vital service of creating dynamic and flexible databases that integrate Projects across multiple Harvard-affiliated hospitals. Finally, a Development Program features five projects, each of which is a candidate for evolution into a full project is promising translational results are obtained. A Career Development Program, which takes a broad view of the development of the physician scientist over the course of a career, is a centerpiece of this application. An administrative structure is in place that will assure oversight, integration, planning, didactic activities, and most importantly, the growth and evolution into a full project if promising translational results are obtained. A Career Development Program, which takes a broad view of the development of the physician scientist over the course of a career, is a centerpiece of this application. An administrative structure is in place that will assure oversight, integration, planning, didactic activities, and most importantly, the growth and evolution of the SPORE over the next five years. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SUN EXPOSURE RECALL--INSTRUMENT DEVELOPMENT & EVALUATION Principal Investigator & Institution: Marrett, Loraine D.; Cancer Care Ontario 620 University Ave, Ste 1500 Toronto, Timing: Fiscal Year 2001; Project Start 11-AUG-2000; Project End 31-JUL-2003 Summary: (Applicant's Description) This project's long-term objective is to improve data collection on early-life sun exposure in etiologic studies of melanoma and other skin cancers; findings may have implications for epidemiologic studies involving recall of other early-life risk factors like diet and physical exercise. The specific aims are: 1) to develop instruments for adult recall of childhood sun exposure through key informant interviews and collegial pretesting, focus groups, cognitive interviewing and field pretesting; 2) to evaluate the developed instruments, through field testing in young adult melanoma cases and population controls, as to response completeness, test-retest reliability, and the effect of these on odds ratio estimates. The investigators have developed, from existing instruments, a life events calendar to help define stable exposure periods and a draft questionnaire. Further preliminary development through interviews with other investigators and collegial pretesting will be unfunded work. Funding is requested for the focus group, cognitive interview, field pretest and evaluation phases. Focus groups of young melanoma cases and like-aged population controls will be invited to discuss the way they think about and retrieve information concerning early life sun exposure (memory triggers, salient aspects, etc.) and then to review the draft questionnaire and provide feedback for improvements. Analysis of these sessions will result in a revised questionnaire. Small-group cognitive interviews will explore how subjects comprehend and prepare answers to the questions in this revised instrument. Resulting refinements to wording and probes will be pretested in telephone interviews and then field tested in a sample of melanoma cases and population controls, with reinterview at least four months later. Evaluation will focus on item nonresponse and reliability in cases and controls, and the effect of these on odds ratio estimates. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
60
Melanoma
•
Project Title: TCR-GENE IMMUNOTHERAPY
MODIFIED
T-CELLS
FOR
ADAPTIVE
Principal Investigator & Institution: Van Besien, Koen Walter.; Associate Professor; Medicine; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2003; Project Start 10-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): It has been demonstrated that tumor reactive T-cells can induce tumor regression in patients with metastatic melanoma and some of the target antigens have been identified. Still, the clinical impact of current immunomodulatory approaches by use of cytokines/biologic response modifiers, vaccination or the use of adoptive immunotherapy remains limited. We have recently identified and cloned the T-cell receptor (TCR) of a CD4 Tumor infiltrating lymphocyte with MHC class I restricted recognition and strong affinity for its target, the 368-376 peptide of tyrosinase. The overall aim of this proposal is to develop an adoptive immunotherapy approach using TCR-gene modified PBL. In specific aim 1 we will determine if the retroviral vector encoding the TCR from an HLA-A2 restricted, tryosinase:368-376 reactive T cell clone (TIL 13831) can engineer normal peripheral blood T cells from normal donors and melanoma patients to recognize melanoma cells with high affinity. For this purpose we will use specifically designed retroviral vectors with a SAMEN backbone that are adapted for the transfer of TCR alpha and beta and that in some cases also express the neo(r) gene for G418 selection. In specific aim 2 we will determine the optimal conditions to TCR gene modify human peripheral blood T cells from normal donors and melanoma patients for patient treatment. For this set of experiments, we will use the previously produced A6 and A7 retroviral vectors that carry the low affinity TIL 5 TCR. Using this model, we will optimize methods of transducing and expanding normal PBL. We will evaluate 2 transduction methodologies, spinoculation and retronectin based transduction. We will also optimize methods for in vitro expansion of transduced T-cell populations and study TCR transduction (by RT-PCR) expression (by tetramer staining) as well as functional activity (by Cytokine release and Cr release assay). It is anticipated that methods developed under specific aim 2, will be applicable for cell populations transduced with newer vectors generated under specific aim 1. In specific aim 3 we will determine if TIL 13831 TCR gene modified T cells can be detected and quantified using RTP-CR and competitive RT-PCR. For this purpose specific primere for TIL 13831 will be designed, as well as a clone specific inhibitor. The validity of the test and its accuracy will be extensively evaluated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE ROLE OF CD4+ T CELLS IN MELANOMA IMMUNOTHERAPY Principal Investigator & Institution: Bullock, Timothy N.; Microbiology; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2002; Project Start 11-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): The candidate is a recently promoted Research Assistant Professor who has been investigating the use of dendritic cells to activate CD8+ T cell responses against melanoma in the laboratory of Dr. V. Engelhard. As part of a move towards independence, the candidate is developing his own research project that extrapolates from his postdoctoral investigations. It is the candidate's intention to use the Temin Award as a foundation to advance intellectually and scientifically under the mentorship provided by Dr. Engelhard, followed by a successful transition to completely independent research in tumor immunotherapy. The University of Virginia
Studies
61
provides an ideal environment for this proposal due to the excellence of the basic science faculty and the potential for collaboration with physicians interested in applying immunotherapy in a clinical setting. The research proposal is based on the accumulated data from several groups that suggests that CD4+ T cells play an integral role in directing adaptive immune responses against tumors, by providing activation stimuli for professional antigen presenting cells, cytokine support the generation of effector and memory CD8+ T cells and direct anti-tumoricidal activity. Therefore, vaccination protocols that elicit CD8+ T cell and CD4+ T cell responses against tumors are likely to be more effective than those that target either arm of the adaptive immune response alone. Based on the hypothesis that the generation of CD4+ T cells that can respond specifically to MHC class II-restricted epitopes derived from melanocyte differentiation proteins will enhance the generation of tumor-specific CD8+ T cell responses, and the generation of memory CD8+ T cells against melanoma, we propose to: 1. Identify and compare HLA-DR*0401- restricted peptides derived from tyrosinase that are presented on dendritic cells, melanoma cells, or both. 2. Characterize the CD4+ T cell response to tyrosinase-derived HLA-DR*0401-restricted peptides in DR4/IEd transgenic mice that either do or do not express tyrosinase in the periphery. 3. Define the role of tyrosinasespecific CD4+ T cells and their epitopes in the generation of tyrosinase-specific CD8+ T cells and anti-melanoma responses. The results derived from this proposal are expected to have immediate impact on our understanding of the immune response to peripherally expressed self-antigens t h a t are relevant to melanoma, and the design of immunotherapeutic interventions against melanoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TOPICAL RETINOIDS FOR CHEMOPREVENTION OF MELANOMA Principal Investigator & Institution: Cattaneo, Maurizio V.; Ivrea, Inc. 216 Ricciuti Dr Quincy, Ma 02169 Timing: Fiscal Year 2003; Project Start 01-JUN-2000; Project End 31-MAR-2005 Summary: (provided by applicant): Malignant melanoma's incidence is increasing by 2.7% annually even as most other cancers are experiencing a decline in incidence. The long-term objective of this project is to commercialize a topical formulation containing retinoic acid (ATRA) for subjects with dysplastic nevi at a higher risk of developing malignant melanoma. However, ATRA is highly irritating to the skin. Several topical delivery systems have been shown to reduce ATRA-induced skin irritation. Phase I studies have shown that the biopolymer chitosan acts as a topical delivery system for ATRA. In this Phase II SBIR study we propose to: (1) standardize the topical formulation containing the ATRA/chitosan delivery system according to our IND 60,073, (2) test the long-term toxicity and irritation of the formulation in both rodents and non-rodents species according to FDA 21 CFR, Part 58, (3) determine whether 6 months of topical ATRA/chitosan will result in a significant clinical improvement of dysplastic nevi, and/or a decrease in the dysplasia grade, and/or a change in the expression of proliferation biomarkers, by performing a multicenter controlled clinical trial involving 16 dysplastic nevi subjects using Internet-based randomization, electronic data capture, coordination and monitoring, and pre and post study clinical and histological assessment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TRANSCRIPTION FACTOR AP2 IN METASTASIS OF MELANOMA Principal Investigator & Institution: Bar-Eli, Menashe; Professor; Surgical Oncology & Cell Biol; University of Texas Md Anderson Can Ctr Cancer Center Houston, Tx 77030
62
Melanoma
Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 31-JAN-2003 Summary: (adapted verbatim from investigator's abstract) The molecular changes associated with the transition of melanoma cells from radial growth phase (RGP) to vertical growth phase (VGP) (metastatic phenotype) are not very well defined. Recent work from this laboratory demonstrated that the expression of the cell surface adhesion molecule MCAM/MUC18, which belongs to the immunoglobulin superfamily, directly correlates with the metastatic potential of human melanoma cells. While none of the MCAM/MUC18-negative cell lines examined have been found to be metastatic, transfection of such cells with MCAM/MUC18 gene rendered them metastatic in nude mice. In addition, we have recently demonstrated that the progression of melanoma is associated with loss of expression of the c-KIT proto-oncogene tyrosine kinase receptor. Furthermore, re-expression of the c-KIT receptor in highly metastatic cell lines inhibited their tumorigenicity and metastatic potential in nude mice. Indeed, exposure of c-KITpositive melanoma cells in vitro and in vivo to stem cell factor (SCF), the ligand for cKIT, triggered apoptosis of these cells but not of normal melanocytes. The mammalian transcription factor AP-2 is a sequence-specific DNA-binding protein expressed in neural crest lineages and regulated by retinoic acid. Our preliminary data indicate that both MCAM/MUC18 and c-KIT gene expression is highly regulated by AP-2. In addition, other genes that are involved in the progression of melanoma such as MMP-2, bel-2, E-cadherin, and p21/WAF-1 are also regulated by the transcription factor AP-2. Our laboratory has recently made the observation that while several nonmetastatic melanoma cell lines express AP-2, the highly metastatic cell lines do not express this transcription factor. Therefore, we hypothesize that loss of AP-2 expression may be a crucial event in the development of malignant melanoma. We are therefore proposing the three Specific Aims: 1) to provide a direct evidence for the involvement of AP-2 in the acquisition of the metastatic phenotype by transfecting metastatic cells with w.t. AP2 and primary melanoma cells with a dominant negative AP-2B genes and subsequently analyze their tumorigenicity and metastatic potential in nude mice. 2) To study the effect of AP-2 and AP-2B on the expression of the above mentioned genes. 3) To evaluate the status of AP-2 expression and function in tumor specimens from patients in well-characterized melanoma database. These experiments will generate valuable information on the progression of melanoma, and help to develop new molecular staging markers and a common target for anti-tumor/metastasis therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TREATMENT AND MOLECULAR ANALYSIS OF ATYPICAL NEVI Principal Investigator & Institution: Becker, Dorothea; Professor of Pathology; Pathology; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2001; Project Start 30-SEP-1998; Project End 31-JUL-2003 Summary: (adapted from the investigator's abstract) The overall objective of this proposal is to determine whether systemic treatment with the biologic agent, interferon a2a, will modulate the molecular, immunologic, histopathologic, and clinical features of atypical nevi, which are the known precursors and risk markers of malignant melanoma. In the setting of familial melanoma, the presence of atypical nevi is associated with a nearly 100% risk of developing primary melanoma by age 70. Likewise, in the case of sporadic melanomas, between 40-60% of them develop from preexisting atypical nevi. Furthermore, patients with a clinical history of primary melanoma and two or more atypical nevi are at an 8-fold greater risk of developing a second primary melanoma. Thus, in light of the rising incidence and mortality rate of
Studies
63
melanoma, it is not only imperative to find and implement strategies that will help cure patients with metastatic disease but also to prevent the progression of atypical nevi to malignant melanoma. We recently demonstrated that direct gene targeting of bFGF/FGFR-1 in human melanomas causes their growth arrest and regression as a result of blocked melanoma proliferation and intratumoral angiogenesis. In addition, we documented expression of these two genes in the dermal nevocytic and stromal compartments of atypical nevi. The results of recent clinical trials provided evidence that IFNa has a significant therapeutic impact on metastatic melanoma, leading in 1995 to an FDA approval of IFNa as the first agent for adjuvant therapy of high-risk melanoma. While IFNa is known to be a potent antiviral, antiproliferative and immunomodulating agent, recent studies have shown that IFNa also functions as a strong angiogenesis inhibitor by blocking bFGF mRNA and protein in human malignancies. Given these findings, we propose to determine whether the biological, histopathological and clinical features of melanoma precursor lesions can be modulated by systemic treatment with low-dose IFNa-2a in patients who have a clinical history of melanoma and multiple atypical nevi. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TUMOR NEOVASCULATURE VECTOR TARGETING Principal Investigator & Institution: Deisseroth, Albert B.; President and Ceo; Sidney Kimmel Cancer Center San Diego, Ca 92121 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2004 Summary: (provided by applicant): The proposed clinical trial for melanoma is based on the protocol developed and tested successfully in a mouse xenograft model of human melanoma. The trial protocol involves administering to melanoma patients an immunoconjugate composed of a human factor VII (fVII) molecule conjugated to the Fc region of a human IgG1 immunoglobulin. The immunoconjugate binds with high affinity and specificity to its natural receptor tissue factor (TF) expressed by tumor blood vessels and tumor cells. The fVII molecule is mutated to prevent initiation of blood coagulation after it binds to TF. The gene encoding the immunoconjugate is carried by a non-replicating adenoviral vector, which is injected directly into skin tumors of a melanoma patient. The adenovirus infects mainly the cells of the injected tumor, which synthesize the immunoconjugate for secretion into the blood, establishing a steady high blood titer of the immunoconjugate for several weeks. The blood-borne immunoconjugate binds to tumor blood vessels and tumor cells throughout a patient?s body, resulting in induction of a powerful cytolytic immune attack against primary and disseminated tumors. The mouse model experiments demonstrated that the immunoconjugate causes regression of human melanoma tumors, associated with extensive destruction of the tumor vasculature. No clinically significant adverse effects on normal tissues were detected in the treated mice. The safety and efficacy of the protocol in the mouse model suggest a similar outcome for the proposed clinical trial. Designed primarily as a dose escalation study of the safety of administering intratumoral injections of an adenoviral vector encoding the fVII immunoconjugate, the trial is also designed to generate efficacy data. Each melanoma patient enrolled in the trial will receive a selected dose of the vector administered at 3-day intervals for a total of 6 doses. Toxicity will be monitored by a panel of tests during and after treatment, including several types of blood and liver function tests. Efficacy will be monitored by measurements of injected skin tumors, and also of skin tumors and internal tumors that were not injected. Because the protocol should be applicable to a broad range of human
64
Melanoma
solid tumors, a favorable outcome for the melanoma trial could lead to a new treatment not only for melanoma but also for other types of cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “melanoma” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for melanoma in the PubMed Central database: •
12(S)-Hydroxyeicosatetraenoic Acid and 13(S)-Hydroxyoctadecadienoic Acid Regulation of Protein Kinase C-[alpha] in Melanoma Cells: Role of ReceptorMediated Hydrolysis of Inositol Phospholipids. by Liu B, Khan WA, Hannun YA, Timar J, Taylor JD, Lundy S, Butovich I, Honn KV.; 1995 Sep 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40977
•
A 170-kDa Membrane-Bound Protease is Associated with the Expression of Invasiveness by Human Malignant Melanoma Cells. by Aoyama A, Chen W.; 1990 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54942
•
A CDKN2-like polymorphism in Xiphophorus LG V is associated with UV-B-induced melanoma formation in platyfish --swordtail hybrids. by Nairn RS, Kazianis S, McEntire BB, Della Coletta L, Walter RB, Morizot DC.; 1996 Nov 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24043
•
A Melanoma-Specific VH Antibody Cloned from a Fusion Phage Library of a Vaccinated Melanoma Patient. by Cai X, Garen A.; 1996 Jun 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39013
•
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. by Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T.; 2001 Aug 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=56954
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
65
•
A Mouse B16 Melanoma Mutant Deficient in Glycolipids. by Ichikawa S, Nakajo N, Sakiyama H, Hirabayashi Y.; 1994 Mar 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43438
•
A Mutated Intron Sequence Codes for an Antigenic Peptide Recognized by Cytolytic T Lymphocytes on a Human Melanoma. by Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T.; 1995 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41269
•
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. by Halaban R, Cheng E, Zhang Y, Moellmann G, Hanlon D, Michalak M, Setaluri V, Hebert DN.; 1997 Jun 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21028
•
Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. by Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD.; 2002 Dec 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=138583
•
AIM1, a novel non-lens member of the [beta][gamma]-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. by Ray ME, Wistow G, Su YA, Meltzer PS, Trent JM.; 1997 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20351
•
An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. by Bhoumik A, Huang TG, Ivanov V, Gangi L, Qiao RF, Woo SL, Chen SH, Ronai Z.; 2002 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151112
•
An autologous oral DNA vaccine protects against murine melanoma. by Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA.; 2000 May 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=25856
•
An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. by Lahav R, Heffner G, Patterson PH.; 1999 Sep 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18062
•
Anti-Melanoma Antibodies from Melanoma Patients Immunized with Genetically Modified Autologous Tumor Cells: Selection of Specific Antibodies from SingleChain Fv Fusion Phage Libraries. by Cai X, Garen A.; 1995 Jul 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41553
•
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. by Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Woude GF.; 2002 Mar 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122471
•
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. by Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R,
66
Melanoma
MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G.; 2003 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153621 •
Biologic and Therapeutic Significance of MYB Expression in Human Melanoma. by Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G, Gewirtz AM.; 1994 May 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43813
•
Biotransformation of the Antimelanoma Agent Betulinic Acid by Bacillus megaterium ATCC 13368. by Chatterjee P, Kouzi SA, Pezzuto JM, Hamann MT.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92230
•
Changes in Expression of Putative Antigens Encoded by Pigment Genes in Mouse Melanomas at Different Stages of Malignant Progression. by Orlow SJ, Hearing VJ, Sakai C, Urabe K, Zhou B, Silvers WK, Mintz B.; 1995 Oct 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40754
•
Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor. by Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA.; 1994 Apr 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43610
•
Comparison of fusion phage libraries displaying VH or single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules. by Cai X, Garen A.; 1997 Aug 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23147
•
Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. by Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA.; 2000 Aug 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27660
•
Cytotoxic T-Lymphocyte Clones from Different Patients Display Limited T-CellReceptor Variable-Region Gene Usage in HLA-A2-Restricted Recognition of the Melanoma Antigen Melan-A/MART-1. by Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wolfel T, Brichard V, thierry Boon, Borbignon C, Anichini A, Parmiani G.; 1995 Jun 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41759
•
Direct Gene Transfer with DNA-Liposome Complexes in Melanoma: Expression, Biologic Activity, and Lack of Toxicity in Humans. by Nabel GJ, Nabel EG, Yang Z, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE.; 1993 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47971
•
Direct visualization of distinct T cell epitopes derived from a melanoma tumorassociated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. by Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom HR, Reiter Y.; 2002 Jul 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=123156
Studies
67
•
Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas. by Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L.; 2001 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86838
•
Effect of public education aimed at early diagnosis of malignant melanoma: cohort comparison study. by MacKie RM, Bray CA, Leman JA.; 2003 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=148894
•
Egress of varicella-zoster virus from the melanoma cell: a tropism for the melanocyte. by Harson R, Grose C.; 1995 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189316
•
Eradication of Human Hepatic and Pulmonary Melanoma Metastases in SCID Mice by Antibody--Interleukin 2 Fusion Proteins. by Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA.; 1996 Apr 2; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39694
•
Exchange of Viral Promoter/Enhancer Elements with Heterologous Regulatory Sequences Generates Targeted Hybrid Long Terminal Repeat Vectors for Gene Therapy of Melanoma. by Diaz RM, Eisen T, Hart IR, Vile RG.; 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109437
•
Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry. by Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE.; 2001 Jul 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=35460
•
Expression Cloning of a CMP-NeuAc:NeuAc[alpha]2-3Gal[beta]1-4Glc[beta]1-1'Cer [alpha]2, 8-Sialyltransferase (GD3 Synthase) from Human Melanoma Cells. by Nara K, Watanabe Y, Maruyama K, Kasahara K, Nagai Y, Sanai Y.; 1994 Aug 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=44522
•
Expression of Tissue Factor by Melanoma Cells Promotes Efficient Hematogenous Metastasis. by Mueller BM, Reisfeld RA, Edgington TS, Ruf W.; 1992 Dec 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50651
•
Fc receptors are required in passive and active immunity to melanoma. by Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV.; 1998 Jan 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18475
•
Fibroblast Cell Interactions with Human Melanoma Cells Affect Tumor Cell Growth as a Function of Tumor Progression. by Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS.; 1991 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52015
•
Functional Hierarchy of Simultaneously Expressed Adhesion Receptors: Integrin [alpha]2[beta]1 but Not CD44 Mediates MV3 Melanoma Cell Migration and Matrix Reorganization within Three-dimensional Hyaluronan-containing Collagen Matrices. by Maaser K, Wolf K, Klein CE, Niggemann B, Zanker KS, Brocker EB, Friedl P.; 1999 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=25559
68
Melanoma
•
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. by Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG, Marincola FM.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=126240
•
Genetic Predisposition of Transgenic Mouse Melanocytes to Melanoma Results in Malignant Melanoma After Exposure to a Low Ultraviolet B Intensity Nontumorigenic for Normal Melanocytes. by larue L, Dougherty N, Mintz B.; 1992 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50166
•
Genomic Organization of the Melanoma-Associated Glycoprotein MUC18: Implications for the Evolution of the Immunoglobulin Domains. by Sers C, Kirsch K, Rothbacher U, Riethmuller G, Johnson JP.; 1993 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47387
•
Heparin- and Sulfatide-Binding Peptides from the Type I Repeats of Human Thrombospondin Promote Melanoma Cell Adhesion. by Guo N, Krutzsch HC, Negre E, Vogel T, Blake DA, Roberts DD.; 1992 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48799
•
Histopathogenesis of Malignant Skin Melanoma Induced in Genetically Susceptible Transgenic Mice. by Mintz B, Silvers WK, Klein-Szanto AJ.; 1993 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47452
•
HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. by Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED.; 1998 Apr 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22520
•
Homozygous Deletions within Human Chromosome Band 9p21 in Melanoma. by Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE, Dracopoli NC.; 1992 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50378
•
HOXB7 constitutively activates basic fibroblast growth factor in melanomas. by Care A, Silvani A, Meccia E, Mattia G, Stoppacciaro A, Parmiani G, Peschle C, Colombo MP.; 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=231486
•
Human CD4+ T Cells Specifically Recognize a Shared Melanoma-Associated Antigen Encoded by the Tyrosinase Gene. by Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA.; 1994 Sep 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=44832
•
Human High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Induction of Humoral Anti-HMW-MAA Immunity and Prolongation of Survival in Patients with
Studies
69
Stage IV Melanoma. by Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S.; 1992 Jan 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48259 •
Human Monoclonal Antibody with Dual GM2/GD2 Specificity Derived from an Immunized Melanoma Patient. by Yamaguchi H, Furukawa K, Fortunato SR, Livingston PO, Lloyd KO, Oettgen HF, Old LJ.; 1990 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=53894
•
Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. by Wang B, Chen YB, Ayalon O, Bender J, Garen A.; 1999 Feb 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15540
•
Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in vivo Tumor Rejection. by Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appell E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA.; 1994 Jul 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=44221
•
Identification of multiple cancer /testis antigens by allogeneic antibody screening of a melanoma cell line library. by Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A, Old LJ.; 1998 Jun 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22686
•
IL-18 regulates IL-1[beta]-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. by Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P, Reznikov LL, Kim SH, Novick D, Rubinstein M, Dinarello CA.; 2000 Jan 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15399
•
Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA --liposome complexes. by Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chang AE.; 1996 Dec 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26414
•
Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications. by Potti A, Hille RC, Koch M.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=280698
•
Immunophenotyping of Melanomas for Tyrosinase: Implications for Vaccine Development. by Chen Y, Stockert E, Tsang S, Coplan KA, Old LJ.; 1995 Aug 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41108
•
Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW Melanoma Cocktail' -- A mixture of monoclonal antibodies to MART-1, melan-A, and tyrosinase. by Shidham VB, Qi D, Rao RN, Acker SM, Chang CC, Kampalath B, Dawson G, Machhi JK, Komorowski RA.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=161792
70
Melanoma
•
In vitro loss of heterozygosity targets the PTEN /MMAC1 gene in melanoma. by Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ, Cavenee WK.; 1998 Aug 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21353
•
In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. by Hishii M, Andrews D, Boyle LA, Wong JT, Pandolfi F, van den Elsen PJ, Kurnick JT.; 1997 Feb 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=19799
•
Inactivation of the NF1 Gene in Human Melanoma and Neuroblastoma Cell Lines Without Impaired Regulation of GTP[center dot]Ras. by Johnson MR, Look AT, DeClue JE, Valentine MB, Lowy DR.; 1993 Jun 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46756
•
Increased Manganese Superoxide Dismutase Expression Suppresses the Malignant Phenotype of Human Melanoma Cells. by Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS, Trent JM.; 1993 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46247
•
Induction of Antigen-Specific Cytolytic T Cells in situ in Human Melanoma by Immunization with Synthetic Peptide-Pulsed Autologous Antigen Presenting Cells. by Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, Mauri F.; 1995 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41290
•
Inhibition of Carcinoma and Melanoma Cell Growth by Type 1 Transforming Growth Factor [beta] is Dependent on the Presence of Polyunsaturated Fatty Acids. by Newman MJ.; 1990 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54361
•
Inhibition of melanoma tumor growth in vivo by survivin targeting. by Grossman D, Kim PJ, Schechner JS, Altieri DC.; 2001 Jan 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=14640
•
Inhibition of Rho Is Required for cAMP-induced Melanoma Cell Differentiation. by Busca R, Bertolotto C, Abbe P, Englaro W, Ishizaki T, Narumiya S, Boquet P, Ortonne JP, Ballotti R.; 1998 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=25356
•
Inhibition of the Motility and Growth of B16F10 Mouse Melanoma Cells by Dominant Negative Mutants of Dok-1. by Hosooka T, Noguchi T, Nagai H, Horikawa T, Matozaki T, Ichihashi M, Kasuga M.; 2001 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87266
•
Integrin [alpha]v[beta]3 Rescues Melanoma Cells from Apoptosis in ThreeDimensional Dermal Collagen. by Montgomery AM, Reisfeld RA, Cheresh DA.; 1994 Sep 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=44705
Studies
71
•
Interleukin 6: A Fibroblast-Derived Growth Inhibitor of Human Melanoma Cells from Early but not Advanced Stages to Tumor Progression. by Lu C, Vickers MF, Kerbel RS.; 1992 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50096
•
Invasive melanoma in Cdk4-targeted mice. by Sotillo R, Garcia JF, Ortega S, Martin J, Dubus P, Barbacid M, Malumbres M.; 2001 Nov 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=60867
•
Involvement of Integrin [alpha]v[beta]3 and Cell Adhesion Molecule L1 in Transendothelial Migration of Melanoma Cells. by Voura EB, Ramjeesingh RA, Montgomery AM, Siu CH.; 2001 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59705
•
Isolation of X-Ray-Inducible Transcripts from Radioresistant Human Melanoma Cells. by Boothman DA, Meyers M, Fukunaga N, Lee SW.; 1993 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47104
•
Localization of a Putative Tumor Suppressor Gene by Using Homozygous Deletions in Melanomas. by Weaver-Feldhaus J, Gruis NA, Neuhausen S, Paslier DL, Stockert E, Skolnick MH, Kamb A.; 1994 Aug 2; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=44442
•
Malignancy of Eye Melanomas Originating in the Retinal Pigment Epithelium of Transgenic Mice after Genetic Ablation of Choroidal Melanocytes. by Mintz B, KleinSzanto AJ.; 1992 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50562
•
Malignant Melanoma in Transgenic Mice. by Bradl M, Klein-Szanto A, Porter S, Mintz B.; 1991 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50770
•
Mass Spectrometric and Edman Sequencing of Lipocortin I Isolated by TwoDimensional SDS/PAGE of Human Melanoma Lysates. by Hall SC, Smith DM, Masiarz FR, Soo VW, Tran HM, Epstein LB, Burlingame AL.; 1993 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45993
•
mda-5: An interferon-inducible putative RNA helicase with double-stranded RNAdependent ATPase activity and melanoma growth-suppressive properties. by Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB.; 2002 Jan 22; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=117358
•
mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. by Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, Dent P, Fisher PB.; 2002 Jul 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=126623
72
Melanoma
•
Mechanism for elimination of a tumor suppressor: Aberrant splicing of a brainspecific exon causes loss of function of Bin1 in melanoma. by Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC.; 1999 Aug 17; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22271
•
Mediation of Lung Metastasis of Murine Melanomas by a Lung-Specific Endothelial Cell Adhesion Molecule. by Zhu D, Cheng C, Pauli BU.; 1991 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52759
•
Melan-A /MART-1 51 --73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4 + T cells. by Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ.; 2000 Jan 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26675
•
Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. by Czubayko F, Schulte AM, Berchem GJ, Wellstein A.; 1996 Dec 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26208
•
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. by Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G.; 2003 Mar 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=152304
•
Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. by Sharma SD, Jiang J, Hadley ME, Bentley DL, Hruby VJ.; 1996 Nov 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=19401
•
Modulation of tumor growth by inhibitory Fc[gamma] receptor expressed by human melanoma cells. by Cassard L, Cohen-Solal JF, Galinha A, Sastre-Garau X, Mathiot C, Galon J, Dorval T, Bernheim A, Fridman WH, Sautes-Fridman C.; 2002 Nov 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151807
•
Molecular Cloning of a Human Melanoma-Associated Chondroitin Sulfate Proteoglycan. by Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA.; 1996 Sep 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38494
•
Monitoring Specific T-Cell Responses to Melanoma Vaccines: ELISPOT, Tetramers, and Beyond. by Gajewski TF.; 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=95840
•
Murine Monoclonal Anti-Idiotope Antibody Breaks Unresponsiveness and Induces a Specific Antibody Response to Human Melanoma-Associated Proteoglycan Antigen in Cynomolgus Monkeys. by Chattopadhyay P, Starkey J, Morrow WJ, Raychaudhuri S.; 1992 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48726
Studies
73
•
Mutation Hotspots Due to Sunlight in the p53 Gene of Nonmelanoma Skin Cancers. by Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE.; 1993 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46477
•
Natural killer cell lines kill autologous [beta]2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy. by Porgador A, Mandelboim O, Restifo NP, Strominger JL.; 1997 Nov 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24276
•
Novel Ras antagonist blocks human melanoma growth. by Jansen B, SchlagbauerWadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler HG, Pehamberger H, Gana-Weisz M, Ben-David E, Kloog Y, Wolff K.; 1999 Nov 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24183
•
Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma. by MacKie RM, Bray CA, Hole DJ.; 2002 Nov 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136925
•
Overexpression of Plasminogen Activator Inhibitor 2 in Human Melanoma Cells Inhibits Spontaneous Metastasis in scid/scid Mice. by Mueller BM, Yu YB, Laug WE.; 1995 Jan 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42846
•
Platelet-Derived Growth Factor (PDGF) in Oncogenesis: Development of a Vascular Connective Tissue Stroma in Xenotransplanted Human Melanoma Producing PDGFBB. by Forsberg K, Valyi-Nagy I, Heldin C, Herlyn M, Westermark B.; 1993 Jan 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45668
•
Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. by Mandl S, Sigal LJ, Rock KL, Andino R.; 1998 Jul 7; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20956
•
Prevalence of Germ-Line Mutations in p16, p19ARF, and CDK4 in Familial Melanoma: Analysis of a Clinic-Based Population. by FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA.; 1996 Aug 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38708
•
Rapid Mass Spectrometric Peptide Sequencing and Mass Matching for Characterization of Human Melanoma Proteins Isolated by Two-Dimensional PAGE. by Clauser KR, Hall SC, Smith DM, Webb JW, Andrews LE, Tran HM, Epstein LB, Burlingame AL.; 1995 May 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41850
•
Retroviral-mediated transmission of a mouse VL30 RNA to human melanoma cells promotes metastasis in an immunodeficient mouse model. by Song X, Wang B, Bromberg M, Hu Z, Konigsberg W, Garen A.; 2002 Apr 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122938
74
Melanoma
•
Retrovirus Targeting by Tropism Restriction to Melanoma Cells. by Martin F, Neil S, Kupsch J, Maurice M, Cosset FL, Collins M.; 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112777
•
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. by Pennati M, Colella G, Folini M, Citti L, Daidone MG, Zaffaroni N.; 2002 Jan 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150847
•
Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375C6. by Muthukkumar S, Nair P, Sells SF, Maddiwar NG, Jacob RJ, Rangnekar VM.; 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230878
•
Role of the [alpha]v[beta]3 Integrin in Human Melanoma Cell Invasion. by Seftor RE, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, Hendrix MJ.; 1992 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48491
•
Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: A projected basis for immunotherapy. by Le Fur N, Kelsall SR, Silvers WK, Mintz B.; 1997 May 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24678
•
Sequence and Insertion Sites of Murine Melanoma-Associated Retrovirus. by Li M, Huang X, Zhu Z, Gorelik E.; 1999 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112951
•
Serological Analysis of Melan-A(MART-1), a Melanocyte-Specific Protein Homogeneously Expressed in Human Melanomas. by Chen Y, Stockert E, Jungbluth A, Tsang S, Coplan KA, Scanlan MJ, Old LJ.; 1996 Jun 11; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39162
•
Serological Response Patterns of Melanoma Patients Immunized with a GM2 Ganglioside Conjugate Vaccine. by Kitamura K, Livingston PO, Fortunato SR, Stockert E, Helling F, Ritter G, Oettgen HF, Old LJ.; 1995 Mar 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42307
•
Stimulation of cAMP and Phosphomonoester Production by Melanotropin in Melanoma Cells: 31P NMR Studies. by Degani H, DeJordy JO, Salomon Y.; 1991 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=51048
•
Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins. by Lougheed JC, Holton JM, Alber T, Bazan JF, Handel TM.; 2001 May 8; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=33244
•
Subcellular Localization of Myosin-V in the B16 Melanoma Cells, a Wild-type Cell Line for the dilute Gene. by Nascimento AA, Amaral RG, Bizario JC, Larson RE, Espreafico EM.; 1997 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=25653
Studies
75
•
Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. by Hu Q, Bally MB, Madden TD.; 2002 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137064
•
Suppression of Lung Metastasis of B16 Mouse Melanoma by NAcetylglucosaminyltransferase III Gene Transfection. by Yoshimura M, Nishikawa A, Ihara Y, Taniguchi S, Taniguchi N.; 1995 Sep 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41045
•
Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. by Hu Z, Sun Y, Garen A.; 1999 Jul 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22205
•
T-Cell Receptor Usage by Melanoma-Specific Clonal and Highly Oligoclonal TumorInfiltrating Lymphocyte Lines. by Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, Rosenberg SA.; 1994 Mar 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43464
•
Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. by Parry D, Peters G.; 1996 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=231381
•
The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. by Stoll R, Renner C, Zweckstetter M, Bruggert M, Ambrosius D, Palme S, Engh RA, Golob M, Breibach I, Buettner R, Voelter W, Holak TA, Bosserhoff AK.; 2001 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=133488
•
The Melanoma Differentiation Associated Gene mda-7 Suppresses Cancer Cell Growth. by Jiang H, Su Z, Lin JJ, Goldstein NI, Young CS, Fisher PB.; 1996 Aug 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38612
•
The role of MHC class I glycoproteins in the regulation of induction of cell death in immunocytes by malignant melanoma cells. by Fishman D, Irena B, Kellman-Pressman S, Karas M, Segal S.; 2001 Feb 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=29327
•
The velocity of ultrasound in human primary melanoma tissue - implications for the clinical use of high resolution sonography. by Weichenthal M, Mohr P, Breitbart EW.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=34515
•
Tissue Factor Promotes Melanoma Metastasis by a Pathway Independent of Blood Coagulation. by Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A.; 1995 Aug 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41125
76
Melanoma
•
Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. by Ohta Y, Kijima H, Ohkawa T, Kashani-Sabet M, Scanlon KJ.; 1996 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=145712
•
Transgenic Mouse Model of Malignant Skin Melanoma. by Mintz B, Silvers WK.; 1993 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47451
•
Upregulation of HMG1 Leads to Melanoma Inhibitory Activity Expression in Malignant Melanoma Cells and Contributes to Their Malignancy Phenotype. by Poser I, Golob M, Buettner R, Bosserhoff AK.; 2003 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=152547
•
Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c 2j gene substituted for the wild-type tyrosinase allele: Utilization in design of syngeneic immunotherapy models. by Le Fur N, Silvers WK, Kelsall SR, Mintz B.; 1997 Jul 8; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23861
•
UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. by Jamal S, Schneider RJ.; 2002 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150409
•
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte --macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. by Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G.; 1998 Oct 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23738
•
Wavelengths Effective in Induction of Malignant Melanoma. by Setlow RB, Grist E, Thompson K, Woodhead AD.; 1993 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46993
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals.
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
Studies
77
To generate your own bibliography of studies dealing with melanoma, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “melanoma” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for melanoma (hyperlinks lead to article summaries): •
A broad spectrum of human papillomavirus types is present in the skin of Australian patients with non-melanoma skin cancers and solar keratosis. Author(s): Forslund O, Ly H, Reid C, Higgins G. Source: The British Journal of Dermatology. 2003 July; 149(1): 64-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12890196&dopt=Abstract
•
A mistake I made from which I learned much: melanoma in a preexisting congenital nevus of Unna's type. Author(s): Ackerman AB. Source: International Journal of Surgical Pathology. 2003 July; 11(3): 213-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12894354&dopt=Abstract
•
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Author(s): Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, Fichtner I, Kratz F. Source: Cancer Research. 2003 July 15; 63(14): 4062-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12874007&dopt=Abstract
•
A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. Author(s): Veierod MB, Weiderpass E, Thorn M, Hansson J, Lund E, Armstrong B, Adami HO. Source: Journal of the National Cancer Institute. 2003 October 15; 95(20): 1530-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14559875&dopt=Abstract
•
A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Author(s): Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG. Source: Melanoma Research. 2003 August; 13(4): 389-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12883365&dopt=Abstract
•
A rare case of intracranial metastatic amelanotic melanoma with cyst. Author(s): Ogawa R, Aoki R, Hyakusoku H. Source: Journal of Clinical Pathology. 2003 July; 56(7): 548-51. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12835304&dopt=Abstract
78
Melanoma
•
About moles, melanomas, and lasers: the dermatologist's schizoph